

CITATION REPORT

List of articles citing

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

DOI: 10.2337/dc08-9025

Diabetes Care, 2009, 32, 193-203.

Source: <https://exaly.com/paper-pdf/46850086/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2362	Drugs used in diabetes mellitus. 83-92		
2361	Type 2 diabetes: where we are today: an overview of disease burden, current treatments, and treatment strategies. 2009 , 49 Suppl 1, S3-9		87
2360	Safety and efficacy of rosiglitazone in the elderly diabetic patient. 2009 , 5, 389-95		12
2359	Efficacy and safety of incretin based therapies: clinical trial data. 2009 , 49 Suppl 1, S30-40		54
2358	Incretin-based therapies: new treatments for type 2 diabetes in the new millennium. 2009 , 5, 683-98		9
2357	Management of obesity, insulin resistance and type 2 diabetes in children: consensus and controversy. 2009 , Volume 2, 185-202		8
2356	Impact of obesity and type 2 diabetes on health-related quality of life in the general population in England. 2009 , Volume 2, 179-184		12
2355	The Current Status of Type 2 Diabetes Management at a University Hospital. 2009 , 33, 241		7
2354	Redefining the role of thiazolidinediones in the management of type 2 diabetes. 2009 , 5, 141-51		42
2353	Safety and Efficacy of Pioglitazone/Metformin Combination Therapy in Treatment of Type 2 Diabetes: A Rationale for Earlier Use. 2009 , 1, CMT.S2370		
2352	Nouveaux traitements du diabète de type 2: quelles stratégies thérapeutiques pour demain?. 2009 , 21, 397-407		2
2351	Potential of liraglutide in the treatment of patients with type 2 diabetes. 2009 , 5, 199-211		51
2350	[Macrovascular diabetic complications: clinical characteristics, diagnosis and management]. 2009 , 53, 698-708		7
2349	Incretin-based Combination Therapy in Type 2 Diabetes Mellitus. 2009 , 52, 1030		1
2348	Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. 2009 , 49 Suppl 1, S16-29		101
2347	Type 2 diabetes: lifestyle changes and drug treatment. 2009 , 11, 237-41		2
2346	Exploration of the DPP-4 inhibitors with a focus on saxagliptin. 2009 , 10, 2927-34		5

2345	DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes. <i>Diabetes Care</i> , 2009 , 32, 1007-13	14.6	103
2344	Toward optimal health: current approaches to standards of care for diabetes in women. Interview by Jodi R. Godfrey. 2009 , 18, 605-10		
2343	Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors. 2009 , 76 Suppl 5, S28-38		48
2342	Barriers to insulin injection therapy: patient and health care provider perspectives. 2009 , 35, 1014-22		98
2341	Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes: Response to Cobitz and Anthony. <i>Diabetes Care</i> , 2009 , 32, e50-e59	14.6	4
2340	Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes: Response to Woo and Eizirik. <i>Diabetes Care</i> , 2009 , 32, e87-e88	14.6	4
2339	Genetic susceptibility to type 2 diabetes and implications for therapy. 2009 , 3, 690-6		6
2338	An overview and commentary on retrospective, continuous glucose monitoring for the optimisation of care for people with diabetes. 2009 , 25, 2389-400		11
2337	Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM. 2009 , 25, 2915-23		33
2336	A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. <i>Diabetes Care</i> , 2009 , 32, 1656-62	14.6	312
2335	Incretin-based therapies: viewpoints on the way to consensus. <i>Diabetes Care</i> , 2009 , 32 Suppl 2, S223-31	14.6	123
2334	Antidiabetic agents and cardiovascular risk in type 2 diabetes. 2009 , 5, 500-6		20
2333	Diabetes: diabetes therapy and cancer risk. 2009 , 5, 651-2		32
2332	New therapeutic horizons: mapping the future of glycemic control with incretin-based therapy. 2009 , 35, 731-4, 738-40, 742-4 passim		7
2331	Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. 2009 , 160, 909-17		106
2330	Initiating and Titrating Insulin in Patients With Type 2 Diabetes. 2009 , 27, 72-76		7
2329	Insulin therapy for type 2 diabetes. <i>Diabetes Care</i> , 2009 , 32 Suppl 2, S253-9	14.6	105
2328	Results of the LEAD-2 study in relation to NICE and ADA/EASD guidelines for the treatment of type 2 diabetes in the UK. 2009 , 9, 177-185		1

2327	Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes: response to Nathan et al. <i>Diabetes Care</i> , 2009 , 32, e34; author reply e37-8	14.6	8
2326	Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Response to Nathan et al. <i>Diabetes Care</i> , 2009 , 32, e58; author reply e59	14.6	11
2325	Insights from the Liraglutide Clinical Development Program--the Liraglutide Effect and Action in Diabetes (LEAD) studies. 2009 , 121, 16-25		34
2324	Diabetes: HOME reveals new data on a cornerstone of treatment. 2009 , 5, 478-9		1
2323	Diabetes: The HEART2D trial--new questions beyond answers. 2009 , 5, 299-300		3
2322	Incretin-based therapies: review of the outpatient literature with implications for use in the hospital and after discharge. 2009 , 37, 7-21		2
2321	Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. 2009 , 121, 5-15		23
2320	The effects of a commercially available weight loss program among obese patients with type 2 diabetes: a randomized study. 2009 , 121, 113-8		34
2319	Beyond glycemic control: treating the entire type 2 diabetes disorder. 2009 , 121, 68-81		19
2318	Comparison of treatment costs in inadequately controlled type 2 diabetes in Germany based on the APOLLO trial with insulin glargine. 2009 , 12, 87-97		2
2317	[Challenge in diabetes therapy: effects of glitazones beyond blood glucose control]. 2009 , 134, 949-54		7
2316	Insulin-based versus triple oral therapy for newly diagnosed type 2 diabetes: which is better?. <i>Diabetes Care</i> , 2009 , 32, 1789-95	14.6	67
2315	Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes: response to Nathan et al. <i>Diabetes Care</i> , 2009 , 32, e35-6; author reply e37-8	14.6	2
2314	Translating clinical trial data into new patterns of practice. 2009 , 35 Suppl 1, 18S-21S		1
2313	The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus. 2009 , 121, 94-107		68
2312	Liraglutide: a once-daily incretin mimetic for the treatment of type 2 diabetes mellitus. 2009 , 43, 1433-44		51
2311	Initiating insulin therapy in type 2 diabetic patients failing on oral hypoglycemic agents: basal or prandial insulin? The APOLLO trial and beyond. <i>Diabetes Care</i> , 2009 , 32 Suppl 2, S260-5	14.6	23
2310	Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity/mortality? Yes. <i>Diabetes Care</i> , 2009 , 32 Suppl 2, S342-8	14.6	24

2309	Target for glycemic control: concentrating on glucose. <i>Diabetes Care</i> , 2009 , 32 Suppl 2, S199-204	14.6	39
2308	Early and Aggressive Initiation of Insulin Therapy for Type 2 Diabetes: What Is the Evidence?. 2009 , 27, 60-68		19
2307	Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. 2009 , 94, 4810-9		187
2306	Genetic ablation or pharmacological blockade of dipeptidyl peptidase IV does not impact T cell-dependent immune responses. 2009 , 10, 19		42
2305	Rosiglitazone: can meta-analysis accurately estimate excess cardiovascular risk given the available data? Re-analysis of randomized trials using various methodologic approaches. 2009 , 2, 5		17
2304	A simulation of the comparative long-term effectiveness of liraglutide and glimepiride monotherapies in patients with type 2 diabetes mellitus. 2009 , 29, 1280-8		10
2303	Diabetes mellitus. Introduction. 2009 , 29, 23S-24S		
2302	Insulin therapy and type 2 diabetes: management of weight gain. 2009 , 11, 601-7		22
2301	Risk for nocturnal hypoglycemia with biphasic insulin aspart 30 compared with biphasic human insulin 30 in adults with type 2 diabetes mellitus: a meta-analysis. 2009 , 31, 1641-51		44
2300	A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus. 2009 , 31, 2472-88		81
2299	Nutritional challenges in the elderly with diabetes. 2009 , 1, 26-31		19
2298	The diabetes epidemic: what can we do?. 2009 , 109, 1160-2		4
2297	Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications. 2009 , 25, 112-26		26
2296	Current literature in diabetes. 2009 , 25, i-x		
2295	Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities. 2009 , 46, 85-95		95
2294	Thiazolidinediones in prediabetes and early type 2 diabetes: what can be learned about that disease's pathogenesis. 2009 , 9, 215-20		11
2293	Is the evidence from clinical trials for cardiovascular risk or harm for glitazones convincing?. 2009 , 9, 342-7		5
2292	Prognostic implications of diabetes phenotyping: new concepts for an old disease. 2009 , 4, 325-9		

2291	DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy. 2009 , 26, 272-80	6
2290	Drug evaluation: vildagliptin-metformin single-tablet combination. 2009 , 26, 138-54	21
2289	Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. 2009 , 26, 488-99	59
2288	Improving patient acceptance and adherence in diabetes management: a focus on insulin therapy. 2009 , 26, 838-46	21
2287	Consensus algorithm of the American Diabetes Association and the European Association for the Study of Diabetes: some concerns. 2009 , 52, 1696-7	1
2286	Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses. 2009 , 52, 1990-2000	86
2285	Contact frequency determines outcome of basal insulin initiation trials in type 2 diabetes. 2009 , 52, 2324-2327	18
2284	Treatment options for type 2 diabetes: introducing the incretin-based therapies. 2009 , 26, 179-183ii	2
2283	The role of incretin-based therapies in the management of type 2 diabetes. 2009 , 26, 186-188i	0
2282	Web-based guided insulin self-titration in patients with type 2 diabetes: the Di@log study. Design of a cluster randomised controlled trial [TC1316]. 2009 , 10, 40	10
2281	The consequences of delaying insulin initiation in UK type 2 diabetes patients failing oral hyperglycaemic agents: a modelling study. 2009 , 9, 19	37
2280	Management of progressive type 2 diabetes: role of insulin therapy. 2009 , 3, 5	1
2279	New developments in incretin-based therapies: the current state of the field. 2009 , 21 Suppl 1, 631-41	2
2278	Optimizing outcomes with incretin-based therapies: practical information for nurse practitioners to share with patients. 2009 , 21 Suppl 1, 642-50	
2277	Incretin-based therapies: therapeutic rationale and pharmacological promise for type 2 diabetes. 2009 , 21 Suppl 1, 623-30	10
2276	Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. 2009 , 63, 1395-406	210
2275	Improving cardiovascular risk--applying evidence-based medicine to glucose-lowering therapy with thiazolidinediones in patients with type 2 diabetes. 2009 , 63, 1354-68	3
2274	Insulin intensification--the rationale and the target. 2009 , 63, 1-5	8

2273	Optimising the medical management of hyperglycaemia in type 2 diabetes in the Middle East: pivotal role of metformin. 2010 , 64, 149-59		11
2272	Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time. 2010 , 64, 267-76		49
2271	Metformin--the gold standard in type 2 diabetes: what does the evidence tell us?. <i>Diabetes, Obesity and Metabolism</i> , 2009 , 11 Suppl 2, 3-8	6.7	95
2270	Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2009 , 11, 804-12	6.7	105
2269	Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2009 , 11, 611-22	6.7	249
2268	Restaging insulin therapy for patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2009 , 11 Suppl 5, 1-5	6.7	14
2267	Starting insulin strategies for patients with an inadequate response to oral therapy. <i>Diabetes, Obesity and Metabolism</i> , 2009 , 11 Suppl 5, 6-9	6.7	1
2266	Long-term glycaemic control with metformin-sulphonylurea-pioglitazone triple therapy in PROactive (PROactive 17). 2009 , 26, 1033-9		33
2265	Pharmacokinetic and pharmacodynamic properties of taspoglutide, a once-weekly, human GLP-1 analogue, after single-dose administration in patients with Type 2 diabetes. 2009 , 26, 1156-64		28
2264	Long-term glycaemic effects of pioglitazone compared with placebo as add-on treatment to metformin or sulphonylurea monotherapy in PROactive (PROactive 18). 2009 , 26, 1242-9		25
2263	What is the evidence base for the randomized controlled trial?. 2009 , 1, 73-5		1
2262	NICE on type 2 diabetes newer drugs: a breath of fresh air. 2009 , 20, 6-7		
2261	Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. 2009 , 15, 540-59		692
2260	Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT. 2009 , 25, 2887-94		66
2259	Safe and simple emergency department discharge therapy for patients with type 2 diabetes mellitus and severe hyperglycemia. 2009 , 15, 696-704		16
2258	Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use. 2009 , 20 Suppl 2, S329-39		33
2257	AMPK: an emerging drug target for diabetes and the metabolic syndrome. 2009 , 9, 407-16		801
2256	[Hospital management of hyperglycemia]. 2009 , 132, 465-75		37

2255	A(1c) control in a primary care setting: self-titrating an insulin analog pre-mix (INITIATEplus trial). 2009 , 122, 1043-9	33
2254	Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use. 2009 , 122, S37-50	92
2253	Pharmacologic management of the older patient with type 2 diabetes mellitus. 2009 , 7, 324-42	57
2252	Rosiglitazone. <i>Primary Care Diabetes</i> , 2009 , 3, 123-4	2.4 1
2251	Three-year efficacy of complex insulin regimens in type 2 diabetes. 2009 , 361, 1736-47	522
2250	[Hospital treatment of hyperglycemia]. 2009 , 56, 303-16	11
2249	Present recommendations in type 2 diabetes treatment. 2009 , 56S4, 46-49	1
2248	Do diabetes drugs modify the risk of pancreatic cancer?. 2009 , 137, 412-5	22
2247	Saxagliptin. 2009 , 69, 2103-14	53
2246	Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. 2009 , 58, 773-95	1832
2245	Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes. 2009 , 25, 1265-72	29
2244	Antidiabetic oral treatment in older people: does frailty matter?. 2009 , 26 Suppl 1, 53-62	26
2243	Standards of medical care in diabetes--2009. <i>Diabetes Care</i> , 2009 , 32 Suppl 1, S13-61	14.6 1378
2242	Vildagliptin in clinical practice: a review of literature. 2009 , 10, 2745-57	30
2241	Genomics of type 2 diabetes mellitus: implications for the clinician. 2009 , 5, 429-36	68
2240	Liraglutide Effect and Action in Diabetes (LEAD) trial. 2009 , 4, 119-129	35
2239	Quality measurement in diabetes care. 2009 , 12, 265-71	10
2238	The perfect storm?. 2009 , 4, 84-86	

2237	Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide. 2009 , 86 Suppl 1, S26-34	22
2236	Thiazolidinediones and clinical outcomes in type 2 diabetes. 2009 , 373, 2088-90	26
2235	Tratamiento de los factores de riesgo vascular, diabetes, hipertensi3n arterial y tabaquismo. 2009 , 10, 2697-2707	
2234	Rflexions pour de nouvelles recommandations de traitement m3dicamenteux du diab3te de type 2 apr3s post-UKPDS, ACCORD, VADT, ADVANCE. 2009 , 3, 147-150	
2233	Current Opinion in Anaesthesiology. Current world literature. 2009 , 22, 822-7	
2232	Signs of improvement: diabetes update 2009. 2009 , 34, 12-22, quiz 23	1
2231	Perioperative management of ambulatory surgical patients with diabetes mellitus. 2009 , 22, 718-24	37
2230	Current therapeutic drugs for type 2 diabetes, still useful after 50 years?. 2009 , 108, 1727-30	4
2229	Translating clinical guidelines into clinical practice: role of the pharmacist in type 2 diabetes management. 2009 , 49, e152-62	5
2228	4. Diagnosis and Treatment of Diabetes Mellitus. 2009 , 98, 2294-2299	
2227	Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes. 2009 , 56, 951-62	41
2226	Efficacy and Safety of Sitagliptin in the Treatment of Type 2 Diabetes. 2009 , 1, CMT.S2313	1
2225	Appraisal of Saxagliptin as Treatment of Type 2 Diabetes. 2010 , 5, 111-117	2
2224	Three cases of severe metformin-related lactic acidosis. 2010 , 27, 666-7	1
2223	Alogliptin: a novel molecule for improving glycemic control in type II diabetes mellitus. 2010 , 6, 410-21	15
2222	Diabetes under control: Understanding oral antidiabetic agents. 2010 , 110, 49-52	2
2221	Saxagliptin (Onglyza) for Type 2 Diabetes. 2010 , 115, 1081-1083	
2220	Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes. 2010 , 18, 213-7	10

2219	Long-term follow-up of the metabolic profiles in obese patients with type 2 diabetes mellitus after Roux-en-Y gastric bypass. 2010 , 251, 1049-55	64
2218	What Dietitians Need to Know About Medical Nutrition Therapy and Pharmacotherapy for Type 2 Diabetes. 2010 , 45, 240-249	2
2217	Behavioral medicine interventions in diabetes. 2010 , 23, 131-8	21
2216	Genetic markers in diabetes mellitus: the need and promise for specific drug therapies in defined subtypes of diabetes patients. 2010 , 7, 309-312	
2215	Liraglutide, the once-daily human GLP-1 analog, in the treatment of Type 2 diabetes. 2010 , 5, 495-505	3
2214	Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 diabetes. 2010 , 16, 629-40	30
2213	Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus. 2010 , 16, 588-99	29
2212	Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin. 2010 , 3, 31-41	31
2211	Type 2 diabetes mellitus: managing hemoglobin A(1c) and beyond. 2010 , 103, 911-6	14
2210	Metformin-induced vitamin B12 deficiency presenting as a peripheral neuropathy. 2010 , 103, 265-7	74
2209	Managing type 2 diabetes in the primary care setting: beyond glucocentricity. 2010 , 340, 133-43	4
2208	A review of insulin pen devices and use in the elderly diabetic population. 2010 , 3, 53-63	9
2207	Clinical overview of saxagliptin for Type 2 diabetes management. 2010 , 5, 809-823	6
2206	Body mass index, fasting plasma glucose levels, and C-peptide levels as predictors of the future insulin use in Japanese type 2 diabetic patients. 2010 , 57, 237-44	32
2205	Treatment of type 1 and type 2 diabetes mellitus with insulin detemir, a long-acting insulin analog. 2010 , 3, 65-80	3
2204	Continuation of oral medications when insulin is initiated. 2010 , 103, 7-8	
2203	Weight management in type 2 diabetes mellitus. 2010 , 77, 533-48	12
2202	Regulation of oxidative stress by glycaemic control: evidence for an independent inhibitory effect of insulin therapy. 2010 , 53, 562-71	111

2201	Guidelines: we'll always need them, we sometimes dislike them, and we have to make them better. 2010 , 53, 2280-4	7
2200	Clinical characteristics of patients with type 2 diabetes mellitus at the time of insulin initiation: INSTIGATE observational study in Spain. 2010 , 47 Suppl 1, 169-75	26
2199	The evolving place of incretin-based therapies in type 2 diabetes. 2010 , 25, 1207-17	25
2198	Thiazolidinediones in the treatment of patients with Post-Transplant-Hyperglycemia or new-onset diabetes mellitus after renal transplantation (NODAT) - A new therapeutic option?. 2010 , 122, 198-202	8
2197	Engaging and empowering patients to manage their type 2 diabetes, Part I: a knowledge, attitude, and practice gap?. 2010 , 27, 321-33	43
2196	Engaging and empowering patients to manage their type 2 diabetes, Part II: Initiatives for success. 2010 , 27, 665-80	14
2195	Incretin therapy for type 2 diabetes mellitus. 2010 , 27, 881-94	1
2194	Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes. 2010 , 1, 45-56	22
2193	Hypophysenstörungen und sekundärer Diabetes mellitus. 2010 , 6, 29-36	1
2192	Type 2 Diabetes and Genetics, 2010: Translating Knowledge into Understanding. 2010 , 4, 437-445	3
2191	Challenges and approaches to managing type 2 diabetes mellitus. 2010 , 10, 7-9	3
2190	Does choice of antidiabetes therapy influence macrovascular outcomes?. 2010 , 10, 24-31	2
2189	Update in new medications for primary care. 2010 , 25, 261-9	1
2188	Glycaemic control in type 2 diabetes: targets and new therapies. 2010 , 125, 328-61	130
2187	Diabetes and cancer: a consensus report. 2010 , 60, 207-21	593
2186	Assessment of efficacy and tolerability of once-daily extended release metformin in patients with type 2 diabetes mellitus. 2010 , 2, 16	21
2185	Could pre-diabetes be considered a clinical condition? opinions from an endocrinologist and a cardiologist. 2010 , 2, 2	8
2184	Algorithm for the treatment of type 2 diabetes: a position statement of Brazilian Diabetes Society. 2010 , 2, 35	12

2183	Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. 2010 , 30, 463-84	103
2182	Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects. 2010 , 30, 609-24	43
2181	A small-molecule glucokinase activator lowers blood glucose in the sulfonylurea-desensitized rat. 2010 , 640, 250-6	15
2180	Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification trial. 2010 , 32, 1756-67	34
2179	A retrospective cohort study of economic outcomes and adherence to monotherapy with metformin, pioglitazone, or a sulfonylurea among patients with type 2 diabetes mellitus in the United States from 2003 to 2005. 2010 , 32, 1308-19	48
2178	Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States. 2010 , 32, 1756-67	15
2177	[What has changed in the therapeutic strategy for type 2 diabetes mellitus?]. 2010 , 210 Suppl 1, 18-25	
2176	[Current clinical practice guidelines in type 2 diabetes: how should they be applied in primary care?]. 2010 , 42 Suppl 1, 9-15	
2175	[Panorama of currently available treatments for patients with type 2 diabetes. The ADA/EASD treatment algorithm. Safety and tolerability]. 2010 , 42 Suppl 1, 24-32	
2174	The association between C-reactive protein levels and insulin therapy in obese vs nonobese veterans with type 2 diabetes mellitus. 2010 , 12, 462-8	3
2173	Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. 2010 , 26, 287-96	198
2172	The A1C and ABCD of glycaemia management in type 2 diabetes: a physician's personalized approach. 2010 , 26, 239-44	90
2171	Type 2 diabetes mellitus and obesity in sub-Saharan Africa. 2010 , 26, 433-45	55
2170	Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. 2010 , 26, 540-9	143
2169	Simple pharmacometric tools for oral anti-diabetic drug development: competitive landscape for oral non-insulin therapies in type 2 diabetes. 2010 , 31, 162-77	15
2168	Discovery of carmegliptin: a potent and long-acting dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. 2010 , 20, 1109-13	45
2167	The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials. 2010 , 10, 183	49
2166	Inadequate glucose control in type 2 diabetes is associated with impaired lung function and systemic inflammation: a cross-sectional study. 2010 , 10, 38	50

2165	Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis. 2010 , 10, 20	69
2164	Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors. 2010 , 9, 45	36
2163	Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention--a retrospective nationwide cohort study. 2010 , 9, 54	50
2162	An aqueous extract of <i>Curcuma longa</i> (turmeric) rhizomes stimulates insulin release and mimics insulin action on tissues involved in glucose homeostasis in vitro. 2011 , 25, 396-401	24
2161	Splenectomy and thrombosis: the case of thalassemia intermedia. 2010 , 8, 2152-8	94
2160	Agents for the treatment of diabetes mellitus. 2010 , 23, 475-9	3
2159	Comparing the actions of older and newer therapies on body weight: to what extent should these effects guide the selection of antidiabetic therapy?. 2010 , 64, 791-801	23
2158	How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes. 2010 , 64, 1415-24	43
2157	Clinical experience with liraglutide. 2010 , 64, 44-8	4
2156	Liraglutide: effects beyond glycaemic control in diabetes treatment. 2010 , 64, 28-34	11
2155	Glycaemic control with liraglutide: the phase 3 trial programme. 2010 , 64, 21-7	9
2154	Liraglutide: can it make a difference in the treatment of type 2 diabetes?. 2010 , 64, 1-3	1
2153	Liraglutide in clinical practice: dosing, safety and efficacy. 2010 , 64, 35-43	29
2152	Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. 2010 , 64, 1619-31	137
2151	A comparison of intermediate and long-acting insulins in people with type 2 diabetes starting insulin: an observational database study. 2010 , 64, 1609-18	32
2150	Emerging treatment options for type 2 diabetes. 2010 , 70, 631-44	42
2149	Determinants of female sexual dysfunction in type 2 diabetes. 2010 , 22, 179-84	112
2148	Liraglutide. 2010 , 9, 267-8	120

2147	Future perspectives for insulinotropic agents in the treatment of type 2 diabetes-DPP-4 inhibitors and sulphonylureas. <i>Diabetes, Obesity and Metabolism</i> , 2010 , 12, 1-11	6.7	36
2146	Analysis of glycaemic control and weight change in patients initiated with human or analog insulin in an US ambulatory care setting. <i>Diabetes, Obesity and Metabolism</i> , 2010 , 12, 54-64	6.7	8
2145	Oral insulin - a review of current status. <i>Diabetes, Obesity and Metabolism</i> , 2010 , 12, 179-85	6.7	95
2144	Diabetes and obesity: therapeutic targeting and risk reduction - a complex interplay. <i>Diabetes, Obesity and Metabolism</i> , 2010 , 12, 267-87	6.7	63
2143	Obesity does not influence the unique pharmacological properties of different biphasic insulin aspart preparations in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2010 , 12, 414-20	6.7	5
2142	Understanding the inter-relationship between improved glycaemic control, hypoglycaemia and weight change within a long-term economic model. <i>Diabetes, Obesity and Metabolism</i> , 2010 , 12, 431-6	6.7	28
2141	Glycaemic goals in patients with type 2 diabetes: current status, challenges and recent advances. <i>Diabetes, Obesity and Metabolism</i> , 2010 , 12, 474-84	6.7	21
2140	Taspoglutide, a novel human once-weekly analogue of glucagon-like peptide-1, improves glucose homeostasis and body weight in the Zucker diabetic fatty rat. <i>Diabetes, Obesity and Metabolism</i> , 2010 , 12, 674-82	6.7	12
2139	Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population. <i>Diabetes, Obesity and Metabolism</i> , 2010 , 12, 485-94	6.7	145
2138	Effect of insulin glargine on glycaemic control and weight in obese and non-obese people with type 2 diabetes: data from the AT.LANTUS trial. <i>Diabetes, Obesity and Metabolism</i> , 2010 , 12, 683-8	6.7	10
2137	Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2010 , 12, 716-21	6.7	104
2136	Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine. <i>Diabetes, Obesity and Metabolism</i> , 2010 , 12, 772-9	6.7	75
2135	Predictors of responders to insulin therapy at 1 year among adults with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2010 , 12, 865-70	6.7	19
2134	A review of treatment response in type 2 diabetes: assessing the role of patient heterogeneity. <i>Diabetes, Obesity and Metabolism</i> , 2010 , 12, 845-57	6.7	34
2133	A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin. <i>Diabetes, Obesity and Metabolism</i> , 2010 , 12, 1058-65	6.7	56
2132	In support of an early polypharmacy approach to the treatment of type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2010 , 12, 929-40	6.7	20
2131	Addition of insulin lispro protamine suspension or insulin glargine to oral type 2 diabetes regimens: a randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2010 , 12, 916-22	6.7	19
2130	Continuation versus discontinuation of insulin secretagogues when initiating insulin in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2010 , 12, 923-5	6.7	27

2129	Prandial-basal insulin regimens plus oral antihyperglycaemic agents to improve mealtime glycaemia: initiate and progressively advance insulin therapy in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2010 , 12, 967-75	6.7	30
2128	A randomized, treat-to-target trial comparing insulin lispro protamine suspension and insulin detemir in insulin-naïve patients with Type 2 diabetes. 2010 , 27, 181-8		30
2127	A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. 2010 , 27, 318-26		112
2126	Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. 2010 , 27, 309-17		158
2125	Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomized double-blind placebo-controlled study. 2010 , 27, 556-62		33
2124	Review: metformin: potential benefits and use in chronic kidney disease. 2010 , 15, 412-8		46
2123	Diabetes:. 75-82		
2122	Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy. 2010 , 2, 7-19		12
2121	Impact of data from recent clinical trials on strategies for treating patients with type 2 diabetes mellitus. 2010 , 6, 17-26		1
2120	Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies. 2010 , Volume 3, 227-242		3
2119	Role of saxagliptin as monotherapy or adjunct therapy in the treatment of type 2 diabetes. 2010 , 6, 233-7		11
2118	Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogs. 2010 , 2, 213-23		27
2117	Liraglutide Therapy for Type 2 Diabetes: Overcoming Unmet Needs. 2010 , 3, 764-781		18
2116	An evaluation of prefilled insulin pens: a focus on the Next Generation FlexPen(4). 2010 , 3, 41-50		4
2115	[Characterization of patients with type 1 diabetes mellitus in southern Brazil: chronic complications and associated factors]. 2010 , 56, 67-73		16
2114	Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk. 2010 , 6, 145-55		59
2113	Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus. 2010 , Volume 3, 49-53		2
2112	Repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update. 2010 , Volume 3, 145-154		2

2111	Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin. 2010 , Volume 3, 31-41	14
2110	Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience. 2010 , 6, 541-8	80
2109	Saxagliptin for type 2 diabetes. 2010 , Volume 3, 325-335	3
2108	Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes. 2010 , Volume 3, 215-226	20
2107	Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes. 2010 , Volume 3, 363-372	4
2106	Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus. 2010 , 5, 23-37	19
2105	Incretins and the specific mechanism of action of liraglutide, the first applicable human glucagon-like peptide 1 analog in the treatment of type 2 diabetes. 2010 , 105	
2104	Impact of race/ethnicity on the efficacy and safety of commonly used insulin regimens: a post hoc analysis of clinical trials in type 2 diabetes mellitus. 2010 , 16, 818-28	27
2103	Comments on the AACE/ACE statement on glycemic control for patients with type 2 diabetes mellitus. 2010 , 16, 130-1; author reply 131-2	1
2102	Abstracts of the 19th Annual Meeting and Clinical Congress of the American Association of Clinical Endocrinologists. April 21-25, 2010. Boston, Massachusetts, USA. 2010 , 16 Suppl 2, 1-49	1
2101	An update on the treatment of type 1 and type 2 diabetes mellitus: focus on insulin detemir, a long-acting human insulin analog. 2010 , 6, 399-410	21
2100	Is liraglutide a useful addition to diabetes therapy?. 2010 , 16, 1028-37	2
2099	Concomitant therapy with pioglitazone and insulin for the treatment of type 2 diabetes. 2010 , 6, 189-97	13
2098	Metformin use and mortality among patients with diabetes and atherothrombosis. 2010 , 170, 1892-9	252
2097	Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. 2010 , 303, 1410-8	370
2096	Current developments in the treatment of diabetes: the incretin therapies. 2010 , 10, 21-30	1
2095	Albiglutide: a new GLP-1 analog for the treatment of type 2 diabetes. 2010 , 10, 801-6	46
2094	Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. <i>Diabetes Care</i> , 2010 , 33, 1173-5	14.6 164

2093	Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation. 2010 , 121, 1868-77		94
2092	Review: Saxagliptin: a review. 2010 , 10, 14-20		2
2091	A new look at established therapies: practical tools for optimizing insulin use. 2010 , 36 Suppl 2, 26S-38S; quiz 39S-40S		4
2090	Secondary failure of metformin monotherapy in clinical practice. <i>Diabetes Care</i> , 2010 , 33, 501-6	14.6	133
2089	Intensive glucose control in the management of diabetes mellitus and inpatient hyperglycemia. 2010 , 67, 798-805		20
2088	Mitiglinide: a novel agent for the treatment of type 2 diabetes mellitus. 2010 , 44, 1615-23		13
2087	Medications. 2010 , 26, 193-213		
2086	Barriers to achieving glycemic targets: who omits insulin and why?. <i>Diabetes Care</i> , 2010 , 33, 450-2	14.6	33
2085	Can postprandial blood glucose excursion be predicted in type 2 diabetes?. <i>Diabetes Care</i> , 2010 , 33, 1913-14	14.6	15
2084	Insulin usage in type 2 diabetes mellitus patients in UK clinical practice: a retrospective cohort-based analysis using the THIN database. 2010 , 10, 178-182		9
2083	Correct use of a new reusable insulin injection pen by patients with diabetes: a design validation study. 2010 , 4, 1229-35		7
2082	Saxagliptin: a new dipeptidyl peptidase 4 inhibitor for type 2 diabetes. 2010 , 44, 1046-53		15
2081	Prevalence of diabetes complications in first line therapy of type 2 diabetes mellitus in a middle size town of Romania. 2010 , 6, 327-334		
2080	Therapeutics of diabetes mellitus: focus on insulin analogues and insulin pumps. 2010 , 2010, 178372		31
2079	Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. 2010 , 170, 1191-1201		425
2078	Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors. 2010 , 122, 71-80		39
2077	The rise and fall of rosiglitazone. 2010 , 31, 773-6		53
2076	Responding to an FDA warning--geographic variation in the use of rosiglitazone. 2010 , 363, 2081-4		62

2075	Insulin pump therapy in patients with type 2 diabetes safely improved glycemic control using a simple insulin dosing regimen. 2010 , 12, 627-33	49
2074	The role of bile acid sequestrants in the management of type 2 diabetes mellitus. 2010 , 8 Suppl 1, S15-21	4
2073	Insulin pump use in type 2 diabetes. 2010 , 12 Suppl 1, S17-21	39
2072	Evaluation of the potential for pharmacokinetic and pharmacodynamic interactions between dutoglipatin, a novel DPP4 inhibitor, and metformin, in type 2 diabetic patients. 2010 , 26, 2003-10	4
2071	SGLT2 inhibitors: glucuretic treatment for type 2 diabetes. 2010 , 10, 193-199	24
2070	Novel therapeutics and targets for the treatment of diabetes. 2010 , 3, 209-29	16
2069	Loss-of-function CYP2C9 variants: finding the correct clinical role for Type 2 diabetes pharmacogenetic testing. 2010 , 8, 339-43	5
2068	Effect of technosphere inhaled insulin on quality of life and treatment satisfaction. 2010 , 12, 49-55	25
2067	Considerations in insulin delivery device selection. 2010 , 12 Suppl 1, S98-S100	4
2066	Pioglitazone: beyond glucose control. 2010 , 8, 1057-67	13
2065	The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes--a comprehensive review. 2010 , 12, 11-24	29
2064	Healthcare utilization changes in relation to treatment intensification with insulin aspart in patients with type 2 diabetes. Data from a large US managed-care organization. 2010 , 13, 16-22	14
2063	Initial nonadherence, primary failure and therapeutic success of metformin monotherapy in clinical practice. 2010 , 26, 2127-35	35
2062	An analysis of dosing equivalence of insulin detemir and insulin glargine: more evidence?. 2010 , 4, 155-7	1
2061	Predictors of initiating rapid-acting insulin analog using vial/syringe, prefilled pen, and reusable pen devices in patients with type 2 diabetes. 2010 , 4, 547-57	4
2060	DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. <i>Diabetes Care</i> , 2010 , 33, 1255-61	14.6 274
2059	Saxagliptin: a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus. 2010 , 67, 1515-25	23
2058	Effect of ranolazine on A1C and glucose levels in hyperglycemic patients with non-ST elevation acute coronary syndrome. <i>Diabetes Care</i> , 2010 , 33, 1163-8	14.6 60

2057	Diabetes and cancer: a consensus report. <i>Diabetes Care</i> , 2010 , 33, 1674-85	14.6	1251
2056	The role of bile acid sequestrants in the management of type 2 diabetes mellitus: summary and future directions. 2010 , 8 Suppl 1, S23-4		
2055	Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. 2010 , 115, 1886-92		258
2054	New perspectives in type 2 diabetes, cardiovascular risk, and treatment goals. 2010 , 122, 52-60		16
2053	Saxagliptin for type 2 diabetes. 2010 , 3, 325-35		3
2052	Choice within sulfonylurea drugs in ischemic heart disease patients. 2010 , 30, 172		
2051	Correlates of insulin injection omission. <i>Diabetes Care</i> , 2010 , 33, 240-5	14.6	278
2050	Use of concentrated insulin human regular (U-500) for patients with diabetes. 2010 , 67, 1526-35		45
2049	Effects of lifestyle measures, antiobesity agents, and bariatric surgery on serological markers of inflammation in obese patients. 2010 , 2010, 364957		22
2048	The painful truth. 2010 , 31, 1284-5		0
2047	Society for Ambulatory Anesthesia consensus statement on perioperative blood glucose management in diabetic patients undergoing ambulatory surgery. 2010 , 111, 1378-87		179
2046	Women and research on cardiovascular diseases in Europe: a report from the European Heart Health Strategy (EuroHeart) project. 2010 , 31, 1677-1681		46
2045	Can therapies that target the incretin system improve our ability to treat type 2 diabetes?. 2010 , 102, 511-23		5
2044	Liraglutide for type 2 diabetes?. 2010 , 48, 50-3		
2043	Therapeutic options that provide glycemic control and weight loss for patients with type 2 diabetes. 2010 , 122, 172-83		7
2042	How to obtain appropriate type 2 diabetes control in the first 180 days of treatment initiation. 2010 , 122, 33-42		3
2041	Overcoming challenges in Type 2 diabetes management to improve patient outcomes. 2010 , 5, 741-751		1
2040	Diabetes: intensive glucose-lowering therapy-weighing up the evidence. 2010 , 6, 9-10		

2039	Delivering the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cost effectiveness analysis. 2010 , 341, c4093	138
2038	Exenatide is non-inferior to insulin in reducing HbA1c: an integrated analysis of 1423 patients with type 2 diabetes. 2010 , 122, 118-28	26
2037	Effective switch from premixed to basal-prandial insulin to achieve glycemic goals in type 2 diabetes. 2010 , 122, 28-32	
2036	Managing highly insulin-resistant diabetes mellitus: weight loss approaches and medical management. 2010 , 122, 163-71	9
2035	Targeting beta-cell function early in the course of therapy for type 2 diabetes mellitus. 2010 , 95, 4206-16	86
2034	The relationship between peroxisome proliferator-activated receptor-gamma and renin: a human genetics study. 2010 , 95, E75-9	8
2033	Reaching HbA1c goals with saxagliptin in combination with other oral antidiabetic drugs. 2010 , 122, 144-52	12
2032	Comparing insulins detemir and glargine in type 2 diabetes: more similarities than differences. Commentary. 2010 , 122, 201-3	4
2031	Partnering with patients to improve therapeutic outcomes: incretin-based therapy for type 2 diabetes. 2010 , 122, 7-15	90
2030	A review of the response to oral antidiabetes agents in patients with type 2 diabetes. 2010 , 122, 43-51	7
2029	Type 2 diabetes: an expanded view of pathophysiology and therapy. 2010 , 122, 145-57	25
2028	The many faces of type 2 diabetes. 2010 , 122, 218-23	
2027	Which insulin, regimen and device in type 2 diabetes?. 2010 , 48, 134-8	1
2026	IMPROVE—observational study of biphasic insulin aspart 30/70 in patients with Type 2 diabetes mellitus. 2010 , 5, 507-516	5
2025	Successes and challenges of insulin therapy for type 2 diabetes in a managed-care setting. 2010 , 26, 9-15	13
2024	Pramlintide for diabetes mellitus. 2010 ,	
2023	Analyse critique du consensus ADA/EASD 2009 : «Back to the past and lost in translation»Critical analysis of the 2009 ADA/EASD consensus statement: Back to the past and lost in translation. 2010 , 4, 191-196	1
2022	Metformina y acidosis láctica: ¿asociación infrecuente o causalidad?. 2010 , 26, 273-275	1

2021 Respuesta de la Dra. Lourdes del Santo Mora. **2010**, 26, 261-264

2020 Respuesta del Dr. Alfredo Michñ Doâ. **2010**, 26, 56-58

2019 Respuesta del Dr. Marcos Lahera Vargas. **2010**, 26, 366-369

2018 Les thrapeutiques hypoglychmiantes en association avec lânsuline dans le diabpe de type 2 :
lesquelles sont souhaitables, facultatives ou peu conseillès?. **2010**, 4, 448-455 1

2017 Influence of glycemic control on the development of diabetic cardiovascular and kidney disease.
2010, 28, 497-516 6

2016 Respuesta del Dr. Juan Carlos Obaya Rebollar. **2010**, 26, 120-122

2015 Incretin-based therapy in chronic kidney disease. **2010**, 17, 439-49 5

2014 Incretins: clinical perspectives, relevance, and applications for the primary care physician in the
treatment of patients with type 2 diabetes mellitus. **2010**, 85, S38-49 14

2013 Incorporating incretin-based therapies into clinical practice: differences between glucagon-like
Peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors. **2010**, 85, S27-37 39

2012 Respuesta del Dr. Manuel Delgado Gñez. **2010**, 26, 440-444

2011 Respuesta del Dr. Esteban Jðar. **2010**, 26, 122-124 1

2010 Recomendaciones para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2.
2010, 26, 331-338 24

2009 Implementaciñ de la estrategia basal plus en la prãtica clñica. **2010**, 26, 339-346 7

2008 Defining and achieving treatment success in patients with type 2 diabetes mellitus. **2010**, 85, S50-9 29

2007 Respuesta del Dr. Francisco Endrino Gñez. **2010**, 26, 53-56

2006 A physiologic and pharmacological basis for implementation of incretin hormones in the treatment
of type 2 diabetes mellitus. **2010**, 85, S5-S14 16

2005 Aspectos prãcticos en la insulinizaciñ del paciente anciano con diabetes. **2010**, 26, 320-325

2004 Glycemic control and weight reduction without causing hypoglycemia: the case for continued safe
aggressive care of patients with type 2 diabetes mellitus and avoidance of therapeutic inertia. **2010**
, 85, S15-26 20

2003 Respuesta del Dr. Juan Jos^oChillar^o Jord^o. **2010**, 26, 265-267

2002 Prise en charge du diab^ote au Maroc : r^osultats de lâInternational Diabetes Management Practices Study (IDMPS) âWague 2: Management of diabetes in Morocco: Results of the International Diabetes Management Practices Study (IDMPS) âWave 2. **2010**, 4, 704-711

8

2001 Respuesta de la Dra. M.a Dolores Prieto Rivas. **2010**, 26, 437-440

2000 The role of glimepiride in the treatment of type 2 diabetes mellitus. **2010**, 6, 225-35

24

1999 Cardiotoxicity Associated with Thiazolidinediones. **2010**, 403-411

1

1998 Non-Insulin Parenteral Therapies. **2010**, 478-493

1

1997 [Evaluation of metabolic control targets in patients with type 2 diabetes mellitus]. **2010**, 57, 434-9

13

1996 [The history of rosiglitazone: key messages]. **2010**, 57, 401-6

0

1995 Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College Of Cardiology Foundation. **2010**, 55, 1885-94

47

1994 The future use of liraglutide: implications of the LEAD-2 study for treatment guidelines in type 2 diabetes. *Primary Care Diabetes*, **2010**, 4, 139-44

2.4

1993 Obesity and diabetes: the links and common approaches. *Primary Care Diabetes*, **2010**, 4, 105-12

2.4

25

1992 Insulin: a new era for an old hormone. **2010**, 61, 1-4

17

1991 Diabetes medications related to an increased risk of falls and fall-related morbidity in the elderly. **2010**, 44, 712-7

98

1990 Starting insulin therapy with basal insulin analog or premix insulin analog in T2DM: a pooled analysis of treat-to-target trials. **2010**, 26, 1621-8

20

1989 Dipeptidyl Peptidase IV Inhibitors for the Treatment of Type 2 Diabetes. **2010**, 107-134

1988 Sitagliptin: a review of its use in the management of type 2 diabetes mellitus. **2010**, 70, 489-512

75

1987 Alogliptin: a review of its use in the management of type 2 diabetes mellitus. **2010**, 70, 2051-72

46

1986 Vildagliptin: a review of its use in type 2 diabetes mellitus. **2010**, 70, 2089-112

62

1985	Benefit-risk assessment of exenatide in the therapy of type 2 diabetes mellitus. 2010 , 33, 87-100	19
1984	Adherence to a fixed-dose combination of rosiglitazone/glimepiride in subjects switching from monotherapy or dual therapy with a thiazolidinedione and/or a sulfonylurea. 2010 , 44, 791-9	34
1983	L'esercizio fisico come terapia del diabete di tipo 2. 2010 , 11, 45-53	
1982	Managing impaired glucose metabolism in acromegalic subjects. <i>Journal of Endocrinological Investigation</i> , 2010 , 33, 71	5.2
1981	A Potent and Selective AMPK Activator That Inhibits de Novo Lipogenesis. 2010 , 1, 478-82	66
1980	Determinants of erectile dysfunction in type 2 diabetes. 2010 , 22, 204-9	112
1979	Tagatose: from a sweetener to a new diabetic medication?. 2010 , 19, 285-94	40
1978	Selected compounds derived from Moutan Cortex stimulated glucose uptake and glycogen synthesis via AMPK activation in human HepG2 cells. 2010 , 131, 417-24	43
1977	[Treatment guidelines for hyperglycaemia in type 2 diabetes patients with stable chronic heart failure or ischemic cardiomyopathy without heart failure]. 2010 , 134, 596-9	2
1976	Effects of insulin initiation on patient-reported outcomes in patients with type 2 diabetes: results from the durable trial. 2010 , 89, 157-66	11
1975	Metformin treatment for Type 2 diabetes in pregnancy?. 2010 , 24, 625-34	22
1974	Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes. 2010 , 123, 468.e9-17	75
1973	Current antihyperglycemic treatment guidelines and algorithms for patients with type 2 diabetes mellitus. 2010 , 123, S12-8	44
1972	Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is going. 2010 , 123, S38-48	87
1971	Confronting the type 2 diabetes epidemic: the emerging role of incretin-based therapies. 2010 , 123, S2-S10	26
1970	Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors. 2010 , 8, 405-18	66
1969	GIP and GLP-1, the two incretin hormones: Similarities and differences. 2010 , 1, 8-23	330
1968	GPR119 agonists for the potential treatment of type 2 diabetes and related metabolic disorders. 2010 , 84, 415-48	37

1967	In search of the holy grail? The quest to reduce macrovascular disease in type 2 diabetes mellitus. 2010 , 5, 2-6		
1966	Old age may not be a contraindication to the use of metformin. 2010 , 73, 615-6	1	
1965	[Clinical practice guidelines in type 2 diabetes mellitus: similarities and discrepancies]. 2010 , 135 Suppl 2, 6-8	2	
1964	[Management of type 2 diabetes: from guidelines to clinical practice]. 2010 , 135 Suppl 2, 9-14	0	
1963	[Assessment of glycemic control: new insights into the evaluation of the diabetic patient]. 2010 , 135 Suppl 2, 15-9	1	
1962	[Safety and tolerability of oral antidiabetes drugs in the treatment of type 2 diabetes mellitus]. 2010 , 135 Suppl 2, 20-6	0	
1961	[Therapeutic behavior to follow in the following clinical case: treatment of type 2 diabetes]. 2010 , 210, 23-7	0	
1960	Añadir glitazonas. Dra. Lourdes Mateos. 2010 , 210, 24-25		
1959	Añadir incretina miméticos. Dr. J. Herraiz García. 2010 , 210, 25-26	0	
1958	Añadir insulina de acción lenta. Dr. J.A. Martín Oterino. 2010 , 210, 26-27		
1957	Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. 2010 , 375, 1365-74	188	
1956	Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. 2010 , 375, 1447-56	485	
1955	Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. 2010 , 375, 2234-43	365	
1954	Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. 2010 , 376, 431-9	503	
1953	Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms. 2010 , 8, 359-72	81	
1952	Standards of medical care in diabetes--2010. <i>Diabetes Care</i> , 2010 , 33 Suppl 1, S11-61	14.6	2438
1951	Rethink Organization to iMprove Education and Outcomes (ROMEO): a multicenter randomized trial of lifestyle intervention by group care to manage type 2 diabetes. <i>Diabetes Care</i> , 2010 , 33, 745-7	14.6	117
1950	Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. <i>Diabetes Care</i> , 2010 , 33, 428-33	14.6	232

1949	Comparativa entre los diversos tratamientos de la hiperglucemia: estrategias para minimizar la ganancia ponderal en la diabetes tipo 2. 2010 , 26, 156-160	1
1948	Diabetes: Individualized therapy for diabetes mellitus--just a promise?. 2010 , 6, 426-7	
1947	Premature cardiovascular events and mortality in south Asians with type 2 diabetes in the United Kingdom Asian Diabetes Study - effect of ethnicity on risk. 2010 , 26, 1873-9	57
1946	Insulin pen use for type 2 diabetes--a clinical perspective. 2010 , 12 Suppl 1, S86-90	7
1945	Health economics and compliance of vials/syringes versus pen devices: a review of the evidence. 2010 , 12 Suppl 1, S101-8	66
1944	Differences between long-acting insulins for the treatment of type 2 diabetes. 2010 , 11, 2027-35	18
1943	[New clinical data with metformin therapy in patients with diabetes mellitus]. 2010 , 151, 2025-30	1
1942	Reusable and disposable insulin pens for the treatment of diabetes: understanding the global differences in user preference and an evaluation of inpatient insulin pen use. 2010 , 12 Suppl 1, S79-85	48
1941	Management of Global Cardiovascular Risk in Older Subjects with Diabetes Mellitus. 2010 , 17, 53-58	
1940	Saxagliptin: a guide to its use in type 2 diabetes mellitus. 2010 , 26, 5-8	
1939	Is insulin treatment a first-line defense against Type 2 diabetes?. 2010 , 8, 483-5	2
1938	Cost-effectiveness of switching to biphasic insulin aspart from human premix insulin in a US setting. 2010 , 13, 212-20	14
1937	Metformin-induced lactic acidosis: no one left behind. 2011 , 15, 107	32
1936	Pharmacogenetics in type 2 diabetes: potential implications for clinical practice. 2011 , 3, 76	22
1935	Exenatide once-weekly clinical development: safety and efficacy across a range of background therapies. 2011 , 13, 1063-9	20
1934	Special considerations for treatment of type 2 diabetes mellitus in the elderly. 2011 , 68, 500-9	31
1933	Comparison of utilization, cost, adherence, and hypoglycemia in patients with type 2 diabetes initiating rapid-acting insulin analog with prefilled pen versus vial/syringe. 2011 , 14, 75-86	23
1932	Adherence and persistence to a regimen of basal insulin in a pre-filled pen compared to vial/syringe in insulin-naïve patients with type 2 diabetes. 2011 , 27, 1709-17	39

1931 Spotlight on tesamorelin in HIV-associated lipodystrophy. **2011**, 25, 405-8

1930 Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials. **2011**, 11, 115-28 128

1929 Diabetes Drugs. **2011**, 25, 285-291

1928 Obesity and type 2 diabetes: what can be unified and what needs to be individualized?. *Diabetes Care*, **2011**, 34, 1424-30 14.6 168

1927 What options are available when considering starting insulin: premix or basal?. **2011**, 13 Suppl 1, S85-92 7

1926 Postprandial and basal glucose in type 2 diabetes: assessment and respective impacts. **2011**, 13 Suppl 1, S25-32 57

1925 Combining basal insulin analogs with glucagon-like peptide-1 mimetics. **2011**, 13, 873-81 14

1924 Rapid improvement of glycemic control in type 2 diabetes using weekly intensive multifactorial interventions: structured glucose monitoring, patient education, and adjustment of therapy-a randomized controlled trial. **2011**, 13, 997-1004 28

1923 Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. **2011**, 343, d4169 496

1922 New therapeutic algorithm of Type 2 diabetes: lights and shadows. *Journal of Endocrinological Investigation*, **2011**, 34, 65-8 5.2

1921 Multifactorial intervention in Type 2 diabetes: the promise of incretin-based therapies. *Journal of Endocrinological Investigation*, **2011**, 34, 69-77 5.2 18

1920 Which is the eligible patient to be treated with pioglitazone? The expert view. *Journal of Endocrinological Investigation*, **2011**, 34, 781-7 5.2 0

1919 Bariatric surgery: an IDF statement for obese Type 2 diabetes. **2011**, 7, 433-47 74

1918 A stepwise approach to insulin therapy in patients with type 2 diabetes mellitus and basal insulin treatment failure. **2011**, 17, 395-403 80

1917 Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US. **2011**, 27, 897-906 13

1916 Patient-reported outcomes in adults with type 2 diabetes using mealtime inhaled technosphere insulin and basal insulin versus premixed insulin. **2011**, 13, 1201-6 20

1915 Management of type 2 diabetes mellitus for general practitioners. **2011**, 16, 75-84

1914 Tailoring treatment for type 2 diabetes: Uncovering the HOW and NOW of GLP-1 receptor agonist therapy. **2011**, 3, 217-236 1

1913	Diabetes and insulin resistance in pediatric obesity. 2011 , 58, 1355-61, ix	31
1912	Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus. 2011 , 86, 444-56	84
1911	Medical management of the liver transplant recipient. 2011 , 15, 821-43	8
1910	Management of unmet needs in type 2 diabetes mellitus: the role of incretin agents. 2011 , 35, 518-27	3
1909	Status of hemoglobin A1c measurement and goals for improvement: from chaos to order for improving diabetes care. 2011 , 57, 205-14	212
1908	Diabetes Clinical Practice: Same Evidence-Based Medicine, Two Different Guidelines. 2011 , 35, 243-244	
1907	L'Éducation thérapeutique du patient diabétique, ou apprendre à gérer l'incertitude. 2011 , 5, 638-642	
1906	Diabète de type 2 après échec de multithérapie orale : critères décisionnels personnalisés pour l'intensification du traitement: Type 2 diabetes after failure of oral combination: Criteria for decision-making customized treatment scale. 2011 , 5, 625-632	2
1905	Sitagliptin/metformin fixed-dose combination: a guide to its use in type 2 diabetes mellitus. 2011 , 27, 1-5	
1904	The contribution of glucose variability to asymptomatic hypoglycemia in persons with type 2 diabetes. 2011 , 13, 813-8	118
1903	Recommendations for the pharmacological treatment of hyperglycemia in type 2 diabetes. 2011 , 58, 112-120	6
1902	Direct health care costs in patients with type 2 diabetes mellitus six months after starting insulin treatment in Spain: The INSTIGATE Study. 2011 , 58, 274-282	10
1901	Glucocentricity or adipocentricity: A critical view of consensus and clinical guidelines for the treatment of type 2 diabetes mellitus. 2011 , 58, 541-549	8
1900	[Recommendations for the pharmacological treatment of hyperglycemia in type 2 diabetes]. 2011 , 58, 112-20	9
1899	[Direct health care costs in patients with type 2 diabetes mellitus six months after starting insulin treatment in Spain: the INSTIGATE study]. 2011 , 58, 274-82	13
1898	[Glucocentricity or adipocentricity: a critical view of consensus and clinical guidelines for the treatment of type 2 diabetes mellitus]. 2011 , 58, 541-9	7
1897	AMP-activated protein kinase and metabolic control. 2011 , 303-30	81
1896	Type 2 Diabetes in Adults. 2011 , 77-137	3

1895	Incretin-based therapies and their future in Type 2 diabetes mellitus. 2011 , 8, 143-152		1
1894	Insulin detemir versus insulin glargine for type 2 diabetes mellitus. 2011 , CD006383		64
1893	Add-on therapies to metformin for type 2 diabetes. 2011 , 12, 47-62		14
1892	Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus. 2011 , 13, 1219-27		59
1891	Bariatric surgery to treat severely obese patients with type 2 diabetes: A consensus statement. 2011 , 5, e1-e78		7
1890	Bariatric surgery: An IDF statement for obese Type 2 diabetes. 2011 , 5, e169-266		5
1889	Initiation of biphasic insulin aspart 30/70 in subjects with type 2 diabetes mellitus in a largely primary care-based setting in Sweden. <i>Primary Care Diabetes</i> , 2011 , 5, 89-94	2.4	8
1888	[Future of glitazones]. 2011 , 137, 20-1		
1887	Emerging GLP-1 receptor agonists. 2011 , 16, 607-18		20
1886	Glucagon-like peptide-1 analogues for type 2 diabetes. 2011 , 342, d410		15
1885	Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. 2011 , 71, 1071-91		13
1884	Sitagliptin/metformin fixed-dose combination: in patients with type 2 diabetes mellitus. 2011 , 71, 349-61		18
1883	Linagliptin: in type 2 diabetes mellitus. 2011 , 71, 611-24		37
1882	Liraglutide: a review of its use in the management of type 2 diabetes mellitus. 2011 , 71, 2347-73		34
1881	Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. 2011 , 71, 1441-67		166
1880	Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents. 2011 , 71, 1675-88		63
1879	Strength training as a countermeasure to aging muscle and chronic disease. 2011 , 41, 289-306		105
1878	Sodium Glucose Cotransporter 2 Inhibitors. 2011 , 359-375		

1877	Sodium-glucose cotransporter 2 inhibitors in the treatment of Type 2 diabetes: a review of Phase II and III trials. 2011 , 1, 145-156	17
1876	Medical management of the patient with intermittent claudication. 2011 , 29, 363-79	10
1875	Pancreatogenic diabetes: special considerations for management. 2011 , 11, 279-94	156
1874	Glucagon-like peptide analogues for type 2 diabetes mellitus. 2011 , CD006423	101
1873	mTOR inhibitors in advanced renal cell carcinoma. 2011 , 25, 835-52	93
1872	Type 2 Diabetes, Pre-Diabetes, and the Metabolic Syndrome. 2011 ,	6
1871	The future of basal insulin supplementation. 2011 , 13 Suppl 1, S103-8	32
1870	Type 2 diabetes mellitus--current therapies and the emergence of surgical options. 2011 , 7, 408-19	53
1869	Pharmacological management of type 2 diabetes mellitus: an update. 2011 , 7, 392-405	54
1868	Pour accélérer et guider la décision thérapeutique dans le diabète de type 2 : HbA1c et profils glychmiques. En solo ou en duo?. 2011 , 5, 619-624	2
1867	Recomendaciones para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2. 2011 , 23, 40-48	
1866	Body mass index and health status in the Bypass Angioplasty Revascularization Investigation 2 Diabetes Trial (BARI 2D). 2011 , 162, 184-92.e3	5
1865	Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. 2011 , 124, S3-18	220
1864	Incretin-based therapies in complex patients: practical implications and opportunities for maximizing clinical outcomes: a discussion with Dr. Vivian A. Fonseca. 2011 , 124, S54-61	15
1863	Insulin therapy in the elderly patient with diabetes. 2011 , 9, 24-36	18
1862	Screening Hodgkin lymphoma survivors for radiotherapy induced cardiovascular disease. 2011 , 37, 391-403	47
1861	Treatment regimens with insulin analogues and haemoglobin A1c target of . 2011 , 92, 1-10	44
1860	Effect of pharmacist intervention on glycemic control in diabetes. 2011 , 92, 145-52	56

1859	Degree of control and delayed intensification of antihyperglycaemic treatment in type 2 diabetes mellitus patients in primary care in Spain. 2011 , 91, 108-14	27
1858	Self-reported experience of hypoglycemia among adults with type 2 diabetes mellitus (Exhype). 2011 , 92, 19-25	18
1857	GLP-1 receptor agonists today. 2011 , 93, 317-27	17
1856	Nateglinide and acarbose for postprandial glucose control after optimizing fasting glucose with insulin glargine in patients with type 2 diabetes. 2011 , 92, 322-8	29
1855	Antidiabetic prescribing trends and predictors of thiazolidinedione discontinuation following the 2007 rosiglitazone safety alert. 2011 , 93, 49-55	21
1854	Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide. 2011 , 93, e15-7	19
1853	Assessing the influences on therapeutic intensification in type 2 diabetes mellitus according to career stage. 2011 , 93, 385-9	
1852	Comparable long-term mortality risk associated with individual sulfonylureas in diabetes patients with heart failure. 2011 , 94, 119-25	18
1851	Effect of diagnosis-time and initial treatment on the onset of type 2 diabetes mellitus complications: a population-based representative cross-sectional study in Hungary. 2011 , 94, e65-7	6
1850	Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. 2011 , 47, 1287-98	118
1849	Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. <i>Diabetes Care</i> , 2011 , 34, 916-22	14.6 501
1848	Cohort study of pioglitazone and cancer incidence in patients with diabetes. <i>Diabetes Care</i> , 2011 , 34, 923-9	14.6 142
1847	Recommendations for insulin initiation based on ethnicity. 2011 , 77, 460-1	6
1846	Primary and secondary prevention strategy for cardiovascular disease in diabetes mellitus. 2011 , 29, 47-70	18
1845	Renal glucose reabsorption inhibitors to treat diabetes. 2011 , 32, 63-71	156
1844	Recomendaciones para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2. 2011 , 37, 74-82	1
1843	Efficacy and safety of patient-directed titration of once-daily pre-dinner premixed biphasic insulin aspart 70/30 injection in Japanese type 2 diabetic patients with oral antidiabetic drug failure: STEP-AKITA study. 2011 , 2, 63-70	1
1842	Prediction of near-future glycated hemoglobin levels using glycated albumin levels before and after treatment for diabetes. 2011 , 2, 304-9	18

1841	Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. <i>Diabetes, Obesity and Metabolism</i> , 2011 , 13, 160-8	6.7	120
1840	Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2011 , 13, 357-65	6.7	74
1839	Patient-reported outcomes are superior in patients with Type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomized, open-label study. 2011 , 28, 715-23		26
1838	Effect of Ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects. 2011 , 31, 839-51		51
1837	Association between glycosylated haemoglobin A(1c) and endothelial function in an adult non-diabetic population. 2011 , 217, 358-63		14
1836	Diet or diet plus physical activity versus usual care in patients with newly diagnosed type 2 diabetes: the Early ACTID randomised controlled trial. 2011 , 378, 129-39		206
1835	The Current Status of Exenatide Once Weekly. 2011 , 3, CMT.S3083		4
1834	Sitagliptin: A DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus. 2011 , 3, CMT.S6227		1
1833	Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases. 2011 , 5, 85-9		7
1832	Glycemic control and hypoglycemia in Veterans Health Administration patients converted from glyburide to glipizide. 2011 , 17, 664-71		12
1831	Beta-3 agonist-induced lipolysis and nitric oxide production: relationship to PPARGgamma agonist/antagonist and AMP kinase modulation. 2011 , 30, 90-9		9
1830	Focus on Type 2 Diabetes Comorbidities: Using Incretin-Based Therapies in Patients With Renal, Cardiovascular, and Hepatic Insufficiencies. 2011 , 17, 1-4		
1829	American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. 2011 , 17 Suppl 2, 1-53		329
1828	Concomitant oral antihyperglycemic agent use and associated treatment outcomes after initiation of insulin therapy. 2011 , 17, 563-7		5
1827	Management of type 2 diabetes mellitus in the elderly: role of the pharmacist in a multidisciplinary health care team. 2011 , 4, 149-54		11
1826	. 2011 ,		1
1825	Place in therapy for liraglutide and saxagliptin for type 2 diabetes. 2011 , 104, 426-39		1
1824	Respuesta al tratamiento periodontal de diabéticos tipo 2 con mal control metabólico y obesos intolerantes a la glucosa, con periodontitis severa. 2011 , 4, 50-53		

1823	Sitagliptin compared with thiazolidinediones as a third-line oral antihyperglycemic agent in type 2 diabetes mellitus. 2011 , 17, 691-8	4
1822	Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes. 2011 , 6, 67-79	45
1821	A New Therapy of Type 2 Diabetes: DPP-4 Inhibitors. 2011 ,	2
1820	Oral Antidiabetic Agents in Patients with Chronic Kidney Disease. 2011 , 12, 194	1
1819	Bariatric surgery: an IDF statement for obese Type 2 diabetes. 2011 , 55, 367-82	34
1818	Diabetes management: optimizing roles for nurses in insulin initiation. 2011 , 4, 15-24	9
1817	Insulin initiation and intensification in patients with T2DM for the primary care physician. 2011 , 4, 253-61	14
1816	Management of diabetes across the course of disease: minimizing obesity-associated complications. 2011 , 4, 353-69	6
1815	What do we really know about VBID? Quality of the evidence and ethical considerations for health plan sponsors. 2011 , 17, 156-74	4
1814	Parameters measuring beta-cell function are only valuable in diabetic subjects with low body mass index, high blood glucose level, or long-standing diabetes. 2011 , 52, 939-47	7
1813	Effectiveness of adding vildagliptin to the treatment of diabetic patients nonresponsive to the combination of metformin and a sulphonylurea. 2011 , 55, 260-5	2
1812	[Dipeptidyl-peptidase-4 inhibitors (gliptins): a new class of oral antidiabetic drugs]. 2011 , 152, 1471-6	0
1811	Weight considerations in pharmacotherapy for type 2 diabetes. 2011 , 2011,	21
1810	Treatment of severe diabetic hypoglycemia with glucagon: an underutilized therapeutic approach. 2011 , 4, 337-46	69
1809	Neuromuscular Manifestations of Acquired Metabolic, Endocrine, and Nutritional Disorders. 2011 , 373-393	
1808	Glucose Homeostasis âMechanism and Defects. 2011 ,	4
1807	Retrospective analysis and patient satisfaction assessment of insulin pump therapy in patients with type 2 diabetes. 2011 , 104, 24-8	12
1806	International Diabetes Center Treatment of Type 2 Diabetes Glucose Algorithm. 2011 , 1, 175-189	12

1805	Progression of type 2 diabetes and insulin initiation. 2011 , 103, 241-6	4
1804	Management of type 2 diabetes: more evidence is required to address the clinical and contextual facets. 2011 , 7, 99-105	2
1803	Type 2 diabetes, genomics, and nursing: necessary next steps to advance the science into improved, personalized care. 2011 , 29, 281-302	0
1802	Thiazolidinediones and type 2 diabetes: from cellular targets to cardiovascular benefit. 2011 , 12, 1498-512	12
1801	Long-acting insulin analogs: a review of "real-world" effectiveness in patients with type 2 diabetes. 2011 , 7, 61-74	17
1800	Respuesta al tratamiento periodontal de diabéticos tipo 2 con mal control metabólico y obesos intolerantes a la glucosa, con periodontitis severa. 2011 , 4, 50-53	
1799	Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis. 2011 , 154, 672-9	104
1798	Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. 2011 , 154, 602-13	386
1797	Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. 2011 , 154, 103-12	405
1796	The role of nanotechnology in diabetes treatment: current and future perspectives. 2011 , 8, 53	7
1795	Encounter frequency and serum glucose level, blood pressure, and cholesterol level control in patients with diabetes mellitus. 2011 , 171, 1542-50	69
1794	Detemir as a once-daily basal insulin in type 2 diabetes. 2011 , 3, 27-37	7
1793	Mild Renal Impairment and the Efficacy and Safety of Liraglutide. 2011 , 17, 345-355	45
1792	Rapid-acting insulin glulisine: an update on clinical experience. 2011 , 6, 527-542	3
1791	[Not Available]. 2011 , 153, 56-63	
1790	[Insulin therapy in type 2 diabetes]. 2011 , 153, 56-9, 61; quiz 62	
1789	Assessment of the pharmacokinetic interaction between the novel DPP-4 inhibitor linagliptin and a sulfonylurea, glyburide, in healthy subjects. 2011 , 26, 123-9	31
1788	Addressing cardiovascular risk in patients with type 2 diabetes: focus on primary care. 2011 , 341, 132-40	5

1787	Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. <i>Diabetes, Obesity and Metabolism</i> , 2011 , 13, 47-54	6.7	65
1786	Pharmacological management of type 2 diabetes: the potential of incretin-based therapies. <i>Diabetes, Obesity and Metabolism</i> , 2011 , 13, 99-117	6.7	30
1785	Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. <i>Diabetes, Obesity and Metabolism</i> , 2011 , 13, 65-74	6.7	247
1784	Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2011 , 13, 207-20	6.7	55
1783	The effect of pramlintide acetate on glycemic control and weight in patients with type 2 diabetes mellitus and in obese patients without diabetes: a systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2011 , 13, 169-80	6.7	51
1782	Comparative pharmacodynamic and pharmacokinetic characteristics of subcutaneous insulin glulisine and insulin aspart prior to a standard meal in obese subjects with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2011 , 13, 251-7	6.7	28
1781	Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. <i>Diabetes, Obesity and Metabolism</i> , 2011 , 13, 221-8	6.7	248
1780	Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2011 , 13, 268-75	6.7	47
1779	An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future. <i>Diabetes, Obesity and Metabolism</i> , 2011 , 13, 394-407	6.7	155
1778	Effects of pioglitazone versus metformin on circulating endothelial microparticles and progenitor cells in patients with newly diagnosed type 2 diabetes--a randomized controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2011 , 13, 439-45	6.7	52
1777	Dipeptidyl peptidase-4 inhibitors and HbA1c target of . <i>Diabetes, Obesity and Metabolism</i> , 2011 , 13, 594-603	6.7	82
1776	Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. <i>Diabetes, Obesity and Metabolism</i> , 2011 , 13, 567-76	6.7	75
1775	The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2011 , 13, 542-50	6.7	48
1774	The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2011 , 13, 644-52	6.7	68
1773	Treatment intensification in patients with type 2 diabetes who failed metformin monotherapy. <i>Diabetes, Obesity and Metabolism</i> , 2011 , 13, 765-9	6.7	56
1772	An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia. <i>Diabetes, Obesity and Metabolism</i> , 2011 , 13, 814-22	6.7	58
1771	Effects of insulin and other antihyperglycaemic agents on lipid profiles of patients with diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2011 , 13, 869-79	6.7	16
1770	Cardiovascular outcomes associated with a new once-weekly GLP-1 receptor agonist vs. traditional therapies for type 2 diabetes: a simulation analysis. <i>Diabetes, Obesity and Metabolism</i> , 2011 , 13, 921-7	6.7	13

1769	Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2011 , 13, 928-38	6.7	302
1768	Glucagon-like peptide-1 receptor agonists versus insulin in inadequately controlled patients with type 2 diabetes mellitus: a meta-analysis of clinical trials. <i>Diabetes, Obesity and Metabolism</i> , 2011 , 13, 972-81	6.7	26
1767	Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month 'proof-of-concept' study. <i>Diabetes, Obesity and Metabolism</i> , 2011 , 13, 1020-7	6.7	74
1766	Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study. <i>Diabetes, Obesity and Metabolism</i> , 2011 , 13, 1028-35	6.7	58
1765	Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study. <i>Diabetes, Obesity and Metabolism</i> , 2011 , 13, 1088-96	6.7	62
1764	Influence of preprandial vs. postprandial insulin glulisine on weight and glycaemic control in patients initiating basal-bolus regimen for type 2 diabetes: a multicenter, randomized, parallel, open-label study (NCT00135096). <i>Diabetes, Obesity and Metabolism</i> , 2011 , 13, 1142-8	6.7	16
1763	Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal-bolus therapies with insulin lispro in type 2 diabetes patients: a prospective randomized open-label trial. <i>Diabetes, Obesity and Metabolism</i> , 2011 , 13, 1149-57	6.7	11
1762	Relationship of baseline HbA1c and HbA1c reduction following insulin therapy in Type 2 diabetes. 2011 , 28, 247		1
1761	DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. 2011 , 28, 705-14		98
1760	Oral anti-diabetic drugs for the prevention of Type 2 diabetes. 2011 , 28, 948-64		23
1759	Bariatric surgery: an IDF statement for obese Type 2 diabetes. 2011 , 28, 628-42		332
1758	Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study. 2011 , 28, 1352-61		180
1757	Current and emerging antiglycaemic pharmacological therapies: the renal perspective. 2011 , 16, 468-75		8
1756	Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes. 2011 , 36, 260-74		8
1755	Patient adherence to medication requirements for therapy of type 2 diabetes. 2011 , 65, 314-22		165
1754	Relationship of baseline HbA1c, HbA1c change and HbA1c target of 2011, 65, 602-12		25
1753	One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. 2011 , 65, 397-407		197
1752	Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naïve patients with type 2 diabetes. 2011 , 65, 930-8		32

1751	A randomized, controlled trial on the effect of non-surgical periodontal therapy in patients with type 2 diabetes. Part I: effect on periodontal status and glycaemic control. 2011 , 38, 142-7	91
1750	Type 2 diabetes as an inflammatory disease. 2011 , 11, 98-107	2207
1749	BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. 2011 , 19, 800-5	94
1748	Increased mitochondrial oxidative phosphorylation in the liver is associated with obesity and insulin resistance. 2011 , 19, 917-24	28
1747	Effects of KCNQ1 polymorphisms on the therapeutic efficacy of oral antidiabetic drugs in Chinese patients with type 2 diabetes. 2011 , 89, 437-42	39
1746	Is there clear and convincing evidence of cardiovascular risk with rosiglitazone?. 2011 , 89, 773-6	5
1745	Analytical goals for HbA1c: are HbA1c results good enough for optimal use?. 2011 , 3, 3-6	4
1744	Metformin as an antitumor agent in cancer prevention and treatment. 2011 , 3, 320-7	53
1743	Self-monitoring of blood glucose: role in type 2 diabetes. 2011 , 3, 93-4	3
1742	First insulinization with basal insulin in patients with Type 2 diabetes in a real-world setting in Asia. 2011 , 3, 208-16	48
1741	Bariatric surgery for diabetes: the International Diabetes Federation takes a position. 2011 , 3, 261-4	34
1740	Update on incretin hormones. 2011 , 1243, E55-74	88
1739	Overcoming obstacles in risk factor management in type 2 diabetes mellitus. 2011 , 13, 613-20	17
1738	The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth. 2011 , 15, 825-36	62
1737	Health-related quality of life in adults with transfusion-independent thalassaemia intermedia compared to regularly transfused thalassaemia major: new insights. 2011 , 87, 73-9	28
1736	Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus. 2011 , 60, 52-6	30
1735	Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes. 2011 , 60, 1-23	203
1734	Medical Management of Type 2 Diabetes. 2011 , 7, 492-501	1

1733	Anti-diabetic effects including diabetic nephropathy of anti-osteoporotic trace minerals on diabetic mice. 2011 , 27, 488-95	13
1732	Impact of thiazolidinedione safety warnings on medication use patterns and glycemic control among veterans with diabetes mellitus. 2011 , 25, 143-50	16
1731	Multiple HbA1c targets and insulin analogues in type 2 diabetes: a systematic review. 2011 , 25, 275-81	15
1730	[Recommendations for the pharmacological treatment of hyperglycemia in type 2 diabetes]. 2011 , 211, 147-55	12
1729	Utilizaci3n de la insulina r3pida en situaciones de mal control de la diabetes. 2011 , 18, 89-93	
1728	Overview of the guidelines and evidence for the pharmacologic management of type 2 diabetes mellitus. 2011 , 31, 37S-43S	8
1727	Beyond metformin: initiating combination therapy in patients with type 2 diabetes mellitus. 2011 , 31, 44S-53S	13
1726	Intensifying treatment of type 2 diabetes mellitus: adding insulin. 2011 , 31, 54S-64S	2
1725	Managing special populations among patients with type 2 diabetes mellitus. 2011 , 31, 65S-72S	6
1724	A review of diabetes treatment adherence and the association with clinical and economic outcomes. 2011 , 33, 74-109	280
1723	Cardiovascular implications of antihyperglycemic therapies for type 2 diabetes. 2011 , 33, 393-407	24
1722	Evaluating treatment algorithms for the management of patients with type 2 diabetes mellitus: a perspective on the definition of treatment success. 2011 , 33, 408-24	22
1721	Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus. 2011 , 33, 511-27	70
1720	Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes. 2011 , 33, 665-78	47
1719	Review of the therapeutic uses of liraglutide. 2011 , 33, 793-811	29
1718	Saxagliptin: a clinical review in the treatment of type 2 diabetes mellitus. 2011 , 33, 1005-22	35
1717	Adherence to oral antidiabetic agents with pioglitazone and metformin: comparison of fixed-dose combination therapy with monotherapy and loose-dose combination therapy. 2011 , 33, 1281-8	16
1716	Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study. 2011 , 33, 1798-808	61

1715	Intensifying insulin therapy in type 2 diabetes mellitus: dosing options for insulin analogue premixes. 2011 , 33, 1630-42	7
1714	Tolerability and pharmacokinetics of lobeglitazone (CKD-501), a peroxisome proliferator-activated receptor- γ agonist: a single- and multiple-dose, double-blind, randomized control study in healthy male Korean subjects. 2011 , 33, 1819-30	33
1713	Tolerability of dipeptidyl peptidase-4 inhibitors: a review. 2011 , 33, 1609-29	57
1712	Efficacy and safety of prandial premixed therapy using insulin lispro mix 50/50 3 times daily compared with progressive titration of insulin lispro mix 75/25 or biphasic insulin aspart 70/30 twice daily in patients with type 2 diabetes mellitus: a randomized, 16-week, open-label study. 2011 , 33, 1400-08	15
1711	Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison. 2011 , 33, 1932-42	52
1710	Gly-Ala-Gly-Val-Gly-Tyr, a novel synthetic peptide, improves glucose transport and exerts beneficial lipid metabolic effects in 3T3-L1 adipocytes. 2011 , 650, 479-85	10
1709	Emerging therapeutic approaches for the management of diabetes mellitus and macrovascular complications. 2011 , 108, 59B-67B	16
1708	[Recommendations for the pharmacological treatment of hyperglycemia in type 2 diabetes]. 2011 , 43, 202.e1-9	9
1707	Targeting the AMP-regulated kinase family to treat diabetes: a research update. 2011 , 1, 333-347	
1706	Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective. 2011 , 12, 1161-91	53
1705	Lixisenatide for type 2 diabetes mellitus. 2011 , 20, 549-57	64
1704	Update on diagnosis, pathogenesis and management of ketosis-prone Type 2 diabetes mellitus. 2011 , 1, 589-600	48
1703	Effects of glucose-lowering drugs on body weight in type 2 diabetes. 2011 , 22, 32-42	
1702	Intensive glycaemic control in type 2 diabetes: where are we now?. 2011 , 22, 6-8	
1701	Metformin-related lactic acidosis in patients with acute kidney injury. 2011 , 43, 1243-8	11
1700	Oral antidiabetic drug therapy in type 2 diabetes mellitus - focus on elderly patients. 2011 , 161, 297-9	4
1699	Hemoglobin glycation rate constant in non-diabetic Individuals. 2011 , 39, 2721-34	12
1698	Non-diabetic hyperglycaemia and cardiovascular risk: moving beyond categorisation to individual interpretation of absolute risk. 2011 , 54, 291-9	11

1697	Glucose metabolism disorders and the risk of cancer. 2011 , 59, 215-30	20
1696	Multiple outcomes associated with the use of metformin and sulphonylureas in type 2 diabetes: a population-based cohort study in Italy. 2011 , 67, 289-99	25
1695	Basalog ⁴ is similar to Lantus ⁴ in producing glycemic control in patients with type 1 diabetes mellitus on multiple daily insulin regimens. 2011 , 31, 26-31	15
1694	Comparing the efficacy, safety, and utility of intensive insulin algorithms for a primary care practice. 2011 , 2, 40-50	3
1693	Enhanced glycemic control with combination therapy for type 2 diabetes in primary care. 2011 , 2, 162-77	10
1692	Addition of sitagliptin to ongoing glimepiride therapy in Japanese patients with type 2 diabetes over 52 weeks leads to improved glycemic control. 2011 , 2, 32-44	34
1691	Long-term safety, tolerability, and efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes. 2011 , 2, 94-105	9
1690	Ipragliflozin (ASP1941), a selective sodium-dependent glucose cotransporter 2 inhibitor, safely stimulates urinary glucose excretion without inducing hypoglycemia in healthy Japanese subjects. 2011 , 2, 172-182	30
1689	State variation in AIDS drug assistance program prescription drug coverage for modifiable cardiovascular risk factors. 2011 , 26, 1426-33	6
1688	Does metformin work for everyone? A genome-wide association study for metformin response. 2011 , 11, 467-9	7
1687	Sulfonylureas or dipeptidyl peptidase (DPP-4) inhibitors in the management of type 2 diabetes: debate is not yet closed. 2011 , 11, 461-2; author reply 463	1
1686	Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. 2011 , 11, 20	336
1685	Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years. 2011 , 11, 9	56
1684	Temporal trends in the initiation of glucose-lowering medications after a first-time myocardial infarction - a nationwide study between 1997 and 2006. 2011 , 10, 5	3
1683	Carbohydrate restricted diet in conjunction with metformin and liraglutide is an effective treatment in patients with deteriorated type 2 diabetes mellitus: Proof-of-concept study. 2011 , 8, 92	10
1682	Psychological insulin resistance: a critical review of the literature. 2011 , 28, 125-128d	27
1681	Long term patterns of use after initiation of oral antidiabetic drug therapy. 2011 , 20, 351-8	11
1680	Drug use among persons with Type 2 diabetes mellitus prior to diagnosis in Belgium. 2011 , 20, 1001-3	1

1679	The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review. 2011 , 27, 528-42	75
1678	Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. 2011 , 21, 3809-12	41
1677	What to add in with metformin in type 2 diabetes?. 2011 , 104, 185-92	12
1676	Healthcare resource utilization and costs assessment of type 2 diabetes patients initiating exenatide BID or glargine: a retrospective database analysis. 2011 , 14, 16-27	11
1675	Current understanding of K ATP channels in neonatal diseases: focus on insulin secretion disorders. 2011 , 32, 765-80	19
1674	The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors. 2011 , 123, 189-201	25
1673	Association between glycemic control and short-term healthcare costs among commercially insured diabetes patients in the United States. 2011 , 14, 108-14	29
1672	Cost-effectiveness of insulin detemir: a systematic review. 2011 , 11, 641-55	6
1671	A new approach to glucose control in type 2 diabetes: the role of kidney sodium-glucose co-transporter 2 inhibition. 2011 , 123, 38-45	7
1670	Type 2 diabetes mellitus and renal impairment in a large outpatient electronic medical records database: rates of diagnosis and antihyperglycemic medication dose adjustment. 2011 , 123, 133-43	52
1669	Bombesin receptor subtype-3 (BRS-3) regulates glucose-stimulated insulin secretion in pancreatic islets across multiple species. 2011 , 152, 4106-15	38
1668	Exercise in the management of type 2 diabetes mellitus: what are the benefits and how does it work?. 2011 , 39, 98-106	17
1667	A Dose-Ranging Study of the DPP-IV Inhibitor PF-734200 Added to Metformin in Subjects With Type 2 Diabetes*. 2011 , 119, 401-7	6
1666	Basal insulin: physiology, pharmacology, and clinical implications. 2011 , 123, 17-26	31
1665	Utilizing current diagnostic criteria and treatment algorithms for managing type 2 diabetes mellitus. 2011 , 123, 54-62	7
1664	Next-generation GLP-1 therapy: an introduction to liraglutide. 2011 , 123, 239-47	3
1663	Clinical and economic outcomes in patients with type 2 diabetes initiating insulin glargine disposable pen versus exenatide BID. 2011 , 14, 673-80	22
1662	The GetGoal clinical trial program of lixisenatide, a once-daily GLP-1 receptor agonist. 2011 , 6, 513-525	5

1661	Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes. 2011 , 123, 63-70	13
1660	Control of postprandial glucose levels with insulin in type 2 diabetes. 2011 , 123, 135-47	19
1659	Hypoglycemic agents in the management of type 2 diabetes mellitus. 2011 , 5, 66-73	14
1658	Dipeptidyl peptidase-4 inhibition: linking chemical properties to clinical safety. 2011 , 18, 4753-60	14
1657	Insulin administration: selecting the appropriate needle and individualizing the injection technique. 2011 , 8, 1395-406	21
1656	International Forum for the Advancement of Diabetes Research and Care, April 29-30, 2011, Athens, Greece. 2011 , 13, 967-79	3
1655	How basal insulin analogs have changed diabetes care. 2011 , 13 Suppl 1, S1-4	3
1654	Basal plus basal-bolus approach in type 2 diabetes. 2011 , 13 Suppl 1, S75-83	15
1653	Effect of exenatide on fat deposition and a metabolic profile in patients with metabolic syndrome. 2011 , 9, 31-4	9
1652	Use of metformin in the setting of mild-to-moderate renal insufficiency. <i>Diabetes Care</i> , 2011 , 34, 1431-7 14.6	304
1651	GLP-1 receptor agonists and HBA1c target of . 2011 , 27, 1519-28	37
1650	Randomized study of repaglinide alone and in combination with metformin in Chinese subjects with type 2 diabetes naive to oral antidiabetes therapy. 2011 , 12, 2791-9	8
1649	Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. <i>Diabetes Care</i> , 2011 , 34, 2015-22	14.6 404
1648	Dedicated ent-kaurene and ent-atiserene synthases for platensimycin and platencin biosynthesis. 2011 , 108, 13498-503	109
1647	Design of a decision support system to help clinicians manage glycemia in patients with type 2 diabetes mellitus. 2011 , 5, 402-11	21
1646	Value-based insurance plus disease management increased medication use and produced savings. 2011 , 30, 100-8	34
1645	When metformin fails in type 2 diabetes mellitus. 2011 , 171, 365-6	12
1644	Clinical implications of exenatide as a twice-daily or once-weekly therapy for type 2 diabetes. 2011 , 123, 228-38	23

1643	Hypoglycemia in patients with type 2 diabetes using concomitant exenatide BID and long-acting insulin therapy. 2011 , 14, 705-8	8
1642	Diabetes oral medication initiation and intensification: patient views compared with current treatment guidelines. 2011 , 37, 78-84	39
1641	Efficacy of insulin analogs in achieving the hemoglobin A1c target of . <i>Diabetes Care</i> , 2011 , 34, 510-7	14.6 101
1640	Kidney and Pancreas Transplantation. 2011 ,	1
1639	DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. 2011 , 96, 1301-10	346
1638	Obesity and type 2 diabetes: what can be unified and what needs to be individualized?. 2011 , 96, 1654-63	290
1637	Dose accuracy of the KlikSTAR, NovoPen 4, and Luxura insulin pens: results of laboratory and field studies. 2011 , 5, 1179-84	8
1636	Cost-effectiveness of implementing the chronic care model for diabetes care in a military population. 2011 , 5, 501-13	16
1635	Glycated hemoglobin as a prognostic risk marker in nondiabetic patients after acute myocardial infarction: what now?. 2011 , 124, 666-8	2
1634	A 16-week open-label, multicenter pilot study assessing insulin pump therapy in patients with type 2 diabetes suboptimally controlled with multiple daily injections. 2011 , 5, 887-93	19
1633	Switching from rosiglitazone: thinking outside the class. 2011 , 305, 820-1	6
1632	Transitioning from inpatient to outpatient therapy in patients with in-hospital hyperglycemia. 2011 , 39, 87-95	4
1631	Antidiabetic pharmacotherapy and anamnestic hypoglycemia in a large cohort of type 2 diabetic patients--an analysis of the DiaRegis registry. 2011 , 10, 66	30
1630	Consensus report: the current role of self-monitoring of blood glucose in non-insulin-treated type 2 diabetes. 2011 , 5, 1529-48	76
1629	Advantages of extended-release metformin in patients with type 2 diabetes mellitus. 2011 , 123, 15-23	45
1628	Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus. 2011 , 2, 230-5	20
1627	The Clinical Efficacy and Safety of Glucagon-Like Peptide-1 (GLP-1) Agonists in Adults with Type 2 Diabetes Mellitus. 2011 , 4, 13-24	2
1626	Updated review: improved glycemic control with repaglinide-metformin in fixed combination for patients with type 2 diabetes. 2011 , 4, 29-37	1

1625	Liraglutide in adults with type 2 diabetes: global perspective on safety, efficacy and patient preference. 2011 , 4, 47-62		11
1624	Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus. 2011 , 8, 125-35		55
1623	Metformin and cancer occurrence in insulin-treated type 2 diabetic patients. <i>Diabetes Care</i> , 2011 , 34, 129-31	14.6	82
1622	Incretin-Related Therapies in Type 2 Diabetes: A Practical Overview. 2011 , 24, 26-35		5
1621	Intensive dietary advice significantly improves HbA(1c) in people with type 2 diabetes who remain hyperglycaemic despite optimised drug treatment. 2011 , 14, 26-27		1
1620	One in five laboratories using various hemoglobin A1c methods do not meet the criteria for optimal diabetes care management. 2011 , 13, 429-33		5
1619	Regional Variation in Medication Adherence. 2011 , 14,		3
1618	Intensive Insulin Therapy as the Primary Treatment for Type 2 Diabetes. 2011 , 29, 151-153		1
1617	Long-Term Care Medicine. 2011 ,		1
1616	Metformin-associated lactic acidosis in Chinese patients with type II diabetes. 2011 , 88, 260-5		9
1615	Prestroke glycemic control is associated with the functional outcome in acute ischemic stroke: the Fukuoka Stroke Registry. 2011 , 42, 2788-94		107
1614	Glucagon-like peptide-1 analogs in the treatment of Type 2 diabetes: a review of the Phase II and III trials. 2011 , 1, 327-343		1
1613	Resolving drug effects from class effects among drugs for type 2 diabetes mellitus: more support for cardiovascular outcome assessments. 2011 , 32, 1832-4		20
1612	Trends in the prevalence of chronic kidney disease, other chronic diseases and health-related behaviors in an adult Korean population: data from the Korean National Health and Nutrition Examination Survey (KNHANES). 2011 , 26, 3975-80		35
1611	Effects of exenatide on measures of β -cell function after 3 years in metformin-treated patients with type 2 diabetes. <i>Diabetes Care</i> , 2011 , 34, 2041-7	14.6	194
1610	Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes. <i>Diabetes Care</i> , 2011 , 34, 2508-14	14.6	174
1609	Standards of medical care in diabetes--2011. <i>Diabetes Care</i> , 2011 , 34 Suppl 1, S11-61	14.6	2104
1608	Using insulin in type 2 diabetes: in need of a renaissance?. 2011 , 5, 829-33		

1607	For type 2 diabetes poorly controlled by metformin monotherapy, the addition of any non-insulin antidiabetic drug reduces HbA1c to a similar extent, but with differing effects on weight and hypoglycaemic risk. 2011 , 16, 39-40		2
1606	What can we learn from patient-reported outcomes of insulin pen devices?. 2011 , 5, 1563-71		40
1605	Insulin analogs and glycosylated hemoglobin target of less than 7% in type 2 diabetes: a systematic review of randomized trials. 2011 , 9, 167-76		2
1604	Dapagliflozin--redefining treatment of T2DM?. 2011 , 7, 696-7		1
1603	Antidiabetic and antisteatotic effects of the selective fatty acid synthase (FAS) inhibitor platensimycin in mouse models of diabetes. 2011 , 108, 5378-83		109
1602	Elevated liver iron concentration is a marker of increased morbidity in patients with β -thalassemia intermedia. 2011 , 96, 1605-12		126
1601	The impact of 90-day prescriptions on adherence at workplace pharmacies compared to traditional mail order. 2011 , 14, 285-91		3
1600	Titration of Insulin Glargine in Patients with Type 2 Diabetes Mellitus in Asia: Physician- Versus Patient-Led? Rationale of the Asian Treat to Target Lantus Study (ATLAS). 2011 , 13, 67-72		10
1599	Management of patients with type 2 diabetes. 2011 , 27, 1931-47		9
1598	Assessment of quality of life in patients with type 2 diabetes mellitus before and after starting biphasic insulin aspart 30 (BIAsp 30) therapy: IMPROVE study in Japan. 2011 , 27, 643-50		10
1597	Diabetes mellitus: new drugs for a new epidemic. 2011 , 107, 65-73		48
1596	Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment. <i>Diabetes Care</i> , 2011 , 34, 314-9	14.6	47
1595	Metformin and colorectal cancer risk in diabetic patients. <i>Diabetes Care</i> , 2011 , 34, 2336-7	14.6	15
1594	Choosing a gliptin. 2011 , 15, 298-308		51
1593	Study on sustained-release metformin hydrochloride from matrix tablet: Influence of hydrophilic polymers and in vitro evaluation. 2011 , 1, 157-63		16
1592	Clinical efficacy of colesevelam in type 2 diabetes mellitus. 2011 , 24, 417-25		2
1591	Metabolic syndrome, chronic kidney disease, and cardiovascular disease: a dynamic and life-threatening triad. 2011 , 2011, 747861		21
1590	Metformin and the risk of cancer: time-related biases in observational studies. <i>Diabetes Care</i> , 2012 , 35, 2665-73	14.6	363

1589	Glycemic control over 5 years in 4,900 people with type 2 diabetes: real-world diabetes therapy in a clinical trial cohort. <i>Diabetes Care</i> , 2012 , 35, 1165-70	14.6	29
1588	Comment on: Inzucchi et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i> 2012;35:1364-1379. <i>Diabetes Care</i> , 2012 , 35, e70; author reply e72-3	14.6	5
1587	Managing diabetes with integrated teams: maximizing your efforts with limited time. 2012 , 124, 64-76		7
1586	Type 2 Diabetes Mellitus. 2012 , 1489-1499		0
1585	Comment on: Inzucchi et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i> 2012;35:1364-1379. <i>Diabetes Care</i> , 2012 , 35, e71; author reply e72-3	14.6	7
1584	Comprehensive evidence-based assessment and prioritization of potential antidiabetic medicinal plants: a case study from canadian eastern james bay cree traditional medicine. 2012 , 2012, 893426		20
1583	Short- and long-term effects of real-time continuous glucose monitoring in patients with type 2 diabetes. <i>Diabetes Care</i> , 2012 , 35, 32-8	14.6	158
1582	Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. 2012 , 9, e1001204		172
1581	Implementation of a pharmacy residency in a Veterans Affairs community-based outpatient clinic. 2012 , 69, 880-4		4
1580	The meaning of insulin to Hispanic immigrants with type 2 diabetes and their families. 2012 , 38, 263-70		20
1579	Efficacy of various antidiabetic agents as add-on treatments to metformin in type 2 diabetes mellitus: systematic review and meta-analysis. 2012 , 2012, 798146		7
1578	Choosing GLP-1 Receptor Agonists or DPP-4 Inhibitors: Weighing the Clinical Trial Evidence. 2012 , 30, 3-12		24
1577	Individualized treatment of type 2 diabetes mellitus using noninsulin agents: clinical considerations for the primary care physician. 2012 , 124, 95-108		6
1576	Basal supplementation of insulin lispro protamine suspension versus insulin glargine and detemir for type 2 diabetes: meta-analysis of randomized controlled trials. <i>Diabetes Care</i> , 2012 , 35, 2698-705	14.6	11
1575	Transient receptor potential vanilloid 1 activation enhances gut glucagon-like peptide-1 secretion and improves glucose homeostasis. 2012 , 61, 2155-65		94
1574	Improving health outcomes in 2011 for people with type 2 diabetes: A report from a symposium held on the occasion of the International Diabetes Federation World Diabetes Congress, Dubai, 5â8 December 2011. 2012 , 12, 101-108		
1573	Liraglutide-associated acute pancreatitis. 2012 , 69, 386-9		23
1572	Dipeptidyl peptidase-IV is a potential molecular biomarker in diabetic kidney disease. 2012 , 9, 301-8		87

1571	Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin. 2012 , 124, 62-73		12
1570	Getting under the skin of clinical inertia in insulin initiation: the Translating Research Into Action for Diabetes (TRIAD) Insulin Starts Project. 2012 , 38, 94-100		52
1569	What have we learned about the treatment of type 2 diabetes? The evolving paradigms. 2012 , 19, 449-64		2
1568	Weightlifting's risky new trend: a case series of 41 insulin users. 2012 , 11, 176-9		12
1567	Insulin initiation in patients with type 2 diabetes mellitus: treatment guidelines, clinical evidence and patterns of use of basal vs premixed insulin analogues. 2012 , 166, 159-70		45
1566	The C allele of ATM rs11212617 does not associate with metformin response in the Diabetes Prevention Program. <i>Diabetes Care</i> , 2012 , 35, 1864-7	14.6	59
1565	Physicians' actions and influence, such as aggressive blood pressure control, greatly improve the health of diabetes patients. 2012 , 31, 140-9		4
1564	Online, direct-to-consumer access to insulin: patient safety considerations and reform. 2012 , 6, 1503-6		5
1563	Reducing renal failure: how low do glucose levels need to go?. 2012 , 2, 25-32		1
1562	The impact of treatment noncompliance on mortality in people with type 2 diabetes. <i>Diabetes Care</i> , 2012 , 35, 1279-84	14.6	143
1561	β-cell function preservation after 3.5 years of intensive diabetes therapy. <i>Diabetes Care</i> , 2012 , 35, 1406-12	14.6	73
1560	Initiating insulin in patients with type 2 diabetes. 2012 , 184, 767-76		17
1559	On- en off-targeteffecten van dipeptidyl peptidase-4-remmers. 2012 , 10, 3-11		
1558	Mechanisms of incretin effects on plasma lipids and implications for the cardiovascular system. 2012 , 10, 289-94		8
1557	GLP-1 agonists exenatide and liraglutide: a review about their safety and efficacy. 2012 , 7, 214-28		39
1556	LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. 2012 , 92, 158-69		178
1555	[Oral treatment of type 2 diabetes mellitus]. 2012 , 137, 1859-68, quiz 1869-72		
1554	Effect of early weight loss on type 2 diabetes mellitus after 2 years of gastric banding. 2012 , 124, 73-81		3

1553	Initial combination therapy with metformin plus colesevelam in drug-naïve Hispanic patients with early type 2 diabetes. 2012 , 124, 7-13	4
1552	Intensification of insulin therapy in patients with type 2 diabetes mellitus: an algorithm for basal-bolus therapy. 2012 , 44, 836-46	22
1551	A nationwide community-based lifestyle program could delay or prevent type 2 diabetes cases and save \$5.7 billion in 25 years. 2012 , 31, 50-60	54
1550	Hypoglycemic potential of current and emerging pharmacotherapies in type 2 diabetes mellitus. 2012 , 124, 74-83	16
1549	Effects of multiple doses of albiglutide on the pharmacokinetics, pharmacodynamics, and safety of digoxin, warfarin, or a low-dose oral contraceptive. 2012 , 124, 55-72	16
1548	Evolving therapeutic options for type 2 diabetes mellitus: an overview. 2012 , 124, 82-9	18
1547	Efficacy and safety of taspoglutide in patients with type 2 diabetes inadequately controlled with metformin plus pioglitazone over 24 weeks: T-Emerge 3 trial. 2012 , 97, 2370-9	23
1546	Personalized medicine in Type 2 diabetes: what does the future hold?. 2012 , 2, 199-204	11
1545	A case of hypoglycemic hemiparesis and literature review. 2012 , 117, 347-51	15
1544	Current treatments and strategies for type 2 diabetes: can we do better with GLP-1 receptor agonists?. 2012 , 44, 338-49	7
1543	Clinical management of elderly patients with type 2 diabetes mellitus. 2012 , 124, 133-43	25
1542	Use of dipeptidyl peptidase-4 inhibitors for the treatment of patients with type 2 diabetes mellitus and chronic kidney disease. 2012 , 124, 138-44	17
1541	Diabetes: East meets West. The Joint American Association of Clinical Endocrinologists-Chinese Society of Endocrinology (AAACE-CSE) Symposium. 2012 , 4, 221-6	
1540	Predictor variables and an equation for estimating HbA1c attainable by initiation of basal supported oral therapy. 2012 , 3, 164-9	4
1539	Patient empowerment and optimal glycemic control. 2012 , 28, 979-89	26
1538	Dipeptidyl peptidase-4 inhibitors: 3 years of experience. 2012 , 14, 350-64	45
1537	Efficacy of liraglutide therapy in Japanese type 2 diabetic patients insufficiently controlled with basal-supported oral therapy. 2012 , 3, 510-6	1
1536	Dosing of insulin glargine to achieve the treatment target in Japanese type 2 diabetes on a basal supported oral therapy regimen in real life: ALOHA study subanalysis. 2012 , 14, 635-43	22

1535	Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States. 2012 , 15, 654-63		17
1534	Assessing achievement and maintenance of glycemic control by patients initiating basal insulin. 2012 , 28, 1647-56		25
1533	The association of mental conditions with blood glucose levels in older adults with diabetes. 2012 , 16, 950-7		17
1532	Linagliptin for type 2 diabetes mellitus: a review of the pivotal clinical trials. 2012 , 3, 113-24		22
1531	The duration of sulfonylurea treatment is associated with β -cell dysfunction in patients with type 2 diabetes mellitus. 2012 , 14, 1033-42		15
1530	Exenatide BID and liraglutide QD treatment patterns among type 2 diabetes patients in Germany. 2012 , 15, 746-57		8
1529	Evaluation of a new reusable insulin pen (ClikSTAR) in Canadian patients with type 1 and type 2 diabetes mellitus receiving insulin glargine. 2012 , 14, 926-35		2
1528	Independent and combined effects of exercise training and metformin on insulin sensitivity in individuals with prediabetes. <i>Diabetes Care</i> , 2012 , 35, 131-6	14.6	138
1527	Saxagliptin for the treatment of type 2 diabetes mellitus: focus on recent studies. 2012 , 44, 157-69		2
1526	Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. <i>Diabetes Care</i> , 2012 , 35, 1473-8	14.6	298
1525	Management of Type 2 Diabetes: What Is the Next Step After Metformin?. 2012 , 30, 72-75		7
1524	Statin use as a moderator of metformin effect on risk for prostate cancer among type 2 diabetic patients. <i>Diabetes Care</i> , 2012 , 35, 1002-7	14.6	43
1523	Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naïve patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. <i>Diabetes Care</i> , 2012 , 35, 252-8	14.6	261
1522	Drugs, nutrients, and phytoactive principles improving the health span of rodent models of human age-related diseases. 2012 , 67, 140-51		10
1521	Medication nonadherence in diabetes: longitudinal effects on costs and potential cost savings from improvement. <i>Diabetes Care</i> , 2012 , 35, 2533-9	14.6	133
1520	Noninferiority effects on glycemic control and β -cell function improvement in newly diagnosed type 2 diabetes patients: basal insulin monotherapy versus continuous subcutaneous insulin infusion treatment. 2012 , 14, 35-42		17
1519	Changes in pharmaceutical treatment of diabetes and family financial burdens. 2012 , 69, 474-91		7
1518	Current insulin analogues in the treatment of diabetes: emphasis on type 2 diabetes. 2012 , 12, 209-21		10

1517	Administration technique and storage of disposable insulin pens reported by patients with diabetes. 2012 , 38, 651-8		18
1516	Insulin initiation in elderly patients with type 2 diabetes in France: a subpopulation of the LIGHT study. 2012 , 28, 503-11		5
1515	Effect of fructose on blood pressure: a systematic review and meta-analysis of controlled feeding trials. 2012 , 59, 787-95		142
1514	Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study. 2012 , 104, 1411-21		89
1513	Review of the safety and efficacy of exenatide once weekly for the treatment of type 2 diabetes mellitus. 2012 , 46, 812-21		13
1512	Managing diabetes in the middle-aged patient when loss of glycemic control occurs. 2012 , 38, 13S-21S; quiz 22S		
1511	Safety and tolerability of glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes. 2012 , 12, 6-16		1
1510	Managing diabetes from first diagnosis: choosing well-tolerated therapies with durability. 2012 , 38, 4S-11S; quiz 12S		5
1509	Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). <i>Diabetes Care</i> , 2012 , 35, 1225-31	14.6	183
1508	Randomized Trials Built on Sand: Examples from COPD, Hormone Therapy, and Cancer. 2012 , 3, e0014		16
1507	The management of type 2 diabetic patients with hypoglycaemic agents. 2012 , 2012, 478120		15
1506	Combination exenatide-sitagliptin therapy used with glipizide in a patient with type 2 diabetes mellitus. 2012 , 69, 1044-8		4
1505	Harnessing the potential clinical use of medicinal plants as anti-diabetic agents. 2012 , 7		11
1504	Pathophysiologic differences among Asians, native Hawaiians, and other Pacific Islanders and treatment implications. <i>Diabetes Care</i> , 2012 , 35, 1189-98	14.6	53
1503	Metformin-Associated Lactic Acidosis following Intentional Overdose Successfully Treated with Tris-Hydroxymethyl Aminomethane and Renal Replacement Therapy. 2012 , 2012, 671595		6
1502	Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus. 2012 , 5, 135-48		46
1501	Beyond PPARs and Metformin. 2012 , 177-192		4
1500	Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register. 2012 , 2,		142

- 1499 The novel use of GLP-1 analogue and insulin combination in type 2 diabetes mellitus. **2012**, 6, 129-35 10
- 1498 Management of type-1 and type-2 diabetes by insulin injections in diabetology clinics - a scientific research review. **2012**, 6, 148-70 10
- 1497 Impact of type 2 diabetes on serial changes in tissue characteristics of coronary plaques: an integrated backscatter intravascular ultrasound analysis. **2012**, 13, 717-23 16
- 1496 Clinical outcomes using long-term combination therapy with insulin glargine and exenatide in patients with type 2 diabetes mellitus. **2012**, 18, 17-25 29
- 1495 newsbites. **2012**, 38, 12
- 1494 Recent safety updates on type 2 diabetes medications: a case report and the evidence for choosing among several available drugs for this patient. **2012**, 112, 49-53
- 1493 Medical Nutrition Therapy for Diabetes Management and Prevention. **2012**, 38, 1-4
- 1492 Effective management of the type 2 diabetes patient with cardiovascular and renal disease: secondary prevention strategies after a myocardial infarction. **2012**, 8, 219-28 2
- 1491 Individual or Group Education for Diabetes Self-Management?. **2012**, 38, 4-6
- 1490 Long-term effects of sleeve gastrectomy and Roux-en-Y gastric bypass surgery on type 2 diabetes mellitus in morbidly obese subjects. **2012**, 256, 1023-9 182
- 1489 Assessing Obesity-Related Health Risks. **2012**, 38, 8-9
- 1488 Non-alcoholic fatty liver disease in type 2 diabetes: pathogenesis and treatment options. **2012**, 10, 162-72 42
- 1487 Clinical Nutrition INSIGHT. **2012**, 38, 10-11 0
- 1486 Debate Over Diabetes Medications. **2012**, 38, 7
- 1485 U-500 concentrated regular insulin: practical application in the outpatient setting. **2012**, 37, 47-52 6
- 1484 Microvesicles/exosomes as potential novel biomarkers of metabolic diseases. **2012**, 5, 247-82 116
- 1483 Hyperglycaemia in inpatients with type 2 diabetes mellitus. **2012**, 73, C124-8
- 1482 Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. **2012**, 156, 405-15 340

1481	Optimizing treatment strategies with insulin glargine in Type 2 diabetes. 2012 , 7, 377-393	4
1480	A review of insulin delivery devices and glucose meters. 2012 , 14, 278-281	
1479	Design, findings and implications of the liraglutide Phase III clinical trial program. 2012 , 2, 59-72	3
1478	Exenatide: role in management of Type 2 diabetes and associated cardiovascular risk factors. 2012 , 9, 23-38	
1477	Evaluation of guideline recommendations on oral medications for type 2 diabetes mellitus: a systematic review. 2012 , 156, 27-36	66
1476	Long-term efficacy of sitagliptin for the treatment of type 2 diabetic patients in Japan. 2012 , 59, 197-204	25
1475	Suicide attempt by an overdose of sitagliptin, an oral hypoglycemic agent: a case report and a review of the literature. 2012 , 59, 329-33	14
1474	The evaluation of risk factors associated with adverse drug reactions by metformin in type 2 diabetes mellitus. 2012 , 35, 933-7	28
1473	Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. 2012 , 379, 1489-97	260
1472	Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial. 2012 , 379, 2270-8	125
1471	Choosing a blood-glucose-lowering agent after metformin. 2012 , 379, 2220-1	5
1470	Insulin use in elderly adults: risk of hypoglycemia and strategies for care. 2012 , 60, 1564-70	60
1469	Glycaemic control in patients with type 2 diabetes switching from premixed insulin to long-acting basal insulin analogue plus oral antidiabetic drugs: an observational study. 2012 , 66, 959-68	9
1468	Using multiple measures of glycemia to support individualized diabetes management: recommendations for clinicians, patients, and payers. 2012 , 14, 973-83; quiz 983	14
1467	Can a tool that automates insulin titration be a key to diabetes management?. 2012 , 14, 675-82	25
1466	Inhibition of complex I regulates the mitochondrial permeability transition through a phosphate-sensitive inhibitory site masked by cyclophilin D. 2012 , 1817, 1628-34	82
1465	Modified release terbutaline (SKP1052) for hypoglycaemia prevention: a proof-of-concept study in people with type 1 diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2012 , 14, 1137-44	6.7
1464	Safety, pharmacokinetics and pharmacodynamics of multiple-ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2012 , 14, 1114-22	6.7 12

1463	The safety and efficacy of adding once-daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in 10 countries. <i>Diabetes, Obesity and Metabolism</i> , 2012 , 14, 1129-36	6.7	43
1462	A study comparing insulin lispro mix 25 with glargine plus lispro therapy in patients with Type 2 diabetes who have inadequate glycaemic control on oral anti-hyperglycaemic medication: results of the PARADIGM study. 2012 , 29, e263-72		30
1461	Pharmacology, efficacy, and safety of linagliptin for the treatment of type 2 diabetes mellitus. 2012 , 46, 358-67		6
1460	Update on insulin therapy for type 2 diabetes. 2012 , 97, 1405-13		26
1459	Exenatide as a novel weight loss modality in patients without diabetes. 2012 , 46, 1700-6		9
1458	Medical Nutrition Therapy for Diabetes: Prioritizing Recommendations Based on Evidence. 2012 , 101-125		
1457	Type 2 diabetes treatment intensification in general practice in France in 2008-2009: the DIAttitude Study. 2012 , 38 Suppl 3, S29-35		29
1456	Therapeutic management of orally treated type 2 diabetic patients, by French general practitioners in 2010: the DIAttitude Study. 2012 , 38 Suppl 3, S36-46		10
1455	Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). <i>Diabetes, Obesity and Metabolism</i> , 2012 , 14, 910-7	6.7	219
1454	Diabetes therapy--focus on Asia: second-line therapy debate: insulin/secretagogues. 2012 , 28 Suppl 2, 85-9		3
1453	Management of diabetes in primary care: individualisation of care. 2012 , 29, 331-334a		2
1452	Factors that influence basal insulin requirement in type 2 diabetes. 2012 , 49, 387-93		3
1451	Prediction of near-future HbA1c levels using glycated albumin levels before and after glimepiride administration for 2 weeks is useful to determine the effectiveness of the treatment. 2012 , 3, 197-201		5
1450	Diabetes and pancreatic cancer. 2012 , 19, F9-F26		92
1449	Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis. 2012 , 15 Suppl 2, 28-37		21
1448	Le transfert des insulines humaines vers les analogues de l'insuline entraîne une amélioration de l'HbA1c et une réduction des hypoglycémies chez les patients diabétiques de type 2 : données de la cohorte algérienne de l'étude A1chieve. 2012 , 6, 511-518		
1447	The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of Cardiology. 2012 , 60, S1-49		476
1446	Insulina aspart en pacientes con diabetes tipo 2. 2012 , 28, 27-31		1

1445	The glucokinase activator AZD6370 decreases fasting and postprandial glucose in type 2 diabetes mellitus patients with effects influenced by dosing regimen and food. 2012 , 98, 436-44	8
1444	Characteristics of patients with sulphonurea-induced hypoglycemia. 2012 , 13, 234-8	23
1443	Doute concernant lâ'efficacit' de la metformine dans le diab' de type 2: Doubts on the efficacy of metformin in the treatment of type 2 diabetes. 2012 , 6, 249-251	
1442	Initiation de lâ'insuline d'â' soir chez des patients diab'tiques de type 2 insulino-na'fs en 'chec aux antidiab'tiques oraux : 'tude de tol'rance et d'â' efficacit' en pratique courante en Alg'rie ('tude IDEALS). 2012 , 6, 332-337	1
1441	Alas, a Patient-Centred Guidelines on the Glycemic Management in People with Type 2 Diabetes Mellitus. 2012 , 36, 87-89	0
1440	Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US. 2012 , 15 Suppl 2, 6-13	30
1439	Estimation of HbA1c response to sitagliptin by change in glycated albumin level for 2 weeks. 2012 , 3, 175-8	9
1438	Metabolic improvements in obese type 2 diabetes subjects implanted for 1 year with an endoscopically deployed duodenal-jejunal bypass liner. 2012 , 14, 183-9	89
1437	Glycemic effectiveness and medication adherence with fixed-dose combination or coadministered dual therapy of antihyperglycemic regimens: a meta-analysis. 2012 , 28, 969-77	39
1436	Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes. 2012 , 28, 439-46	26
1435	Efficacy and safety of insulin lispro protamine suspension as basal supplementation in patients with type 2 diabetes. 2012 , 3, 99-108	4
1434	Telecare Provides comparable efficacy to conventional self-monitored blood glucose in patients with type 2 diabetes titrating one injection of insulin glulisine-the ELEONOR study. 2012 , 14, 175-82	39
1433	Impact of self-treated hypoglycaemia in type 2 diabetes: a multinational survey in patients and physicians. 2012 , 28, 1947-58	45
1432	A long-term analysis evaluating the cost-effectiveness of biphasic insulin lispro mix 75/25 and mix 50/50 versus long-acting basal insulin analogs in the United States. 2012 , 15, 766-75	6
1431	Incidence of cardiovascular events in Italian patients with early discontinuations of antihypertensive, lipid-lowering, and antidiabetic treatments. 2012 , 25, 549-55	10
1430	Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis. 2012 , 15, 1039-50	18
1429	The Kidney as a Treatment Target for Type 2 Diabetes. 2012 , 25, 29-36	6
1428	Comparison of hemoglobin A1c goal achievement with the addition of pioglitazone to maximal/highest tolerated doses of sulfonylurea and metformin combination therapy. 2012 , 1, 34-9	

1427	Combination therapy in type 2 diabetes mellitus: adding linagliptin to a stable regimen of metformin and a sulfonylurea. 2012 , 13, 1535-9	2
1426	Standards of medical care in diabetes--2012. <i>Diabetes Care</i> , 2012 , 35 Suppl 1, S11-63	14.6 1663
1425	Type 2 diabetes after gastric bypass: remission in five models using HbA1c, fasting blood glucose, and medication status. 2012 , 8, 548-55	91
1424	Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial. 2012 , 167, 287-94	41
1423	Type 2 diabetes: an epidemic requiring global attention and urgent action. <i>Diabetes Care</i> , 2012 , 35, 943-4	4.6 114
1422	The effect of sitagliptin versus glibenclamide on arterial stiffness, blood pressure, lipids, and inflammation in type 2 diabetes mellitus patients. 2012 , 14, 561-7	52
1421	Intensifying insulin therapy with insulin analog premixes: transitioning from basal insulin in type 2 diabetes. 2012 , 14, 533-9	2
1420	[Prevalence of diabetes mellitus in geriatric patients in nursing homes of Cádiz. Diagerca study]. 2012 , 47, 114-8	8
1419	ENPP1 mRNA levels in white blood cells and prediction of metformin efficacy in type 2 diabetic patients: a preliminary evidence. 2012 , 22, e5-6	2
1418	High L-carnitine concentrations do not prevent late diabetic complications in type 1 and 2 diabetic patients. 2012 , 32, 320-7	8
1417	Insulin and GLP-1 analog combinations in type 2 diabetes mellitus: a critical review. 2012 , 21, 1463-74	10
1416	Add-on therapies to metformin in type 2 diabetes: what modulates the respective decrements in postprandial and basal glucose?. 2012 , 14, 943-50	12
1415	Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis. 2012 , 97, 2347-53	171
1414	Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus. 2012 , 110, 826-33	128
1413	Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications. 2012 , 125, 302.e1-7	93
1412	The cardiovascular effects of peroxisome proliferator-activated receptor agonists. 2012 , 125, 126-33	56
1411	Effects on post-prandial glucose and AGE precursors from two initial insulin strategies in patients with type 2 diabetes uncontrolled by oral agents. 2012 , 26, 333-8	4
1410	Long-term prognosis of patients with acute myocardial infarction in the era of acute revascularization (from the Heart Institute of Japan Acute Myocardial Infarction [HIJAMI] registry). 2012 , 159, 205-10	15

1409	Should all women with PCOS be treated for insulin resistance?. 2012 , 97, 18-22	90
1408	Role of CABG in the management of obstructive coronary arterial disease in patients with diabetes mellitus. 2012 , 12, 134-41	4
1407	Insulin therapy for diabetes mellitus: treatment regimens and associated costs. 2012 , 38, 156-63	20
1406	Starting or switching to biphasic insulin aspart 30 (BIAsp 30) in type 2 diabetes: a multicenter, observational, primary care study conducted in Finland. 2012 , 95, 10-8	4
1405	Metformin effects revisited. 2012 , 95, 1-9	42
1404	Potential for use of 1,5-anhydroglucitol when initiating insulin therapy in people with type 2 diabetes and suboptimal control with oral antidiabetic drugs. 2012 , 96, e66-9	2
1403	Resource utilisation and clinical data before and after switching between short-acting human insulin and rapid-acting insulin analogues in patients with type 2 diabetes: the SWING study. 2012 , 97, 231-41	3
1402	Association of KCNJ11 E23K gene polymorphism with hypoglycemia in sulfonylurea-treated type 2 diabetic patients. 2012 , 98, 119-24	29
1401	Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis. 2012 , 98, 159-63	52
1400	Recommendations for diagnosis and management of metformin-induced vitamin B12 (Cbl) deficiency. 2012 , 97, 359-67	60
1399	KCNJ11 gene E23K variant and therapeutic response to sulfonylureas. 2012 , 23, 245-9	69
1398	Rationale and design of the multinational observational study assessing insulin use: the MOSAIC study. 2012 , 12, 20	12
1397	Oral antidiabetic treatment in type-2 diabetes in the elderly: balancing the need for glucose control and the risk of hypoglycemia. 2012 , 11, 122	77
1396	Insulin resistance predicts progression of de novo atherosclerotic plaques in patients with coronary heart disease: a one-year follow-up study. 2012 , 11, 71	44
1395	The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial. 2012 , 4, 36	52
1394	Are diabetes management guidelines applicable in 'real life'?. 2012 , 4, 47	4
1393	A randomized non-inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with type 2 diabetes experiencing inadequate glycaemic control on metformin and sitagliptin. 2012 , 29, e417-24	30
1392	Personalizing treatment in type 2 diabetes: a self-monitoring of blood glucose inclusive innovative approach. 2012 , 14, 373-8	20

1391	Low risk of severe hypoglycaemia in patients with type 2 diabetes mellitus starting insulin therapy with premixed insulin analogues BID in outpatient settings. 2012 , 66, 1033-41	6
1390	How do we gauge the success of treatment of diabetes?. 2012 , 4, 193-4	1
1389	Challenges in achieving optimal glycemic control in type 2 diabetes patients with declining renal function: The Southeast Asia perspective. 2012 , 3, 481-9	6
1388	Repaglinide: a review of its use in type 2 diabetes mellitus. 2012 , 72, 249-72	57
1387	Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU. 2012 , 72, 229-48	16
1386	Cardiovascular, ocular and bone adverse reactions associated with thiazolidinediones: a disproportionality analysis of the US FDA adverse event reporting system database. 2012 , 35, 315-23	29
1385	Clinical pharmacokinetics and pharmacodynamics of vildagliptin. 2012 , 51, 147-62	72
1384	Pharmacokinetic study of saxagliptin in healthy Chinese subjects. 2012 , 32, 465-73	9
1383	Clinical pharmacokinetics and pharmacodynamics of linagliptin. 2012 , 51, 411-27	78
1382	Thiazolidinedione safety. 2012 , 11, 565-79	159
1381	Glitazones: Could They Have a Rosy Future in Critical Care?. 2012 , 138-146	1
1380	Management of Type 2 Diabetes Mellitus. 2012 , 167-191	
1379	Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. 2012 , 28, 513-23	147
1378	Glycemic control in diabetic kidney disease patients. 2012 , 1, 111-114	3
1377	Cardiovascular effects of noninsulin, glucose-lowering agents: need for more outcomes data. 2012 , 110, 32B-42B	5
1376	Physicians' prescribing patterns for patients with diabetes are changing for the better. 2012 , 125, e11-2	2
1375	Effects of cardiorespiratory fitness on aging: glucose trajectory in a cohort of healthy men. 2012 , 22, 617-22	12
1374	Metformin affects the circadian clock and metabolic rhythms in a tissue-specific manner. 2012 , 1822, 1796-806	55

1373	Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus. 2012 , 34, 1761-71	22
1372	Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial. 2012 , 34, 1909-19.e15	44
1371	Utilization and costs of glucose lowering therapies following health technology assessment for the new reimbursement scheme in Sweden. 2012 , 108, 207-15	3
1370	Tratamiento de la diabetes: insulinoterapia. 2012 , 11, 1082-1088	
1369	Cost-effectiveness of saxagliptin (Onglyza [®]) in type 2 diabetes in Sweden. <i>Primary Care Diabetes</i> , 2012 , 6, 127-36	2.4 30
1368	[Metabolic control and weight loss in patients with obesity and type 2 diabetes mellitus, treated with exenatide]. 2012 , 139, 572-8	3
1367	[Consensus document on the management after hospital discharge of patient with hyperglycaemia]. 2012 , 138, 666.e1-666.e10	8
1366	A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. 2012 , 98, 271-84	117
1365	Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. 2012 , 344, e1369	309
1364	Global Cardiovascular Risk Reduction in People with Diabetes Mellitus and Hypertension. 2012 , 129-141	
1363	Molecular action and pharmacogenetics of metformin: current understanding of an old drug. 2012 , 2, 439-452	13
1362	Metformin and heart failure: never say never again. 2012 , 13, 1-8	23
1361	New Therapies for Diabetes Mellitus. 2012 , 1241-1257	
1360	Comparative efficacy and safety of long-acting insulin analogs in patients with type 2 diabetes failing on oral therapy: Systemic review and meta-analyses. 2012 , 3, 283-93	7
1359	Cellular and molecular mechanisms of metformin: an overview. 2012 , 122, 253-70	1094
1358	Diabetes. 2012 , 806-832	
1357	A multiple-ascending-dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist, TAK-875, in subjects with type 2 diabetes. 2012 , 92, 29-39	77
1356	Exenatide, a GLP-1 agonist in the treatment of Type 2 diabetes. 2012 , 7, 15-26	6

1355 Diabetes Mellitus and Peripheral Vascular Disease. **2012**, 27-38

1354 A UK analysis of the cost-effectiveness of Humalog Mix75/25 and Mix50/50 versus long-acting basal insulin. **2012**, 29, 1051-66

4

1353 Initial combination with linagliptin and metformin in newly diagnosed type 2 diabetes and severe hyperglycemia. **2012**, 29, 1005-15

10

1352 A pharmacist care program: positive impact on cardiac risk in patients with type 2 diabetes. **2012**, 17, 57-64

58

1351 Glucose and low-density lipoprotein cholesterol lowering in elderly patients with type 2 diabetes: focus on combination therapy with colesevelam HCl. **2012**, 29, e1-e12

5

1350 Frailty and safety: the example of diabetes. **2012**, 35 Suppl 1, 63-71

11

1349 Gestational diabetes mellitus: risks and management during and after pregnancy. **2012**, 8, 639-49

322

1348 Diabetes and Peripheral Vascular Disease. **2012**,

1

1347 Insulin therapy in type 2 diabetes mellitus. **2012**, 41, 119-44

20

1346 The Ideal Diabetes Therapy: What Will It Look Like? How Close Are We?. **2012**, 30, 44-53

33

1345 Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre-specified analysis adjusting for the most recently measured HbA(1c) value. **2012**, 28, 1281-7

15

1344 Diabetes and Hypertension. **2012**,

0

1343 Physical Activity and Inflammation. **2012**, 99-108

1

1342 A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. *Diabetes Care*, **2012**, 35, 2140-7

14.6 96

1341 Sex and Gender Differences in Pharmacology. **2012**,

26

1340 Pantoprazole improves glycemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled trial. **2012**, 97, E2105-8

42

1339 Clinical Outcomes After Insulin Initiation in Patients with Type 2 Diabetes: 24-Month Results from INSTIGATE. **2012**, 3, 9

12

1338 Patients with Type 2 Diabetes Initiating Exenatide Twice Daily or Insulin in Clinical Practice: CHOICE Study. **2012**, 3, 6

8

1337	Insulinotropic effect of the non-steroidal compound STX in pancreatic β -cells. 2012 , 7, e34650	
1336	Potential formula for the calculation of starting and incremental insulin glargine doses: ALOHA subanalysis. 2012 , 7, e41358	16
1335	Type 2 Diabetes Mellitus. 2012 , e95-e108	0
1334	Managing the Broad Spectrum of Type 2 Diabetes. 2012 , 43-56	
1333	Diabetes Mellitus. 2012 , 103-110	1
1332	Glycemic Effects of Once-a-Day Rapid-Acting Insulin Analogue Addition on a Basal Insulin Analogue in Korean Subjects with Poorly Controlled Type 2 Diabetes Mellitus. 2012 , 36, 230-6	7
1331	Quantitative Evaluation of Compliance with Recommendation for Sulfonylurea Dose Co-Administered with DPP-4 Inhibitors in Japan. 2012 , 4, 479-93	9
1330	Grand challenges in diabetes. 2012 , 3, 37	
1329	Quality of life and patient-perceived difficulties in the treatment of type 2 diabetes. 2012 , 9, 46-54	8
1328	Liraglutide in Combination with Metformin or Sulfonylurea for the Treatment of Type 2 Diabetes in Adult patients. 2012 , 4, CMT.S7283	
1327	Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis. 2012 , 8, 255-64	20
1326	Persistence of initial oral antidiabetic treatment in patients with type 2 diabetes mellitus. 2012 , 18, CR72-77	23
1325	Use of concomitant glucose-lowering therapies and associated treatment results observed in clinical trials of twice-daily exenatide. 2012 , 18, 227-37	11
1324	Streptococcus milleri Group Cutaneous Abscess Associated with Insulin Injection to Distal Lower Extremity in an Insulin-Dependent Diabetic Man. 2012 , 47, 783-787	1
1323	Diabetes mellitus, insulin, oral antidiabetes agents, obesity. 2012 , 572-586	
1322	The role of dipeptidyl peptidase-4 inhibitors. 2012 , 344, e1213	2
1321	Letter: the risk of bladder cancer in korean diabetic subjects treated with pioglitazone (diabetes metab j 2012;36:371-8). 2012 , 36, 460-1	1
1320	Effectiveness of metformin and lifestyle interventions as an initial treatment in Japanese patients with newly diagnosed type 2 diabetes: a prospective observational study. 2012 , 59, 166-73	9

1319	Rosiglitazone prior authorization safety policy: a cohort study. 2012 , 18, 225-33	7
1318	Prescribing trends for the outpatient treatment of adolescents and young adults with type 2 diabetes mellitus. 2012 , 18, 607-14	1
1317	Alleviation of insulin resistance and liver damage by oral administration of Imm124-E is mediated by increased Tregs and associated with increased serum GLP-1 and adiponectin: results of a phase I/II clinical trial in NASH. 2012 , 5, 141-50	54
1316	Recent Studies and Patents in Salivary Protein Biomarkers for Diabetes. 2012 , 2, 1-5	3
1315	Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data. 2012 , 11, 6	61
1314	Linagliptin: new DPP-4 inhibitor for type 2 diabetes mellitus. 2012 , 23, 39-44	1
1313	The preparation of a complex of insulin-phospholipids and their interaction mechanism. 2012 , 18, 541-8	15
1312	The therapeutic potential of GPR119 agonists for type 2 diabetes. 2012 , 21, 321-8	72
1311	Clinical practice. Glycemic management of type 2 diabetes mellitus. 2012 , 366, 1319-27	117
1310	Bariatric surgery versus intensive medical therapy in obese patients with diabetes. 2012 , 366, 1567-76	1654
1309	Transient vision loss in a patient with severe metformin-associated lactic acidosis. 2012 , 105, 781-3	12
1308	Initial and subsequent therapy for newly diagnosed type 2 diabetes patients treated in primary care using data from a vendor-based electronic health record. 2012 , 21, 920-8	20
1307	Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults. 2012 , 46, 68-78	17
1306	Clinical practice. Diagnosis of diabetes. 2012 , 367, 542-50	134
1305	Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks. <i>Diabetes Care</i> , 2012 , 35, 683-9	14.6 80
1304	A review of exenatide: optimizing glycemic control and associated cardiovascular risk factors in type 2 diabetes. 2012 , 3, 1-16	5
1303	Diabetes and cancer II: role of diabetes medications and influence of shared risk factors. 2012 , 23, 991-1008	71
1302	A review and critical analysis of professional societies' guidelines for pharmacologic management of type 2 diabetes mellitus. 2012 , 12, 246-54	11

1301	The role of combination therapy in type 2 diabetes in the post-ACCORD era. 2012 , 12, 227-9		
1300	Alogliptin as an initial therapy in patients with newly diagnosed, drug naïve type 2 diabetes: a randomized, control trial. 2012 , 41, 435-41		25
1299	SU-derivaten bij starten insuline: toch maar stoppen?. 2012 , 55, 152-158		2
1298	Population pharmacokinetics of metformin in obese and non-obese patients with type 2 diabetes mellitus. 2012 , 68, 961-8		32
1297	Serum ferritin levels and endocrinopathy in medically treated patients with β -thalassemia major. 2012 , 91, 1107-14		59
1296	Transaminase levels in the upper normal range are associated with oral hypoglycemic drug therapy failure in patients with type 2 diabetes. 2012 , 49, 193-7		6
1295	Incretin-based therapies. 2012 , 4, 55-67		29
1294	Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence. <i>Diabetes, Obesity and Metabolism</i> , 2012 , 14, 101-11	6.7	50
1293	Using albumin to improve the therapeutic properties of diabetes treatments. <i>Diabetes, Obesity and Metabolism</i> , 2012 , 14, 121-9	6.7	8
1292	The economic and clinical benefits of adequate insulin initiation and intensification in people with type 2 diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2012 , 14, 47-57	6.7	26
1291	Variations in tissue selectivity amongst insulin secretagogues: a systematic review. <i>Diabetes, Obesity and Metabolism</i> , 2012 , 14, 130-8	6.7	60
1290	Time to treatment initiation with oral antihyperglycaemic therapy in US patients with newly diagnosed type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2012 , 14, 149-54	6.7	17
1289	Wisdom-based and evidence-based medicine. <i>Diabetes, Obesity and Metabolism</i> , 2012 , 14 Suppl 1, 1-2	6.7	
1288	Outcomes with insulin glargine in patients with type 2 diabetes previously on NPH insulin: evidence from clinical practice in Spain. 2012 , 66, 281-8		9
1287	Review of linagliptin for the treatment of type 2 diabetes mellitus. 2012 , 34, 993-1005		24
1286	Long-term effects of adding exenatide to a regimen of metformin and/or sulfonylurea in type 2 diabetes: an uncontrolled, open-label trial in Hungary. 2012 , 34, 1301-13		3
1285	The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials. 2012 , 37, 386-98		32
1284	Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes. 2012 , 37, 510-24		35

1283	Effect of short-term intensive insulin therapy on quality of life in type 2 diabetes. 2012 , 18, 256-61		14
1282	Sitagliptin add-on to low dosage sulphonylureas: efficacy and safety of combination therapy on glycaemic control and insulin secretion capacity in type 2 diabetes. 2012 , 66, 465-76		40
1281	Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. 2012 , 66, 446-56		219
1280	The role of the nurse practitioner in the diagnosis and early management of type 2 diabetes. 2012 , 24 Suppl 1, 225-33		5
1279	Insulin initiation in type 2 diabetes: what are the treatment regimen options and how can we best help patients feel empowered?. 2012 , 24 Suppl 1, 249-59		10
1278	Intensifying insulin treatment: options, practical issues, and the role of the nurse practitioner. 2012 , 24 Suppl 1, 260-9		10
1277	Trends of insulin use among US adults with type 2 diabetes: the Behavioral Risk Factor Surveillance System, 1995-2007. 2012 , 26, 17-22		15
1276	Adulteration of herbal antidiabetic products with undeclared pharmaceuticals: a case series in Hong Kong. 2012 , 73, 795-800		28
1275	Proportion of patients at HbA1c target . <i>Diabetes, Obesity and Metabolism</i> , 2012 , 14, 228-33	6.7	109
1274	Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2012 , 14, 409-18	6.7	35
1273	Metabolic control and risk of hypoglycaemia during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2012 , 14, 433-46	6.7	32
1272	Weight change in people with type 2 diabetes: secular trends and the impact of alternative antihyperglycaemic drugs. <i>Diabetes, Obesity and Metabolism</i> , 2012 , 14, 424-32	6.7	38
1271	Adding saxagliptin to extended-release metformin vs. uptitrating metformin dosage. <i>Diabetes, Obesity and Metabolism</i> , 2012 , 14, 365-71	6.7	23
1270	GLP-1 based therapies: differential effects on fasting and postprandial glucose. <i>Diabetes, Obesity and Metabolism</i> , 2012 , 14, 675-88	6.7	91
1269	Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2012 , 14, 470-8	6.7	82
1268	Current challenges in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2012 , 14 Suppl 2, 1-3	6.7	1
1267	The design of the liraglutide clinical trial programme. <i>Diabetes, Obesity and Metabolism</i> , 2012 , 14 Suppl 2, 4-12	6.7	8
1266	Liraglutide in oral antidiabetic drug combination therapy. <i>Diabetes, Obesity and Metabolism</i> , 2012 , 14 Suppl 2, 13-9	6.7	13

1265	Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents. <i>Diabetes, Obesity and Metabolism</i> , 2012 , 14 Suppl 2, 20-32	6.7	18
1264	Liraglutide: from clinical trials to clinical practice. <i>Diabetes, Obesity and Metabolism</i> , 2012 , 14 Suppl 2, 33-40	6.7	32
1263	Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study. <i>Diabetes, Obesity and Metabolism</i> , 2012 , 14, 565-74	6.7	115
1262	Glucose-lowering treatment and clinical results in 163 121 patients with type 2 diabetes: an observational study from the Swedish national diabetes register. <i>Diabetes, Obesity and Metabolism</i> , 2012 , 14, 717-26	6.7	22
1261	Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study. <i>Diabetes, Obesity and Metabolism</i> , 2012 , 14, 745-52	6.7	30
1260	Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis. <i>Diabetes, Obesity and Metabolism</i> , 2012 , 14, 803-9	6.7	78
1259	Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2012 , 14, 810-20	6.7	126
1258	Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients. <i>Diabetes, Obesity and Metabolism</i> , 2012 , 14, 852-8	6.7	54
1257	Effects of saxagliptin and sitagliptin on glycaemic control and pancreatic β -cell mass in a streptozotocin-induced mouse model of type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2012 , 14, 918-26	6.7	38
1256	No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects. <i>Diabetes, Obesity and Metabolism</i> , 2012 , 14, 937-43	6.7	23
1255	Effect of anti-IL-1 β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2012 , 14, 1088-96	6.7	97
1254	Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2012 , 14, 944-50	6.7	253
1253	Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range. <i>Diabetes, Obesity and Metabolism</i> , 2012 , 14, 951-9	6.7	117
1252	Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus. 2012 , 29, 313-20		39
1251	Risk of acute renal failure in patients with Type 2 diabetes mellitus. 2012 , 29, 614-21		46
1250	Validation of a tool to assess medication treatment satisfaction in patients with Type 2 diabetes: the Diabetes Medication System Rating Questionnaire (DMSRQ). 2012 , 29, 1060-6		11
1249	Optimization of insulin therapy in patients with type 2 diabetes mellitus: beyond basal insulin. 2012 , 29, e13-20		39
1248	Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. 2012 , 29, 682-9		392

1247	A retrospective database study of insulin initiation in patients with Type 2 diabetes in UK primary care. 2012 , 29, e191-8	49
1246	Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus. 2012 , 4, 8	13
1245	Strategies for insulin initiation: insights from the French LIGHT observational study. 2012 , 28, 97-105	19
1244	Dysregulation of glucose metabolism in HIV patients: epidemiology, mechanisms, and management. 2012 , 41, 1-10	55
1243	Fixed-dose combinations for treatment of type 2 diabetes mellitus. 2012 , 29, 1-13	46
1242	Fixed-dose combination antidiabetic therapy: real-world factors associated with prescribing choices and relationship with patient satisfaction and compliance. 2012 , 29, 26-40	38
1241	Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin. 2012 , 29, 163-77	40
1240	Efficacy of the Roux-en-Y gastric bypass compared to medically managed controls in meeting the American Diabetes Association composite end point goals for management of type 2 diabetes mellitus. 2012 , 22, 367-74	26
1239	Two additional cases of metformin-associated encephalopathy in patients with end-stage renal disease undergoing hemodialysis. 2013 , 17, 111-5	11
1238	Putting medications where they belong: practical advice for managing type 2 diabetes in clinical practice. 2013 , 25, 65-76	1
1237	Evaluation of insulin use and value for money in type 2 diabetes in the United kingdom. 2013 , 4, 51-66	9
1236	Comparison of National/Regional Diabetes Guidelines for the Management of Blood Glucose Control in non-Western Countries. 2013 , 4, 91-102	26
1235	Predictive clinical characteristics for the efficacy of vildagliptin monotherapy in Japanese patients with type 2 diabetes mellitus: a multicenter study. 2013 , 4, 179-185	1
1234	Baseline predictive factors for glycemic control in Japanese type 2 diabetes patients treated with insulin glargine plus oral antidiabetic drugs: ALOHA study subanalysis. 2013 , 4, 16-22	13
1233	Treatment of type 2 diabetes with saxagliptin: a pharmacoeconomic evaluation in Argentina. 2013 , 3, 11	17
1232	Safety, effectiveness, and cost of dipeptidyl peptidase-4 inhibitors versus intermediate acting insulin for type 2 diabetes: protocol for a systematic review and network meta-analysis. 2013 , 2, 47	3
1231	Diabetes Mellitus Prevention and Treatment. 2013 , 63-79	
1230	Diabetes. 2013 ,	7

1229	Bariatric surgery to treat obesity. 2013 , 33, 75-89		54
1228	Practical management of everolimus-related toxicities in patients with advanced solid tumors. 2013 , 36, 295-302		25
1227	Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. 2013 , 11, 43		206
1226	The role of co-morbidity in the selection of antidiabetic pharmacotherapy in type-2 diabetes. 2013 , 12, 62		22
1225	Effects of sitagliptin beyond glycemic control: focus on quality of life. 2013 , 12, 35		32
1224	Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers. 2013 , 35, 226-35		22
1223	RETRACTED: Evaluation of the positive effects on insulin-resistance and β -cell measurements of vildagliptin in addition to metformin in type 2 diabetic patients. 2013 , 73, 20-6		17
1222	Longitudinal decline of β -cell function: comparison of a direct method vs a fasting surrogate measure: the Insulin Resistance Atherosclerosis Study. 2013 , 98, 4152-9		9
1221	Detection, evaluation and treatment of diabetes mellitus in chronic pancreatitis: recommendations from PancreasFest 2012. 2013 , 13, 336-42		147
1220	Insulin therapy for type 2 diabetes. 2013 , 43, 529-34		8
1219	Risk vs benefit in diabetes pharmacotherapy: a rational approach to choosing pharmacotherapy in type 2 diabetes. 2013 , 13, 319-28		2
1218	Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study. <i>Diabetes, Obesity and Metabolism</i> , 2013 , 15, 1136-45	6.7	109
1217	Everolimus: side effect profile and management of toxicities in breast cancer. 2013 , 140, 453-62		61
1216	[Management of type 2 diabetes: new or previous agents, how to choose?]. 2013 , 42, 861-70		3
1215	The role of pharmacogenetics in drug disposition and response of oral glucose-lowering drugs. 2013 , 52, 833-54		22
1214	The Role of Metformin in Metformin-Associated Lactic Acidosis (MALA): Case Series and Formulation of a Model of Pathogenesis. 2013 , 36, 733-46		54
1213	Medical management for the prevention and treatment of diabetic macular edema. 2013 , 58, 459-65		34
1212	The early treatment of type 2 diabetes. 2013 , 126, S2-9		39

1211	Effect of sulfonylurea dose escalation on hemoglobin A1c in Veterans Affairs patients with type 2 diabetes. 2013 , 50, 261-5		6
1210	Molecular dynamics and free energy studies of chirality specificity effects on aminobenzo[a]quinolizine inhibitors binding to DPP-IV. 2013 , 19, 1167-77		4
1209	Stepwise intensification of insulin therapy in type 2 diabetes management--exploring the concept of the basal-plus approach in clinical practice. 2013 , 30, 276-88		37
1208	Sécurité et efficacité de l'insuline d'initiation chez les patients algériens diabétiques de type 2: Résultats de l'étude A1chieve. 2013 , 7, 369-374		
1207	Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. 2013 , 166, 823-30.e5		162
1206	Lifetime direct medical costs of treating type 2 diabetes and diabetic complications. 2013 , 45, 253-61		141
1205	Estado actual del tratamiento farmacológico de la diabetes mellitus. Una aproximación práctica. 2013 , 11, 2730-2740		
1204	Latest insights into the risk of cancer in diabetes. 2013 , 4, 225-32		60
1203	Revisiting the mechanisms of metformin action in the liver. 2013 , 74, 123-9		41
1202	The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. <i>Diabetes Care</i> , 2013 , 36, 858-64	14.6	186
1201	Cohort study of insulin glargine and risk of breast, prostate, and colorectal cancer among patients with diabetes. <i>Diabetes Care</i> , 2013 , 36, 3953-60	14.6	24
1200	Initiating basal insulin therapy in type 2 diabetes: practical steps to optimize glycemic control. 2013 , 126, S21-7		25
1199	Options for combination therapy in type 2 diabetes: comparison of the ADA/EASD position statement and AACE/ACE algorithm. 2013 , 126, S10-20		57
1198	lpragliflozin does not prolong QTc interval in healthy male and female subjects: a phase I study. 2013 , 35, 1150-1161.e3		8
1197	LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose. 2013 , 345, 250-9		131
1196	Complications of diabetes therapy. 2013 , 42, 947-70		16
1195	Impact of behavioral interventions in the management of adults with type 2 diabetes mellitus. 2013 , 13, 860-8		4
1194	Baseline and 1-year interim follow-up assessment of Japanese patients initiating insulin therapy who were enrolled in the cardiovascular risk evaluation in people with type 2 diabetes on insulin therapy study: an international, multicenter, observational study. 2013 , 12, 131		8

1193	Are concomitant treatments confounding factors in randomized controlled trials on intensive blood-glucose control in type 2 diabetes? a systematic review. 2013 , 13, 107	7
1192	Intensification of insulin therapy in patients with type 2 diabetes: a retrospective, non-interventional cohort study of patients treated with insulin glargine or biphasic human insulin in daily clinical practice. 2013 , 5, 43	2
1191	Medication utilization patterns among type 2 diabetes patients initiating Exenatide BID or insulin glargine: a retrospective database study. 2013 , 13, 20	8
1190	Metabolic Surgery for Type 2 Diabetes in Patients with a BMI of . 2013 , 23, 809-18	14
1189	Clinical experience with insulin detemir in patients with type 2 diabetes from the near East countries. 2013 , 4, 399-408	6
1188	Management of type 2 diabetes mellitus in older patients: current and emerging treatment options. 2013 , 4, 239-56	20
1187	Comparative efficacy of glimepiride and metformin in monotherapy of type 2 diabetes mellitus: meta-analysis of randomized controlled trials. 2013 , 5, 70	9
1186	Standard and Novel Treatment Options for Metabolic Syndrome and Diabetes Mellitus. 2013 , 15, 706	
1185	Predictors of change in objectively measured and self-reported health behaviours among individuals with recently diagnosed type 2 diabetes: longitudinal results from the ADDITION-Plus trial cohort. 2013 , 10, 118	5
1184	Safety and efficacy of sulfonylurea drugs in type 2 diabetes mellitus. 2013 , 10, 165-168	3
1183	Once weekly exenatide: efficacy, tolerability and place in therapy. <i>Diabetes, Obesity and Metabolism</i> , 2013 , 15, 871-81	6.7 20
1182	Choice of early treatment regimen and impact on β -cell preservation in type 2 diabetes. 2013 , 67, 876-87	15
1181	The importance of synthetic drugs for type 2 diabetes drug discovery. 2013 , 8, 1339-63	26
1180	Linagliptin provides effective, well-tolerated add-on therapy to pre-existing oral antidiabetic therapy over 1 year in Japanese patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2013 , 15, 833-43	6.7 26
1179	An open-label drug-drug interaction study of the steady-state pharmacokinetics of topiramate and glyburide in patients with type 2 diabetes mellitus. 2013 , 33, 929-38	3
1178	AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism. 2013 , 54, 134-51	118
1177	Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. 2013 , 31, 3069-75	210
1176	Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden. 2013 , 16, 1442-52	24

1175	Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents. <i>Diabetes, Obesity and Metabolism</i> , 2013 , 15, 760-6	6.7	33
1174	Impact of diabetes duration on hypoglycaemia in patients with type 2 diabetes treated with insulin glargine or NPH insulin. <i>Diabetes, Obesity and Metabolism</i> , 2013 , 15, 1085-92	6.7	9
1173	Drug-drug interactions between rosuvastatin and oral antidiabetic drugs occurring at the level of OATP1B1. 2013 , 41, 592-601		48
1172	Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2013 , 15, 432-40	6.7	108
1171	Synergy to reduce emergency department visits for uncontrolled hyperglycemia. 2013 , 39, 354-64		14
1170	Pharmacologic agents for type 2 diabetes therapy and regulation of adipogenesis. 2013 , 119, 139-50		17
1169	A practice-based approach to the 2012 position statement of the American Diabetes Association and the European Association for the Study of Diabetes. 2013 , 29, 793-9		5
1168	Insulin treatment of type 2 diabetes: considerations when converting from human insulin to insulin analogs. 2013 , 45, 129-40		2
1167	Glycemic control and the first use of oral antidiabetic agents among patients with type 2 diabetes mellitus. 2013 , 29, 1587-97		1
1166	SGLT2 inhibition: a novel prospective strategy in treatment of diabetes mellitus. 2013 , 35, 566-72		4
1165	Association of sulphonylurea treatment with all-cause and cardiovascular mortality: a systematic review and meta-analysis of observational studies. 2013 , 10, 302-14		63
1164	Brand name or generic? What are the health professionals prescribed for treating diabetes? A longitudinal analysis of the National Health Insurance reimbursement database. 2013 , 22, 752-9		7
1163	Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. 2013 , 494, 256-60		565
1162	Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonylureas: a primary care database analysis. <i>Diabetes, Obesity and Metabolism</i> , 2013 , 15, 55-61	6.7	69
1161	Contribution of insulin deficiency and insulin resistance to the development of type 2 diabetes: nature of early stage diabetes. 2013 , 50, 39-45		24
1160	The Spanish Pancreatic Club's recommendations for the diagnosis and treatment of chronic pancreatitis: part 2 (treatment). 2013 , 13, 18-28		46
1159	Diabetes management in the kidney patient. 2013 , 97, 135-56		17
1158	Characterization of and costs associated to the profile of patients with type 2 diabetes treated with metformin who are added a second oral antidiabetic drug: A population study. 2013 , 60, 557-569		4

1157	Efficacy of treatment with a basalâprandial insulin regimen in patients with type 2 diabetes mellitus previously treated with premixed insulin. 2013 , 29, 12-18	2
1156	Glucagon-like peptide-1 reduces contractile function and fails to boost glucose utilization in normal hearts in the presence of fatty acids. 2013 , 168, 4085-92	12
1155	A randomized placebo controlled double blind crossover study of pioglitazone on left ventricular diastolic function in type 2 diabetes. 2013 , 167, 1329-32	14
1154	Evidence from randomized clinical trials demonstrating improved glycemic control with GLP-1 receptor agonists when used with other agents vs other combination therapy strategies. 2013 , 5, 43-50	
1153	The ARMS-D out performs the SDSCA, but both are reliable, valid, and predict glycemic control. 2013 , 102, 96-104	56
1152	Successful Primary Care Management of Type II DiabetesContents. 2013 , 4-111	
1151	Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study. 2013 , 382, 409-416	109
1150	[Recommendations of the Spanish Pancreatic Club on the diagnosis and treatment of chronic pancreatitis: part 2 (treatment)]. 2013 , 36, 422-36	5
1149	Patient-reported adherence to insulin regimen is associated with glycemic control among Japanese patients with type 2 diabetes: Diabetes Distress and Care Registry at Tenri (DDCRT 3). 2013 , 100, 189-94	23
1148	Clinical decision making in diabetes: Use of glucagon-like peptide-1 (GLP-1) receptor agonists in clinical practice (where, when, and which?)âIntroduction. 2013 , 5, 31-32	
1147	HbA1c levels and all-cause mortality in type 2 diabetic patients: epidemiological evidence of the need for personalised therapeutic targets. 2013 , 23, 300-6	14
1146	Clinical and economical consequences of the combination of metformin with dipeptidyl peptidase inhibitors in type 2 diabetes patients. 2013 , 213, 377-84	13
1145	[Characterization of and costs associated to the profile of patients with type 2 diabetes treated with metformin who are added a second oral antidiabetic drug: a population study]. 2013 , 60, 557-69	5
1144	Drug treatments to restore vascular function and diabetesity. 2013 , 71, 27-33	3
1143	Anti-diabetic activity of the petroleum ether extract of Guar gum in streptozotocin-induced diabetic rats: A comparative study. 2013 , 2, 51-59	6
1142	Clinical and economical consequences of the combination of metformin with dipeptidyl peptidase inhibitors in type 2 diabetes patients. 2013 , 213, 377-384	
1141	Anti-diabetic effect of ramulus mori polysaccharides, isolated from Morus alba L., on STZ-diabetic mice through blocking inflammatory response and attenuating oxidative stress. 2013 , 16, 93-9	48
1140	[Metformin in type 2 diabetes: what if we get it wrong?]. 2013 , 42, 132-3	

1139	Sensitive measurement of polyols in urine by capillary zone electrophoresis coupled with amperometric detection using on-column complexation with borate. 2013 , 915-916, 39-45	6
1138	Effects of metformin on markers of oxidative stress and antioxidant reserve in patients with newly diagnosed type 2 diabetes: a randomized clinical trial. 2013 , 32, 179-85	129
1137	The role of mammalian target of rapamycin (mTOR) inhibition in the treatment of advanced breast cancer. 2013 , 15, 14-23	19
1136	Crosstalk between diabetes and brain: glucagon-like peptide-1 mimetics as a promising therapy against neurodegeneration. 2013 , 1832, 527-41	90
1135	Taspoglutide, a once-weekly glucagon-like peptide 1 analogue, vs. insulin glargine titrated to target in patients with Type 2 diabetes: an open-label randomized trial. 2013 , 30, 109-13	25
1134	Treating the obese diabetic. 2013 , 6, 171-83	6
1133	Assessment of baseline characteristics, glycemic control and oral antidiabetic treatment in Asian patients with diabetes: The Registry for Assessing OAD Usage in Diabetes Management (REASON) Asia study. 2013 , 5, 309-18	3
1132	Diabetes Drugs. 2013 , 205-243	
1131	Canagliflozin, a new sodium-glucose cotransporter 2 inhibitor, in the treatment of diabetes. 2013 , 70, 311-9	27
1130	The Role of Diet in the Prevention and Treatment of Diabetes. 2013 , 615-628	
1129	Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors. 2013 , 47, 490-505	28
1128	Periodontal disease epidemiology - learned and unlearned?. 2013 , 62, 37-58	59
1127	Efficacy and safety of dipeptidyl peptidase-4 inhibitors in combination with metformin. 2013 , 30, 337-53	9
1126	Haemoglobin A1c: Historical overview and current concepts. 2013 , 99, 75-84	55
1125	The Role of Pharmacogenomics in Diabetes, HIV Infection, and Pain Management. 2013 , 247-271	
1124	Laparoscopic sleeve gastrectomy and medical management for the treatment of type 2 diabetes mellitus in non-morbidly obese patients: a single-center experience. 2013 , 15, 281-8	10
1123	Comparison of equations for dosing of medications requiring renal adjustment. 2013 , 53, 54-7	8
1122	Efficacy and safety of glimepiride/metformin sustained release once daily vs. glimepiride/metformin twice daily in patients with type 2 diabetes. 2013 , 67, 236-43	8

1121	Role of AMPK in UVB-induced DNA damage repair and growth control. 2013 , 32, 2682-9	61
1120	Evaluating the risk of type 2 diabetes mellitus using artificial neural network: an effective classification approach. 2013 , 100, 111-8	57
1119	Nephropathy in diabetes. 2012 , 771, 107-22	54
1118	Therapies for type 2 diabetes. 2013 , 205-223	1
1117	A comparison between sitagliptin or glibenclamide in addition to metformin + pioglitazone on glycaemic control and β -cell function: the triple oral therapy. 2013 , 30, 846-54	10
1116	Drug-induced macular edema. 2013 , 73, 789-802	28
1115	Development of a novel non-radioactive cell-based method for the screening of SGLT1 and SGLT2 inhibitors using 1-NBDG. 2013 , 9, 2010-20	12
1114	Methods to enhance delivery of prandial insulin and basal-prandial insulin. <i>Diabetes, Obesity and Metabolism</i> , 2013 , 15 Suppl 1, 11-7	6.7 6
1113	Unleash metformin: reconsideration of the contraindication in patients with renal impairment. 2013 , 47, 1488-97	28
1112	Optimizing glycemic control: lixisenatide and basal insulin in combination therapy for the treatment of Type 2 diabetes mellitus. 2013 , 6, 603-12	3
1111	The joint association of physical activity, blood-pressure control, and pharmacologic treatment of hypertension for all-cause mortality risk. 2013 , 26, 1005-10	25
1110	Incretins as a novel therapeutic strategy in patients with diabetes and heart failure. 2013 , 18, 141-8	27
1109	Interventions to promote treatment adherence in type 2 diabetes mellitus. 2013 , 18, 267-74	12
1108	Avoidance of weight gain is important for oral type 2 diabetes treatments in Sweden and Germany: patient preferences. 2013 , 39, 397-403	30
1107	Prognostic implications of DPP-4 inhibitor vs. sulfonylurea use on top of metformin in a real world setting - results of the 1 year follow-up of the prospective DiaRegis registry. 2013 , 67, 1005-14	30
1106	Clinical evidence for the earlier initiation of insulin therapy in type 2 diabetes. 2013 , 15, 776-85	55
1105	Canagliflozin, a novel SGLT2 inhibitor for treatment of type 2 diabetes. 2013 , 47, 1301-11	22
1104	Obesity and diabetes. 2012 , 307-40	3

1103	Switching from premixed insulin to basal-bolus insulin glargine plus rapid-acting insulin: the ATLANTIC study. 2013 , 68, 28-33	14
1102	Glucocorticoid-induced hyperglycemia. 2013 , 345, 274-277	91
1101	Anti-Diabetic Compounds and their Patent Information: An Update. 2013 , 7, 35-48	2
1100	Comparison of physician practice patterns for older adults compared to NHANES diabetes cohort on oral/other therapy. 2013 , 13, 153-60	
1099	Effect of the combination of metformin and fenofibrate on glucose homeostasis in diabetic Goto-Kakizaki rats. 2013 , 45, e30	8
1098	[Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride]. 2013 , 138 Suppl 1, S16-26	3
1097	Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. 2013 , 83, 517-23	209
1096	[Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin]. 2013 , 138 Suppl 1, S27-38	7
1095	Insulin analogs for the management of type 2 diabetes. 2013 , 70, 320-34	2
1094	Vildagliptin in the Treatment of Type 2 Diabetes Mellitus. 2013 , 20, 165-176	
1093	[Diabetes treatment in patients with chronic kidney disease]. 2013 , 138, 1109-18; quiz 1119-22	2
1092	[Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin]. 2013 , 138 Suppl 1, S6-15	10
1091	Online disease management of diabetes: engaging and motivating patients online with enhanced resources-diabetes (EMPOWER-D), a randomized controlled trial. 2013 , 20, 526-34	143
1090	Time to initiation of oral antihyperglycemic and statin therapy in previously untreated patients with type 2 diabetes in the United States. 2013 , 29, 801-6	1
1089	How do we continue treatment in patients with type 2 diabetes when therapeutic goals are not reached with oral antidiabetes agents and lifestyle? Incretin versus insulin treatment. <i>Diabetes Care</i> , 2013 , 36 Suppl 2, S180-9	14.6 12
1088	Physiologic and weight-focused treatment strategies for managing type 2 diabetes mellitus: the metformin, glucagon-like peptide-1 receptor agonist, and insulin (MGI) approach. 2013 , 125, 112-26	9
1087	Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. 2013 , 3,	207
1086	Gender-dependent effects of metformin on vaspin and adiponectin in type 2 diabetes patients: a randomized clinical trial. 2013 , 45, 319-25	7

1085	Challenges in the management of type 2 diabetes mellitus and cardiovascular risk factors in obese subjects: what is the evidence and what are the myths?. 2013 , 2013, 856793	9
1084	Metformin inhibits goitrogenous effects of type 2 diabetes. 2013 , 169, 9-15	18
1083	Is there evidence to support use of premixed or prandial insulin regimens in insulin-naïve or previously insulin-treated type 2 diabetic patients?. <i>Diabetes Care</i> , 2013 , 36 Suppl 2, S205-11	14.6 8
1082	Barriers to insulin progression among patients with type 2 diabetes: a systematic review. 2013 , 39, 53-65	58
1081	Insulinization: A promising strategy for the treatment of type 2 diabetes mellitus. 2013 , 6, 1300-1306	7
1080	Cardiovascular importance of hyperglycemia and hypoglycemia. <i>Diabetes Care</i> , 2013 , 36 Suppl 2, S267-71	14.6 5
1079	Pharmacogenetics of oral antidiabetic drugs. 2013 , 2013, 686315	28
1078	The effects of bariatric procedures versus medical therapy for obese patients with type 2 diabetes: meta-analysis of randomized controlled trials. 2013 , 2013, 410609	16
1077	Characterisation of oral and i.v. glucose handling in truncally vagotomised subjects with pyloroplasty. 2013 , 169, 187-201	42
1076	Alveolar Gas Exchange and Pulmonary Functions in Patients with Type II Diabetes Mellitus. 2013 , 7, 1874-7	17
1075	Perceptions of Usability and Design for Prefilled Insulin Delivery Devices for Patients With Type 2 Diabetes. 2013 , 26, 16-28	3
1074	Diabetes and cancer: placing the association in perspective. 2013 , 20, 81-6	20
1073	Considerations for diabetes: treatment with insulin pen devices. 2013 , 20, 694-702	17
1072	Recent and emerging therapeutic medications in type 2 diabetes mellitus: incretin-based, Pramlintide, Colesevelam, SGLT2 Inhibitors, Tagatose, Succinobucol. 2013 , 20, 638-53	8
1071	Understanding heterogeneity in response to antidiabetes treatment: a post hoc analysis using SIDES, a subgroup identification algorithm. 2013 , 7, 420-30	15
1070	Initial antihyperglycemic drug therapy among 241 327 adults with newly identified diabetes from 2005 through 2010: a surveillance, prevention, and management of diabetes mellitus (SUPREME-DM) study. 2013 , 47, 1280-91	14
1069	Race as a factor for intensification of diabetes medications. 2013 , 39, 335-43	3
1068	Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. <i>Diabetes Care</i> , 2013 , 36 Suppl 2, S127-38	14.6 179

1067	Linagliptin as add-on therapy to insulin for patients with type 2 diabetes. 2013 , 9, 681-94	11
1066	The use of targeted therapies in pancreatic neuroendocrine tumours: patient assessment, treatment administration, and management of adverse events. 2013 , 5, 286-300	5
1065	Individualized glycaemic targets and pharmacotherapy in type 2 diabetes. 2013 , 10, 397-409	30
1064	Satisfaction with glucose-lowering treatment and well-being in patients with type 2 diabetes and myocardial infarction: a DIGAMI2 QoL sub-study. 2013 , 10, 263-9	6
1063	Optimizing the Clinical Use of the GLP-1 Receptor Agonist Exenatide Once Weekly. 2013 , 26, 46-52	1
1062	Liraglutide for the treatment of type 2 diabetes: a clinical update. 2013 , 20, 178-88	22
1061	Metformin and survival in pancreatic cancer: a retrospective cohort study. 2013 , 42, 1054-9	50
1060	HbA(1c) as a diagnostic tool for diabetes and pre-diabetes: the Bangladesh experience. 2013 , 30, e70-7	15
1059	Determining in-patient diabetes treatment satisfaction in the UK--the DIPSat study. 2013 , 30, 731-8	12
1058	Efficacy and safety of switching from basal insulin to sitagliptin in Japanese type 2 diabetes patients. 2013 , 45, 231-8	2
1057	Safety and efficacy of sitagliptin-metformin in fixed combination for the treatment of type 2 diabetes mellitus. 2013 , 6, 25-37	6
1056	Metformin-associated lactic acidosis in an older adult after colonoscopy: an uncommon trigger for a rare complication. 2013 , 61, 2257-2258	5
1055	Prescribing pattern of glucose lowering drugs in the United Kingdom in the last decade: a focus on the effects of safety warnings about rosiglitazone. 2013 , 75, 861-8	35
1054	Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes. 2013 , 5, 68-79	35
1053	Risk factors for type 2 diabetes mellitus preceded by β -cell dysfunction, insulin resistance, or both in older adults: the Cardiovascular Health Study. 2013 , 177, 1418-29	46
1052	Preferences for medication attributes among patients with type 2 diabetes mellitus in the UK. <i>Diabetes, Obesity and Metabolism</i> , 2013 , 15, 802-9	6.7 38
1051	Spontaneous quadriceps hematoma in an elderly adult taking therapeutic doses of warfarin. 2013 , 61, 2258-2260	1
1050	Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin. <i>Diabetes, Obesity and Metabolism</i> , 2013 , 15, 750-9	6.7 59

1049	Metformin therapy and kidney disease: a review of guidelines and proposals for metformin withdrawal around the world. 2013 , 22, 1027-35		37
1048	Barriers to the delivery of diabetes care in the Middle East and South Africa: a survey of 1,082 practising physicians in five countries. 2013 , 67, 1144-50		12
1047	Postprandial serum C-peptide value is the optimal index to identify patients with non-obese type 2 diabetes who require multiple daily insulin injection: Analysis of C-peptide values before and after short-term intensive insulin therapy. 2013 , 4, 618-25		10
1046	Baseline HbA1c predicts attainment of 7.0% HbA1c target with structured titration of insulin glargine in type 2 diabetes: a patient-level analysis of 12 studies. <i>Diabetes, Obesity and Metabolism</i> , 2013 , 15, 819-25	6.7	35
1045	Analysis of hypoglycemic events using negative binomial models. 2013 , 12, 233-42		12
1044	Effects of insulin changes on quality of life and glycemic control in Japanese patients with type 2 diabetes mellitus: The insulin-changing study intending to gain patients' insights into insulin treatment with patient-reported health outcomes in actual clinical treatments (INSIGHTs) study. 2013 , 4, 518-26		9
1043	The fate of tasoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial. <i>Diabetes Care</i> , 2013 , 36, 498-504	14.6	80
1042	Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X). <i>Diabetes Care</i> , 2013 , 36, 2945-51	14.6	193
1041	Flexible insulin dosing improves health-related quality-of-life (HRQoL): a time trade-off survey. 2013 , 16, 1357-65		32
1040	Management of the patient with diabetes and coronary artery disease: a contemporary review. 2013 , 9, 387-403		7
1039	Decline in placebo-controlled trial results suggests new directions for comparative effectiveness research. 2013 , 32, 1116-25		18
1038	Predictors of medication adherence in patients with type 2 diabetes mellitus. 2013 , 29, 1275-86		84
1037	The association between use of mealtime insulin pens versus vials and healthcare charges and resource utilization in patients with type 2 diabetes: a retrospective cohort study. 2013 , 16, 1231-7		8
1036	Efficacy and safety of adding pioglitazone or sitagliptin to patients with type 2 diabetes insufficiently controlled with metformin and a sulfonylurea. 2013 , 19, 980-8		28
1035	Efficacy and safety of stepwise introduction of insulin lispro mix 50 in Japanese patients with type 2 diabetes inadequately controlled by oral therapy. 2013 , 60, 763-72		4
1034	Pharmacometric Approaches to Guide Dose Selection of the Novel GPR40 Agonist TAK-875 in Subjects With Type 2 Diabetes Mellitus. 2013 , 2, e22		11
1033	Preadmission metformin use and mortality among intensive care patients with diabetes: a cohort study. 2013 , 17, R192		36
1032	Metformin decreases high-fat diet-induced renal injury by regulating the expression of adipokines and the renal AMP-activated protein kinase/acetyl-CoA carboxylase pathway in mice. 2013 , 32, 1293-302		40

1031 Insulinothérapie dans le diabète de type 2. **2013**, 10, 1-8

1030 Changing Diagnostic and Treatment Criteria for Chronic Illness: A Critical Consideration of their Impact on Low-Income Hispanic Patients. **2013**, 72, 242-253

3

1029 Bromocriptine for type 2 diabetes mellitus. **2013**,

1028 How insulin analogues can benefit patients. **2013**, 38, 44-8

1

1027 Diagnosis and treatment of diabetes mellitus in chronic pancreatitis. **2013**, 19, 7276-81

109

1026 The impact of brief high-intensity exercise on blood glucose levels. **2013**, 6, 113-22

81

1025 Trends in antidiabetic prescription patterns in Japan from 2005 to 2011. **2013**, 54, 93-7

68

1024 Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes. **2013**, 9, 155-63

119

1023 Lixisenatide as add-on therapy to basal insulin. **2013**, 8, 25-38

5

1022 Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years. **2013**, 6, 31-41

24

1021 Efficacy and safety of biphasic insulin aspart 30/70 in type 2 diabetes suboptimally controlled on oral antidiabetic therapy in Korea: a multicenter, open-label, single-arm study. **2013**, 37, 117-24

5

1020 Safety and efficacy of modern insulin analogues. **2013**, 37, 181-9

10

1019 Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus. **2013**, 8, 419-30

32

1018 Profile of vildagliptin in type 2 diabetes: efficacy, safety, and patient acceptability. **2013**, 9, 247-57

11

1017 Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies. **2013**, 6, 877-95

43

1016 The Effects of Nutrition Education and Diet Therapy on Glycemic and Lipidemic Control in Iranian Patients with Type 2 Diabetes Faezeh. **2013**, S3,

4

1015 Effect of a multidisciplinary-assisted resident diabetes clinic on resident knowledge and patient outcomes. **2013**, 5, 145-9

4

1014 Association between methylenetetrahydrofolate reductase C677T polymorphism and bone mineral density: the Dong-gu Study and the Namwon Study. **2013**, 28, 965-8

2

1013 Glucose: Glucose Tolerance. **2013**, 381-386

1012 Effect of baseline glycosylated hemoglobin A1c on glycemic control and diabetes management following initiation of once-daily insulin detemir in real-life clinical practice. **2013**, 19, 462-70 16

1011 A standardized vascular disease health check in europe: a cost-effectiveness analysis. **2013**, 8, e66454 30

1010 Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. **2013**, 8, e71583 300

1009 Update on Pharmacotherapy for Type 2 Diabetes. **2013**, 3, 250-361

1008 Association of dietary vitamin C and e intake and antioxidant enzymes in type 2 diabetes mellitus patients. **2013**, 5, 183-7 35

1007 Synergistic interaction between metformin and sulfonylureas on diclofenac-induced antinociception measured using the formalin test in rats. **2013**, 18, 253-8 6

1006 Metabolic and other effects of pioglitazone as an add-on therapy to metformin in the treatment of polycystic ovary syndrome (PCOS). **2013**, 12, 363-78 18

1005 Role of insulin in the type 2 diabetes therapy: past, present and future. **2013**, 11, 137-44 17

1004 A review of sitagliptin with special emphasis on its use in moderate to severe renal impairment. **2013**, 7, 893-903 12

1003 [Diabetes: time to redefine goals?]. **2013**, 57, 545-9 2

1002 Predictors of poor glycemic control in type 2 diabetic patients attending public hospitals in Dar es Salaam. **2014**, 6, 155-65 56

1001 Diabetes self-management education improves quality of care and clinical outcomes determined by a diabetes bundle measure. **2014**, 7, 533-42 79

1000 Tolerability of saxagliptin in patients with inadequately controlled type 2 diabetes: results from 6 phase III studies. **2014**, 20, 120-9 8

999 Use of metformin and vildagliptin for treatment of type 2 diabetes in the elderly. **2014**, 8, 811-8 9

998 Association of vitamin B12 deficiency and metformin use in patients with type 2 diabetes. **2014**, 29, 965-72 53

997 Effects of Patient Empowerment Programme (PEP) on clinical outcomes and health service utilization in type 2 diabetes mellitus in primary care: an observational matched cohort study. **2014**, 9, e95328 53

996 Prediction of glycated hemoglobin levels at 3 months after metabolic surgery based on the 7-day plasma metabolic profile. **2014**, 9, e109609 9

995	Higher prevalence of metformin-induced vitamin B12 deficiency in sulfonylurea combination compared with insulin combination in patients with type 2 diabetes: a cross-sectional study. 2014 , 9, e109878	16
994	Metformin protects skeletal muscle from cardiotoxin induced degeneration. 2014 , 9, e114018	33
993	Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. 2014 , 3, e02242	628
992	Light to moderate alcohol consumption is protective for type 2 diabetes mellitus in normal weight and overweight individuals but not the obese. 2014 , 2014, 634587	16
991	Optimal management of type 2 diabetes in patients with increased risk of hypoglycemia. 2014 , 7, 85-94	7
990	Towards a conceptual model of diabetes self-management among Chinese immigrants in the United States. 2014 , 11, 6727-42	12
989	Treating the elderly diabetic patient: special considerations. 2014 , 7, 391-400	6
988	Clinical utility in the treatment of type 2 diabetes with the saxagliptin/metformin fixed combination. 2014 , 8, 227-36	4
987	Efficacy and safety of insulin lispro in obese patients with type 2 diabetes: a retrospective metaanalysis of 7 randomized controlled trials. 2014 , 20, 389-98	2
986	Type 2 Diabetes Treatment Recommendations Update: Appropriate Use of Dipeptidyl Peptidase-4 Inhibitors. 2014 , 05,	1
985	The role of insulin resistance in diabetic neuropathy in Koreans with type 2 diabetes mellitus: a 6-year follow-up study. 2014 , 55, 700-8	16
984	Managing loss of glycemic control in middle-aged patients with diabetes: the role of GLP-1 receptor agonists in combination-therapy regimens. 2014 , 114, S14-21	0
983	Managing recent-onset diabetes: choosing durable, well-tolerated therapies and understanding the role of incretin-based therapies. 2014 , 114, S6-13	1
982	Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents. 2014 , 3, 212264	34
981	Does metformin have a "buffer effect" on serum TSH levels in euthyroid diabetic patients?. 2015 , 14, 280-5	6
980	Understanding insulin management: Role of the pharmacist. 2014 , 20, 85-95	2
979	Valoraci3n de la funci3n renal en diab3ticos tipo 2 y su adecuaci3n al tratamiento antidiab3tico oral. 2014 , 7, 8-13	
978	Metformin, but not rosiglitazone, attenuates the increasing plasma levels of a new cardiovascular marker, fibulin-1, in patients with type 2 diabetes. <i>Diabetes Care</i> , 2014 , 37, 760-6	14.6 9

977	tinyUPnP usage for home medical equipments control: Case study diabetes management. 2014 ,		1
976	Pancreatic gene variants potentially associated with dipeptidyl peptidase-4 inhibitor treatment response in Type 2 diabetes. 2014 , 15, 235-49		4
975	Hospital readmission and emergency department use based on prescribing patterns in patients with severely uncontrolled type 2 diabetes mellitus. 2014 , 16, 150-5		12
974	Streptozotocin-nicotinamide-induced rat model of type 2 diabetes (review). 2014 , 101, 408-20		112
973	Patients with type 2 diabetes mellitus failing on oral agents and starting once daily insulin regimen; a small randomized study investigating effects of adding vildagliptin. 2014 , 7, 579		2
972	Resting heart rate as a marker for identifying the risk of undiagnosed type 2 diabetes mellitus: a cross-sectional survey. 2014 , 14, 1052		17
971	Cardiometabolic risk is associated with atherosclerotic burden and prognosis: results from the partners coronary computed tomography angiography registry. <i>Diabetes Care</i> , 2014 , 37, 555-64	14.6	11
970	It's not black and white: individualizing metformin treatment in type 2 diabetes. 2014 , 99, 3125-8		5
969	Diabetes mellitus â an overview. 2014 , 1-57		3
968	Premi�re ann�e de suivi des patients diab�tiques de type 2 mis sous insuline en vie r�elle (�tude CREDIT-France). 2014 , 8, 623-629		
967	Rate of hypoglycemia in patients with type 2 diabetes receiving metformin plus saxagliptin versus metformin plus sulfonylurea: a retrospective observational cohort study using administrative claims data. 2014 , 9, 183-191		4
966	Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus. 2014 , 6, 107-13		20
965	Diabetes and related remedies in medieval Persian medicine. 2014 , 18, 142-9		24
964	Self-mixed/split insulin regimen: a serious omission in the ADA/EASD position statement. <i>Diabetes Care</i> , 2014 , 37, 3-4	14.6	2
963	Effect of diet or diet plus physical activity versus usual care on inflammatory markers in patients with newly diagnosed type 2 diabetes: the Early ACTivity in Diabetes (ACTID) randomized, controlled trial. 2014 , 3, e000828		18
962	IRS1 G972R missense polymorphism is associated with failure to oral antidiabetes drugs in white patients with type 2 diabetes from Italy. 2014 , 63, 3135-40		14
961	Management of diabetes mellitus type-2 in the geriatric population: Current perspectives. 2014 , 6, 151-7		9
960	Influence of baseline glycemia on outcomes with insulin glargine use in patients uncontrolled on oral agents. 2014 , 126, 111-25		4

959	Dipeptidyl peptidase-4 inhibitors as a third-line oral antihyperglycaemic agent in patients with type 2 diabetes mellitus: the impact of ethnicity. 2014 , 2014, 354040	3
958	Insulin analogs and cancer: a note of caution. 2014 , 5, 79	11
957	Low utilisation of diabetes medicines in Iran, despite their affordability (2000-2012): a time-series and benchmarking study. 2014 , 4, e005859	21
956	Technological solutions in chronic disease management for monitoring diabetes. 2014 , 15, 380	1
955	Application of clinical judgment and guidelines to achieving glycemic goals in type 2 diabetes: focus on pharmacologic therapy. 2014 , 126, 95-106	7
954	Glycemic targets and medication limitations for type 2 diabetes mellitus in the older adult. 2014 , 29, 110-23	8
953	Safety and effectiveness of dipeptidyl peptidase-4 inhibitors versus intermediate-acting insulin or placebo for patients with type 2 diabetes failing two oral antihyperglycaemic agents: a systematic review and network meta-analysis. 2014 , 4, e005752	30
952	Management of patients using combination therapy with pioglitazone and a dipeptidyl peptidase-4 inhibitor: an analysis of initial versus sequential combination therapy. 2014 , 126, 47-55	
951	Three years of liraglutide treatment offers continuously optimal glycemic control in a pediatric patient with maturity-onset diabetes of the young type 3. 2015 , 28, 327-31	6
950	Long-term tolerance and efficacy of adjunctive exenatide therapy on glycaemic control and bodyweight in type 2 diabetes: a retrospective study from a specialist diabetes outpatient clinic. 2014 , 44, 345-53	3
949	Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea. <i>Diabetes, Obesity and Metabolism</i> , 2014 , 16, 403-9	6.7 47
948	Systemic Allergic Reaction to the GLP-1 Receptor Agonist Exenatide. 2014 , 30, 182-186	1
947	Glycemic control parameters in insulin-naïve patients with uncontrolled type 2 diabetes referred to endocrinologists, and degree of implementation of the national Spanish consensus for the management of hyperglycemia. 2014 , 61, 541-547	
946	Pharmacotherapy for Hyperglycemia in Noncritically Ill Hospitalized Patients. 2014 , 27, 180-8	26
945	Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release. <i>Diabetes Care</i> , 2014 , 37, 3309-16	14.6 78
944	A systematic literature review of methodologies used to assess medication adherence in patients with diabetes. 2014 , 30, 1071-85	61
943	Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer. 2014 , 25, 763-773	58
942	Intensification of antihyperglycemic therapy among patients with incident diabetes: a Surveillance Prevention and Management of Diabetes Mellitus (SUPREME-DM) study. 2014 , 23, 699-710	30

941	Development and validation of the Diabetes Medication System Rating Questionnaire-Short Form. 2014 , 31, 1237-44		5
940	Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus. 2014 , 5, 382-91		81
939	Foodinformatics. 2014 ,		9
938	Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naïve patients with type 2 diabetes: a randomized, double-blind, 6-month study. <i>Diabetes, Obesity and Metabolism</i> , 2014 , 16, 613-21	6.7	46
937	Predictive factors of durability to sitagliptin: Slower reduction of glycated hemoglobin, older age and higher baseline glycated hemoglobin. 2014 , 5, 51-9		6
936	Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1). 2014 , 31, 176-84		93
935	Physical characteristics that predict final basal insulin dose in type 2 diabetes mellitus, with a special focus on BMI. 2014 , 24, 1354-9		3
934	Glycemic control parameters in insulin-naïve patients with uncontrolled type 2 diabetes referred to endocrinologists, and degree of implementation of the national Spanish consensus for the management of hyperglycemia. 2014 , 61, 541-7		2
933	Continuing improvement in type 2 diabetes care through performance-based evaluations. 2014 , 5, 107-11		2
932	Comparison of the efficacy of sitagliptin and glimepiride dose-up in Japanese patients with type 2 diabetes poorly controlled by sitagliptin and glimepiride in combination. 2014 , 5, 320-6		6
931	Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects. 2014 , 54, 792-9		32
930	Glycemic control among patients with type 2 diabetes who initiate basal insulin: a retrospective cohort study. 2014 , 17, 21-31		20
929	Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy. <i>Diabetes, Obesity and Metabolism</i> , 2014 , 16, 206-14	6.7	7
928	A drug and disease model for lixisenatide, a GLP-1 receptor agonist in type 2 diabetes. 2014 , 54, 267-78		10
927	Targeted learning in real-world comparative effectiveness research with time-varying interventions. 2014 , 33, 2480-520		32
926	Stevia rebaudiana Bertoni. Un potencial adyuvante en el tratamiento de la diabetes mellitus. 2014 , 12, 218-226		5
925	The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy. <i>Diabetes Care</i> , 2014 , 37, 1924-30	14.6	40
924	Barriers to initiating insulin in type 2 diabetes patients: development of a new patient education tool to address myths, misconceptions and clinical realities. 2014 , 7, 437-50		43

923 **Is It Really No Big Deal?** Suggestions for Providers From Patients With Type 2 Diabetes. **2014**, 2, 32-39

922 Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR). **2014**, 14, 170

49

921 Validation of a hemoglobin A1c model in patients with type 1 and type 2 diabetes and its use to go beyond the averaged relationship of hemoglobin A1c and mean glucose level. **2014**, 12, 328

11

920 Adding a DPP-4 inhibitor to metformin therapy may be safer than you think. **2014**, 30, 791-4

1

919 Single-fiber electromyography of facial and limb muscles in diabetic patients with or without neuropathy. **2014**, 31, 450-5

1

918 Chronic care model as a framework to improve diabetes care at an academic internal medicine faculty-resident practice. **2014**, 37, 42-50

6

917 A Case of a Patient With Type 2 Diabetes and Respiratory Comorbidities. **2014**, 29, 313-324

2

916 Bioequivalence of saxagliptin/metformin extended-release (XR) fixed-dose combination tablets and single-component saxagliptin and metformin XR tablets in healthy adult Chinese subjects. **2014**, 34, 763-72

3

915 Optimal CD4 count for initiating HIV treatment: impact of CD4 observation frequency and grace periods, and performance of dynamic marginal structural models. **2014**, 25, 194-202

3

914 Management of type 2 diabetes mellitus in self-motivated patients: optimized diet, exercise, and medication for weight loss and cardiometabolic fitness. **2014**, 42, 49-59

4

913 Commonly used endocrine drugs. **2014**, 120, 809-24

4

912 DPP-IV, An Important Target for Antidiabetic Functional Food Design. **2014**, 177-212

3

911 Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes. **2014**, 126, 60-72

20

910 Combining clinical judgment with guidelines for the management of type 2 diabetes: overall standards of comprehensive care. **2014**, 126, 85-94

5

909 A critical appraisal of antihyperglycemic and cardioprotective activities of liraglutide: A glucagon-like peptide-1 analog. **2014**, 4, 141

2

908 Insulin increases ceramide synthesis in skeletal muscle. **2014**, 2014, 765784

77

907 The use of clinical guidelines highlights ongoing educational gaps in physicians' knowledge and decision making related to diabetes. **2014**, 14, 186

17

906 Clinical study of treatment switching from premixed insulin to basal insulin combined with oral hypoglycemic drugs in patients with type 2 diabetes. **2014**, 6, 37

6

905	Association between hyperglycemia at admission during hospitalization for acute myocardial infarction and subsequent diabetes: insights from the veterans administration cardiac care follow-up clinical study. <i>Diabetes Care</i> , 2014 , 37, 409-18	14.6	21
904	The relationship between uncontrolled glycemia and the cost of hospitalization. 2014 , 28, 283-7		2
903	Factors influencing self-management in patients with type 2 diabetes: a quantitative systematic review protocol. 2014 , 70, 187-200		22
902	Two diets with different haemoglobin A1c and antiglycaemic medication effects despite similar weight loss in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2014 , 16, 90-3	6.7	65
901	[INERTIA study: Clinical inertia in non-insulinized patients on oral hypoglycemic treatment. A study in Spanish primary and specialty care settings]. 2014 , 142, 478-84		14
900	A weight loss program in a chiropractic practice: a retrospective analysis. 2014 , 20, 125-9		3
899	Clinical and economic characteristics associated with type 2 diabetes. 2014 , 214, 121-30		11
898	Effects of metformin dose on cancer risk reduction in patients with type 2 diabetes mellitus: a 6-year follow-up study. 2014 , 34, 36-45		24
897	Efficacy and safety of initial combination of DPP-IV inhibitors and metformin versus metformin monotherapy in type 2 diabetes: a systematic review of randomized controlled trials. <i>Diabetes, Obesity and Metabolism</i> , 2014 , 16, 179-185	6.7	6
896	A nomogram to estimate the proportion of patients at hemoglobin A1c target . 2014 , 51, 305-11		6
895	“Why I do not want to take insulin shots” Findings from a qualitative study among diabetic patients in Malaysia. 2014 , 22, 3-11		5
894	Braun gastrointestinal bypass surgery exerts similar hypoglycemic effects, with minimal operation time and earlier functional recovery, than Roux-en-Y bypass in type 2 diabetic rats. 2014 , 24, 171-8		
893	Cloud based intelligent system for delivering health care as a service. 2014 , 113, 346-59		98
892	Metformin is associated with improved survival in endometrial cancer. 2014 , 132, 438-42		117
891	Intervenci3 farmac3utica en la prescripci3 de metformina en pacientes con diabetes mellitus tipo 2 e insuficiencia renal. 2014 , 30, 17-22		
890	Simple HPLC-UV method for the quantification of metformin in human plasma with one step protein precipitation. 2014 , 22, 483-7		37
889	Incidence and predictors of hypoglycemia in Japanese patients with type 2 diabetes treated by insulin glargine and oral antidiabetic drugs in real-life: ALOHA post-marketing surveillance study sub-analysis. 2014 , 6, 20		11
888	Prevalence of undiagnosed and inadequately treated type 2 diabetes mellitus, hypertension, and dyslipidemia in morbidly obese patients who present for bariatric surgery. 2014 , 24, 927-35		11

- 887 The Relationship of Type 2 Diabetes, Oral Diabetes Medications, and Insulin Therapy to Risk for Breast Cancer. **2014**, 3, 1-8
- 886 An observational study of socioeconomic and clinical gradients among diabetes patients hospitalized for avoidable causes: evidence of underlying health disparities in China?. **2014**, 13, 9 3
- 885 Trends in insulin initiation and treatment intensification among patients with type 2 diabetes. **2014**, 29, 320-7 18
- 884 Saxagliptin as initial therapy in treatment-naïve Indian adults with type 2 diabetes mellitus inadequately controlled with diet and exercise alone: a randomized, double-blind, placebo-controlled, phase IIb clinical study. **2014**, 34, 201-209 8
- 883 Therapeutic properties of VO(dmpp)2 as assessed by in vitro and in vivo studies in type 2 diabetic GK rats. **2014**, 131, 115-22 18
- 882 Updates on the management of diabetes in dialysis patients. **2014**, 27, 135-45 86
- 881 Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK health care cost perspective. *Diabetes, Obesity and Metabolism*, **2014**, 16, 366-75 6.7 34
- 880 Chronic metformin treatment improves post-stroke angiogenesis and recovery after experimental stroke. **2014**, 39, 2129-38 89
- 879 A multistate model and an algorithm for measuring long-term adherence to medication: a case of diabetes mellitus type 2. **2014**, 17, 266-74 11
- 878 Fiches cliniques. **2014**, 407-413
- 877 Periprocedural glycemic control in patients with diabetes mellitus undergoing coronary angiography with possible percutaneous coronary intervention. **2014**, 113, 1474-80 6
- 876 Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis. *Diabetes, Obesity and Metabolism*, **2014**, 16, 30-7 6.7 83
- 875 Metformin accumulation: lactic acidosis and high plasmatic metformin levels in a retrospective case series of 66 patients on chronic therapy. **2014**, 52, 129-35 72
- 874 A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON). *Diabetes, Obesity and Metabolism*, **2014**, 16, 636-44 6.7 138
- 873 Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis. *Diabetes, Obesity and Metabolism*, **2014**, 16, 433-42 6.7 64
- 872 Synthesis and biological evaluation of some new pyrazoline substituted benzenesulfonylurea/thiourea derivatives as anti-hyperglycaemic agents and aldose reductase inhibitors. **2014**, 80, 209-17 16
- 871 Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials. **2014**, 30, 241-56 55
- 870 Phenotypic screening to identify small-molecule enhancers for glucose uptake: target identification and rational optimization of their efficacy. **2014**, 53, 5102-6 16

- 869 The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. **2014**, 30, 269-83 27
- 868 Effect of trimetazidine on recurrent angina pectoris and left ventricular structure in elderly multivessel coronary heart disease patients with diabetes mellitus after drug-eluting stent implantation: a single-centre, prospective, randomized, double-blind study at 2-year follow-up. **2014**, 34, 251-8 18
- 867 The older patient with diabetes: a practical approach. **2014**, 30, 88-95 9
- 866 Investigating G protein signalling bias at the glucagon-like peptide-1 receptor in yeast. **2014**, 171, 3651-65 35
- 865 Lixisenatide, a novel GLP-1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus. *Diabetes, Obesity and Metabolism*, **2014**, 16, 588-601 6.7 26
- 864 Barriers to the delivery of optimal antidiabetic therapy in the Middle East and Africa. **2014**, 68, 503-11 7
- 863 Combined antidiabetic benefits of exenatide and dapagliflozin in diabetic mice. *Diabetes, Obesity and Metabolism*, **2014**, 16, 376-80 6.7 14
- 862 Glycemic targets in diabetes. **2016**, 36, 359-369
- 861 Prevention of Obesity and Type 2 Diabetes with Aged Citrus Peel (Chenpi) Extract. **2016**, 64, 2053-61 70
- 860 A clinical study of the anti-diabetic effect of a simple Chinese herbal formula, PSP-1. **2016**, 8, 458-464
- 859 Disease Control Among Patients With Diabetes and Severe Depressive Symptoms. **2016**, 7, 130-4 6
- 858 Glucose-lowering therapy in type 2 diabetes. New hope after the EMPA-REG outcome trial. **2016**, 41, 208-16 3
- 857 Newly detected abnormal glucose regulation and long-term prognosis after acute myocardial infarction: Comparison of an oral glucose tolerance test and glycosylated haemoglobin A1c. **2016**, 214, 310-5 18
- 856 Solubility and solution thermodynamics of Meldrum's adduct in ethyl acetate plus (acetonitrile, ethanol, hexane) binary solvent mixtures. **2016**, 220, 354-363 4
- 855 Genetic variations in TCF7L2 influence therapeutic response to sulfonylureas in Indian diabetics. **2016**, 121, 35-40 10
- 854 Psychometric Evaluation of a Turkish Version of the Diabetes Fear of Self-injecting and Self-testing Questionnaire (D-FISQ). **2016**, 10, 195-200 2
- 853 Tratamiento de la diabetes mellitus (II). Hipoglucemiantes no insulínicos. **2016**, 12, 1013-1025
- 852 Hepatic ZIP14-mediated Zinc Transport Contributes to Endosomal Insulin Receptor Trafficking and Glucose Metabolism. **2016**, 291, 23939-23951 24

851	Comparison of antidiabetic potential of (+) and (–)-thoephaphenol, a pair of enantiomers isolated from <i>Ampelocissus indica</i> (L.) and <i>Vateria indica</i> Linn., with respect to inhibition of digestive enzymes and induction of glucose uptake in L6 myotubes. 2016 , 6, 77075-77082	10
850	Sesquiterpenes from Baizhu Stimulate Glucose Uptake by Activating AMPK and PI3K. 2016 , 44, 963-79	12
849	Efficacy and safety of once-daily insulin degludec dosed flexibly at convenient times vs fixed dosing at the same time each day in a Japanese cohort with type 2 diabetes: A randomized, 26-week, treat-to-target trial. 2016 , 7, 711-7	10
848	Short-term and long-term effects of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus patients with renal impairment: a meta-analysis of randomized controlled trials. 2016 , 32, 460-9	7
847	Effects of Resveratrol on Receptor for Advanced Glycation End Products (RAGE) Expression and Oxidative Stress in the Liver of Rats with Type 2 Diabetes. 2016 , 30, 66-71	51
846	Comparison of charges and resource use associated with saxagliptin and sitagliptin. 2016 , 6, 26	1
845	Insulinotropic Effects of Whey: Mechanisms of Action, Recent Clinical Trials, and Clinical Applications. 2016 , 69, 56-63	34
844	New glycemic targets for patients with diabetes from the Japan Diabetes Society. 2016 , 7, 327-330	3
843	Predictors of efficacy of GLP-1 agonists and DPP-4 inhibitors: A systematic review. 2016 , 121, 27-34	22
842	Glycemic control and adherence to basal insulin therapy in Taiwanese patients with type 2 diabetes mellitus. 2016 , 7, 881-888	9
841	Do We Need Updated Guidelines on the Use of Insulin Pump Therapy in Type 2 Diabetes? A Review of National and International Practice Guidelines. 2016 , 10, 1388-1398	2
840	Comparison of cardiovascular and metabolic outcomes in people with type 2 diabetes on insulin versus non-insulin glucose-lowering therapies (GLTs): A systematic review and meta-analysis of clinical trials. 2016 , 121, 69-85	10
839	Recent advances in the development of protein tyrosine phosphatase 1B inhibitors for Type 2 diabetes. 2016 , 8, 1239-58	40
838	Next-generation phenotypic screening. 2016 , 8, 1331-47	34
837	The cost-effectiveness of exenatide twice daily (BID) vs insulin lispro three times daily (TID) as add-on therapy to titrated insulin glargine in patients with type 2 diabetes. 2016 , 19, 1167-1174	6
836	Effect of supplementation of low-molecular-weight chitosan oligosaccharide, GO2KA1, on postprandial blood glucose levels in healthy individuals following bread consumption. 2016 , 25, 911-914	6
835	The transcription factor Prep1 controls hepatic insulin sensitivity and gluconeogenesis by targeting nuclear localization of FOXO1. 2016 , 481, 182-188	4
834	Basal-bolus Therapy in Patients with Type 2 Diabetes Mellitus in the UK: Patient Characteristics, Treatment Patterns and the Effect of Switching to Premixed Insulin. 2016 , 7, 793-807	4

833	Chronic administration of ethanol leaf extract of <i>Moringa oleifera</i> Lam. (Moringaceae) may compromise glycaemic efficacy of Sitagliptin with no significant effect in retinopathy in a diabetic rat model. 2016 , 194, 895-903			16
832	Investigation of Risk Factors Affecting Lactate Levels in Japanese Patients Treated with Metformin. 2016 , 39, 2022-2027			4
831	Safety, Efficacy, and Patient Acceptability of Everolimus in the Treatment of Breast Cancer. 2016 , 10, 239-252			7
830	Early treatment revisions by addition or switch for type 2 diabetes: impact on glycemic control, diabetic complications, and healthcare costs. <i>BMJ Open Diabetes Research and Care</i> , 2016 , 4, e000099	4.5		14
829	Use of an electronic health record to identify prevalent and incident cardiovascular disease in type 2 diabetes according to treatment strategy. <i>BMJ Open Diabetes Research and Care</i> , 2016 , 4, e000206	4.5		5
828	The level of netrin-1 is decreased in newly diagnosed type 2 diabetes mellitus patients. 2016 , 16, 33			24
827	Influence of health warnings on the use of rosiglitazone and pioglitazone in an area of Spain: A time-series study. 2016 , 4, 2050312116653054			3
826	Metformine-intoxicatie: een combinatie van ernstige hypoglykemie en lactatacidose. 2016 , 14, 49-51			
825	Effects of saxagliptin add-on therapy to insulin on blood glycemic fluctuations in patients with type 2 diabetes: A randomized, control, open-labeled trial. 2016 , 95, e5229			13
824	A checklist that enhances the provision of education during insulin initiation simulation: a randomized controlled trial. 2016 , 33, 1204-10			1
823	CYP2C8 and SLCO1B1 Variants and Therapeutic Response to Thiazolidinediones in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2016 , 39, 1902-1908	14.6		40
822	Sulfonylurea use and the risk of hospital readmission in patients with type 2 diabetes. 2016 , 16, 4			9
821	Therapeutic inertia or individualization? Delay in clinical management of type 2 diabetes mellitus. 2016 , 32, 1477-8			6
820	Selection Bias When Using Instrumental Variable Methods to Compare Two Treatments But More Than Two Treatments Are Available. 2016 , 12, 219-32			12
819	Stability-Indicating HPLC-DAD Method for the Determination of Linagliptin in Tablet Dosage Form: Application to Degradation Kinetics. 2016 , 54, 1560-1566			19
818	The Impact of Laparoscopic Adjustable Gastric Banding on an NHS Cohort of Type 2 Diabetics: a Prospective Cohort Study. 2016 , 26, 2006-2013			5
817	Cross-National Variation in Glycemic Control and Diabetes-Related Distress Among East Asian Patients Using Insulin: Results from the MOSAIC Study. 2016 , 7, 349-60			5
816	Predictors for achieving target glycemic control in Japanese patients with type 2 diabetes after initiation of basal supported oral therapy using insulin glargine: sub-analysis of the ALOHA2 study, drug use surveillance in Japan. 2016 , 7, 188-198			5

815	A reliable serum C-peptide index for the selection of an insulin regimen to achieve good glycemic control in obese patients with type 2 diabetes: an analysis from a short-term study with intensive insulin therapy. 2016 , 7, 235-243	0
814	Clinical and genetic predictors of dipeptidyl peptidase-4 inhibitor treatment response in Type 2 diabetes mellitus. 2016 , 17, 867-81	16
813	Comparative risk for cardiovascular diseases of dipeptidyl peptidase-4 inhibitors vs. sulfonylureas in combination with metformin: Results of a two-phase study. 2016 , 30, 1339-46	5
812	Autovigilância da doença e qualidade de vida dos doentes diabéticos: estudo observacional em farmácias comunitárias. 2016 , 34, 11-19	1
811	A Comparison of the Use and Quality of Antidiabetic Medication Regimens Between Non-Hispanic Black and White Adults With Uncontrolled Type 2 Diabetes in the US: NHANES 2003-2012. 2016 , 42, 234-42	2
810	PeopleSave: Recommending effective drugs through web crowdsourcing. 2016 ,	0
809	Glibenclamide-induced profound hypoglycaemic crisis: a case report. 2016 , 7, 84-7	2
808	Simulation of a computed HbA1c using a weighted average glucose. 2016 , 5, 226	3
807	Sodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effects. 2016 , 2, 244-55	29
806	Pharmacokinetics and Pharmacodynamics of Henagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, in Chinese Patients with Type 2 Diabetes Mellitus. 2016 , 36, 195-202	6
805	Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes. 2016 , 30, 227-36	29
804	Metformin: A candidate for the treatment of gynecological tumors based on drug repositioning. 2016 , 11, 1287-1293	25
803	Cardiovascular safety of anti-diabetic drugs. 2016 , 2, 32-43	34
802	Coronary Artery Disease and Diabetes Mellitus. 2016 , 12, 117-33	12
801	Advances in Healthcare Informatics and Analytics. 2016 ,	2
800	Glucose lowering effect of montbretin A in Zucker Diabetic Fatty rats. 2016 , 411, 373-81	10
799	Clinical coaching in primary care: Capable of improving control in patients with type 2 diabetes mellitus?. <i>Primary Care Diabetes</i> , 2016 , 10, 171-8	2.4 2
798	Changes in Type 2 Diabetes Mellitus Patients in German Primary Care Prior to (2006) and After (2010, 2014) Launch of New Drugs. 2016 , 10, 414-20	11

797	Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. 2016 , 4, 411-9	308
796	Short-Chain Fatty Acid Acetate Stimulates Adipogenesis and Mitochondrial Biogenesis via GPR43 in Brown Adipocytes. 2016 , 157, 1881-94	66
795	Efficacy and safety assessment of basal supported oral therapy (BOT) with insulin glargine in a real-life clinical setting, stratified by concomitant orally administered antidiabetic agent (OAD) regimens including dipeptidyl peptidase-4 inhibitor (DPP-4i): subanalysis of the ALOHA2 study, drug-use surveillance in Japan. 2016 , 7, 299-307	3
794	The impact of initial antidiabetic agent and use of monitoring agents on prescription costs in newly treated type 2 diabetes: A retrospective cohort analysis. 2016 , 113, 152-9	4
793	A systematic review of the safety of incretin-based therapies in type 2 diabetes. 2016 , 11, 217-232	4
792	Gastroretentive systems - a proposed strategy to modulate anthocyanin release and absorption for the management of diabetes. 2016 , 23, 1892-901	6
791	Effects of Metformin and Exercise Training, Alone or in Combination, on Cardiac Function in Individuals with Insulin Resistance. 2016 , 5, 63-73	8
790	A Novel Allosteric Insulin Receptor-Activating Antibody Reduces Hyperglycemia without Hypoglycemia in Diabetic Cynomolgus Monkeys. 2016 , 356, 466-73	9
789	Relationship of Serum Adiponectin Levels and Metformin Therapy in Patients with Type 2 Diabetes. 2016 , 48, 92-8	25
788	Drug usage patterns and treatment costs in newly-diagnosed type 2 diabetes mellitus cases, 2007 vs 2012: findings from a large US healthcare claims database analysis. 2016 , 19, 655-62	12
787	Time to insulin initiation and long-term effects of initiating insulin in people with type 2 diabetes mellitus: the Hoorn Diabetes Care System Cohort Study. 2016 , 174, 563-71	14
786	Metabolic Response of Slowly Absorbed Carbohydrates in Type 2 Diabetes Mellitus. 2016 ,	
785	Antihyperglycemic and antidiabetic effects of Ethyl (S)-2-(1-cyclohexylsulfamide carbamoyloxy) propanoate in streptozotocin-induced diabetic Wistar rats. 2016 , 779, 122-30	2
784	Hypoglycemia and diabetes: increased need for awareness. 2016 , 32, 1479-86	7
783	Hyperglycemic and Hypoglycemic Drugs. 2016 , 419-458	
782	Exercise at lunchtime: effect on glycemic control and oxidative stress in middle-aged men with type 2 diabetes. 2016 , 116, 573-82	23
781	Lifetime risk of developing impaired glucose metabolism and eventual progression from prediabetes to type 2 diabetes: a prospective cohort study. 2016 , 4, 44-51	128
780	In vitro effects of bis(1,2-dimethyl-3-hydroxy-4-pyridinonato)oxidovanadium(IV), or VO(dmppp)2, on insulin secretion in pancreatic islets of type 2 diabetic Goto-Kakizaki rats. 2016 , 154, 29-34	10

779	Dapagliflozin combination therapy in type 2 diabetes mellitus. 2016 , 128, 124-36	2
778	Hypoglycemic events analysis via recurrent time-to-event (HEART) models. 2016 , 26, 280-98	5
777	Medication Adherence Does Not Explain Black-White Differences in Cardiometabolic Risk Factor Control among Insured Patients with Diabetes. 2016 , 31, 188-195	13
776	Designing of the fixed-dose gastroretentive bilayer tablet for sustained release of metformin and immediate release of atorvastatin. 2016 , 42, 340-9	10
775	The influence of hyperglycemia during radiotherapy on survival in patients with primary glioblastoma. 2016 , 55, 201-7	23
774	Telemedicine compared with standard care in type 2 diabetes mellitus: A randomized trial in an outpatient clinic. 2016 , 22, 363-8	29
773	Evaluation of the long-term cost-effectiveness of liraglutide therapy for patients with type 2 diabetes in France. 2016 , 19, 121-34	15
772	Ameliorative Effect of Adjunct Therapy of Metformin with Atorvastatin on Streptozotocin-induced Diabetes Mellitus in Rats. 2016 , 66, 28-32	4
771	Perceptions of Insulin Treatment Among African Americans With Uncontrolled Type 2 Diabetes. 2016 , 27, 172-80	4
770	Risk of overall mortality and cardiovascular events in patients with type 2 diabetes on dual drug therapy including metformin: A large database study from the Cleveland Clinic. 2016 , 8, 279-85	16
769	Glycated hemoglobin detection with electrochemical sensing amplified by gold nanoparticles embedded N-doped graphene nanosheet. 2017 , 89, 578-584	56
768	The relationship of regional hemoglobin A1c testing and amputation rate among patients with diabetes. 2017 , 25, 142-148	0
767	α-Glucosidase and α-Amylase inhibitors from seed oil: A review of liposoluble substance to treat diabetes. 2017 , 57, 3438-3448	64
766	Structured self-monitoring of blood glucose regimens improve glycemic control in poorly controlled Chinese patients on insulin therapy: Results from COMPASS. 2017 , 9, 495-501	10
765	Management of Diabetes in the Pre-End-Stage Renal Disease and Chronic Kidney Disease. 2017 , 57-75	
764	Managing Diabetic Nephropathies in Clinical Practice. 2017 ,	
763	The role of insulin pump therapy for type 2 diabetes mellitus. 2017 , 33, e2822	13
762	Metformin; a review of its history and future: from lilac to longevity. 2017 , 18, 10-16	75

761	The Effect of Prolonged Glucosamine Usage on HbA1c Levels and New-Onset Diabetes Mellitus in Overweight and Obese Middle-Aged Women. 2017 , 130, 731-737.e6		6
760	Antihyperglycemic Medications. 2017 , 2, 25-38		
759	Changes in the management of type 2 diabetic patients in family medicine practices in the Bursa region. <i>Primary Care Diabetes</i> , 2017 , 11, 178-183	2.4	1
758	Delay of insulin initiation in patients with type 2 diabetes mellitus inadequately controlled with oral hypoglycemic agents (analysis of patient- and physician-related factors): A prospective observational DIPP-FACTOR study in Korea. 2017 , 8, 346-353		17
757	Pancreatogenic diabetes: etiology, implications, and management. 2017 , 211-224		
756	Hypoglycemic drugs induce antioxidant aldehyde dehydrogenase activity and remain high in patients with glycemic control in type 2 diabetes. 2017 , 800, 57-62		3
755	Effects of a lifestyle education program on glycemic control among patients with diabetes at Kigali University Hospital, Rwanda: A randomized controlled trial. 2017 , 126, 129-137		17
754	Long-term treatment study of global standard dose metformin in Japanese patients with type 2 diabetes mellitus. 2017 , 8, 286-295		12
753	DPP-4 Inhibitor and Estrogen Share Similar Efficacy Against Cardiac Ischemic-Reperfusion Injury in Obese-Insulin Resistant and Estrogen-Deprived Female Rats. 2017 , 7, 44306		13
752	Pharmacogenetics in type 2 diabetes: precision medicine or discovery tool?. 2017 , 60, 800-807		41
751	Antidiabetic effect of SN158 through PPAR γ dual activation in ob/ob mice. 2017 , 268, 24-30		5
750	Effects of medication-treated diabetes on incidence and progression of knee osteoarthritis: a longitudinal analysis of the Osteoarthritis Initiative data. 2017 , 37, 983-991		11
749	Dynamic population pharmacokinetic-pharmacodynamic modelling and simulation supports similar efficacy in glycosylated haemoglobin response with once or twice-daily dosing of canagliflozin. 2017 , 83, 1072-1081		8
748	Metformin depresses overactivated Notch1/Hes1 signaling in colorectal cancer patients with type 2 diabetes mellitus. 2017 , 28, 531-539		5
747	Hyperglycemia. 225-230		1
746	Hypoglycaemia seriousness and weight gain as determinants of cardiovascular disease outcomes among sulfonylurea users. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 1425-1435	6.7	28
745	A Comparison of the Use of Antidepressant Treatment Between Non-Hispanic Black and White and Mexican American Adults With Type 2 Diabetes in the United States. 2017 , 43, 171-179		4
744	Metformin causes a futile intestinal-hepatic cycle which increases energy expenditure and slows down development of a type 2 diabetes-like state. 2017 , 6, 737-747		15

743	Lysophosphatidic acid counteracts glucagon-induced hepatocyte glucose production via STAT3. 2017 , 7, 127	5
742	Pancreatic Cancer. 2017 ,	1
741	Prescription of oral antidiabetic drugs in Tyrol - Data from the Tyrol diabetes registry 2012-2015. 2017 , 129, 46-51	5
740	Metformin, the aspirin of the 21st century: its role in gestational diabetes mellitus, prevention of preeclampsia and cancer, and the promotion of longevity. 2017 , 217, 282-302	139
739	BPI-3016, a novel long-acting hGLP-1 analogue for the treatment of Type 2 diabetes mellitus. 2017 , 122, 130-139	6
738	Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes receiving conventional therapy: clinical implication of the importance of exercise habits during treatment with ipragliflozin. 2017 , 8, 275-285	5
737	Management of Hyperglycemia and Diabetes in the Emergency Department. 2017 , 17, 56	13
736	Assessing Psychological Insulin Resistance in Type 2 Diabetes: a Critical Comparison of Measures. 2017 , 17, 46	7
735	Blood glucose monitoring in type 2 diabetes - Nepalese patients' opinions and experiences. 2017 , 10, 1322400	3
734	Metformin combined with acarbose vs. single medicine in the treatment of type 2 diabetes: A meta-analysis. 2017 , 13, 3137-3145	6
733	Metformin alters the gut microbiome of individuals with treatment-naïve type 2 diabetes, contributing to the therapeutic effects of the drug. 2017 , 23, 850-858	732
732	Knowledge, attitude and practice related to diabetes mellitus among the general public in Galle district in Southern Sri Lanka: a pilot study. 2017 , 17, 535	27
731	CONCENTRATED INSULINS: CLINICAL APPLICATIONS & USE IN PRACTICAL SETTINGS. 2017 , 23, 1-30	
730	Continuum Deformation of Multi-Agent Systems Under Directed Communication Topologies. 2017 , 139,	8
729	Adding Prandial Insulin to Basal Insulin Plus Oral Antidiabetic Drugs in Chinese Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Single-Arm Study. 2017 , 8, 611-621	
728	Update on Glucose Management Among Noncritically Ill Patients Hospitalized on Medical and Surgical Wards. 2017 , 1, 247-259	5
727	Co-treatment of breast cancer cells with pharmacologic doses of 2-deoxy-D-glucose and metformin: Starving tumors. 2017 , 37, 2418-2424	23
726	Obesity-associated digestive cancers: A review of mechanisms and interventions. 2017 , 39, 101042831769502023	23

725	Exenatide Add-on to Continuous Subcutaneous Insulin Infusion Therapy Reduces Bolus Insulin Doses in Patients with Type 2 Diabetes: A Randomized, Controlled, Open-Label Trial. 2017 , 8, 177-187	13
724	New glycemic targets for patients with diabetes from the Japan Diabetes Society. 2017 , 8, 123-125	33
723	Patterns of diabetes care in Slovenia, Croatia, Serbia, Bulgaria and Romania : An observational, non-interventional, cross-sectional study. 2017 , 129, 192-200	6
722	Anti-diabetic effect of the ethyl acetate fraction of <i>Clerodendrum volubile</i> : protocatchuic acid suppresses phagocytic oxidative burst and modulates inflammatory cytokines. 2017 , 86, 307-315	29
721	The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial. 2017 , 8, 101-114	74
720	Premixed vs basal-bolus insulin regimen in Type 2 diabetes: comparison of clinical outcomes from randomized controlled trials and real-world data. 2017 , 34, 1728-1736	13
719	Micellar Nanomedicine of Novel Fatty Acid Modified <i>Xenopus</i> Glucagon-like Peptide-1: Improved Physicochemical Characteristics and Therapeutic Utilities for Type 2 Diabetes. 2017 , 14, 3954-3967	18
718	Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders. 2017 , 214, 3219-3238	288
717	Managing diabetes in the presence of renal impairment. 2017 , 28, 24-30	4
716	Oxamate Enhances the Anti-Inflammatory and Insulin-Sensitizing Effects of Metformin in Diabetic Mice. 2017 , 100, 218-228	5
715	Gastrointestinal Adverse Events of Dipeptidyl Peptidase 4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-analysis. 2017 , 39, 1780-1789.e33	21
714	Finding the sweet spot for metformin in 18F-FDG-PET. 2017 , 38, 875-880	4
713	Non-Atherosclerotic Vascular Disease in Women. 2017 , 19, 78	3
712	Guideline-Recommended Medications and Physical Function in Older Adults with Multiple Chronic Conditions. 2017 , 65, 2619-2626	4
711	Network meta-analysis of lorcaserin and oral hypoglycaemics for patients with type 2 diabetes mellitus and obesity. 2017 , 7, 337-346	7
710	Antihyperglycemic Medications: A Claims-Based Estimate of First-line Therapy Use Prior to Initialization of Second-line Medications. <i>Diabetes Care</i> , 2017 , 40, 1500-1505	14.6 4
709	Potential of insulin nanoparticle formulations for oral delivery and diabetes treatment. 2017 , 264, 247-275	129
708	Practical Approach to Initiating SGLT2 Inhibitors in Type 2 Diabetes. 2017 , 8, 953-962	25

707	Prescription trends and the selection of initial oral antidiabetic agents for patients with newly diagnosed type 2 diabetes: a nationwide study. 2017 , 152, 20-27			4
706	Contrôle glycémique avec insuline glargine : étude observationnelle menée au Maroc auprès de patients diabétiques de type 2 insuffisamment contrôlés par metformine, seule ou en association avec un sulfamide hypoglycémiant et/ou une insuline basale. 2017 , 11, 183-187			
705	α-Glucosidase and pancreatic lipase inhibitory activities and glucose uptake stimulatory effect of phenolic compounds from <i>Dendrobium formosum</i> . 2017 , 27, 480-487			44
704	Medical Therapy of Peripheral Artery Disease. 2017 , 111-127			
703	Characteristics Associated with the Choice of First Injectable Therapy Among US Patients With Type 2 Diabetes. 2017 , 39, 2399-2408			13
702	Cost-effectiveness analysis of different dipeptidyl-peptidase 4 inhibitor drugs for treatment of type 2 diabetes mellitus. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2017 , 11 Suppl 2, S859-S865	8.9	6	
701	Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial. 2017 , 318, 45-56			152
700	Prostate Cancer Patients With Unmanaged Diabetes or Receiving Insulin Experience Inferior Outcomes and Toxicities After Treatment With Radiation Therapy. 2017 , 15, 326-335.e3			33
699	Studies on Activity Guided Fractionation of Pomegranate Peel Extracts and Its Effect on Antidiabetic and Cardiovascular Protection Properties. 2017 , 41, e13108			26
698	The effectiveness of multimedia education for patients with type 2 diabetes mellitus. 2017 , 73, 943-954			12
697	Comparison of Insulin Resistance and β-Cell Dysfunction Between the Young and the Elderly in Normal Glucose Tolerance and Prediabetes Population: A Prospective Study. 2017 , 49, 135-141			9
696	Seasonal variation of hemoglobin A1c levels in patients with type 2 diabetes. 2017 , 37, 432-436			3
695	Spectroscopic, structural characterizations and antioxidant capacity of the chromium (III) niacinamide compound as a diabetes mellitus drug model. 2017 , 173, 122-131			17
694	Increased cost of illness among European patients with type 2 diabetes treated with insulin. 2017 , 33, 47-54			3
693	Comparison of insulin lispro mix 25 with insulin lispro mix 50 as insulin starter in Chinese patients with type 2 diabetes mellitus (CLASSIFY study): Subgroup analysis of a Phase 4 open-label randomized trial. 2017 , 9, 575-585			11
692	Lactoferrin potentially facilitates glucose regulation and enhances the incretin effect. 2017 , 95, 155-161			6
691	Higher hemoglobin A1c levels are associated with impaired left ventricular diastolic function and higher incidence of adverse cardiac events in patients with nonischemic dilated cardiomyopathy. 2017 , 32, 446-457			5
690	Randomized Trial of an Integrated Behavioral Health Home: The Health Outcomes Management and Evaluation (HOME) Study. 2017 , 174, 246-255			70

689	Comparative Effectiveness of Diabetic Oral Medications Among HIV-Infected and HIV-Uninfected Veterans. <i>Diabetes Care</i> , 2017 , 40, 218-225	14.6	11
688	Adapting clinical guidelines in low-resources countries: a study on the guideline on the management and prevention of type 2 diabetes mellitus in Indonesia. 2017 , 23, 121-127		10
687	Coût du diabète de type 2 en France : une analyse des données de l'INSEE. 2017 , 11, IIS24-IIS27		2
686	High-energy breakfast based on whey protein reduces body weight, postprandial glycemia and HbA _{1c} in Type 2 diabetes. 2017 , 49, 1-7		31
685	Prevalence of Vitamin B12 Deficiency in Patients with Type II Diabetes Mellitus on Metformin: A Study from Khyber Pakhtunkhwa. 2017 , 9, e1577		14
684	. 2017 ,		5
683	MALONDIALDEHYDE, ADIPONECTIN, NITRIC OXIDE, C-REACTIVE PROTEIN, TUMOR NECROSIS FACTOR-ALPHA AND INSULIN RESISTANCE RELATIONSHIPS AND INTER-RELATIONSHIPS IN TYPE 2 DIABETES EARLY STAGE IS METFORMIN ALONE ADEQUATE IN THIS STAGE. 2017 , 9, 176		4
682	Evaluation of prescription pattern and efficacy of anti-diabetic drugs in Coimbatore, India. 2017 , 6, 27-33		
681	Euglycemic Diabetic Ketoacidosis When Reducing Insulin Dosage in Patients Taking Sodium Glucose Cotransporter 2 Inhibitor. 2017 , 40, 55		1
680	Mitochondrial and Morphologic Alterations in Native Human Corneal Endothelial Cells Associated With Diabetes Mellitus. 2017 , 58, 2130-2138		37
679	Prevalence of sexual dysfunction in saudi women with Type 2 diabetes: Is it affected by age, glycemic control or obesity?. 2017 , 33, 732-737		3
678	Long-term Effect of Biomaterialized Insulin Nanoparticles on Type 2 Diabetes Treatment. 2017 , 7, 4301-4312		10
677	Insulin adherence and persistence among Chinese patients with type 2 diabetes: a retrospective database analysis. 2017 , 11, 237-245		22
676	Effects of Low-Molecular-Weight Fucoidan and High Stability Fucoxanthin on Glucose Homeostasis, Lipid Metabolism, and Liver Function in a Mouse Model of Type II Diabetes. 2017 , 15,		61
675	Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management. 2017 , 8, 6		463
674	Painful and Prolonged Muscle Cramps Following Insulin Injections in a Patient with Type 2 Diabetes Mellitus: Revisiting the 1992 Duke Case. 2017 , 8, 243		2
673	Personalized Care and the Role of Insulin as a Vehicle to Optimizing Treatments in Diabetes Care. 2017 , 23, 1160-1168		2
672	Practical Focus on American Diabetes Association/European Association for the Study of Diabetes Consensus Algorithm in Patients with Type 2 Diabetes Mellitus: Timely Insulin Initiation and Titration (Iran-AFECT). 2017 , 41, 31-37		1

671	Basic Fibroblast Growth Factor Inhibits Apoptosis and Promotes Proliferation of Adipose-Derived Mesenchymal Stromal Cells Isolated from Patients with Type 2 Diabetes by Reducing Cellular Oxidative Stress. 2017 , 2017, 3027109	24
670	Metformin Impairs Spatial Memory and Visual Acuity in Old Male Mice. 2017 , 8, 17-30	38
669	Effect of prescribing metformin according to eGFR instead of serum creatinine level: A study based on Korean National Health and Nutrition Examination Survey (KNHANES) 2009-2014. 2017 , 12, e0175334	1
668	Comparative effectiveness of oral antidiabetic drugs in preventing cardiovascular mortality and morbidity: A network meta-analysis. 2017 , 12, e0177646	27
667	Diabetes, use of metformin, and the risk of meningioma. 2017 , 12, e0181089	10
666	Mortality in persons with undetected and diagnosed hypertension, type 2 diabetes, and hypothyroidism, compared with persons without corresponding disease - a prospective cohort study; The HUNT Study, Norway. 2017 , 18, 98	7
665	Impact of a structured multicomponent educational intervention program on metabolic control of patients with type 2 diabetes. 2017 , 17, 77	5
664	A qualitative study to explore the perception and behavior of patients towards diabetes management with physical disability. 2017 , 9, 58	9
663	Evaluation of pharmacotherapy complexity in residents of long-term care facilities: a cross-sectional descriptive study. 2017 , 18, 59	13
662	Insulin therapy. 2017 , 323-337	
661	Liquigroud technique: a new concept for enhancing dissolution rate of glibenclamide by combination of liquisolid and co-grinding technologies. 2017 , 7, 5-12	8
660	Comparative effectiveness of glycemic control in patients with type 2 diabetes treated with GLP-1 receptor agonists: a network meta-analysis of placebo-controlled and active-comparator trials. 2017 , 10, 111-122	19
659	Clinical audit for the adherence to safety monitoring for pioglitazone use in patients with type 2 diabetes in the Al-Wazarat primary care center, Saudi Arabia. 2017 , Volume 9, 25-31	
658	Lactic Acidosis in a Man with Diabetes: Is Metformin the Culprit?. 2017 , 09,	
657	Type 2 diabetes mellitus treatment habits in a specialized care setting: the START-DIAB study. 2017 , 10, 165-179	2
656	Association between metformin and the risk of gastric cancer in patients with type 2 diabetes mellitus: a meta-analysis of cohort studies. 2017 , 8, 55622-55631	37
655	Assessment of post operative wound healing in diabetic patients after extraction. 2017 , 3, 77	1
654	Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy for the Treatment of Type 2 Diabetes: Are Two Agents Better Than One?. 2018 , 36, 138-147	5

- 653 Safety of non-insulin glucose-lowering drugs in pregnant women with pre-gestational diabetes: A cohort study. *Diabetes, Obesity and Metabolism*, **2018**, 20, 1642-1651 6.7 9
- 652 Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers. **2018**, 130, 381-393 17
- 651 Direct Medical Costs of Type 2 Diabetes in France: An Insurance Claims Database Analysis. **2018**, 2, 209-219 18
- 650 Effect of a long-term treatment with metformin in dystrophic mdx mice: A reconsideration of its potential clinical interest in Duchenne muscular dystrophy. **2018**, 154, 89-103 22
- 649 Microvascular endothelial function is an independent predictor for albuminuria progression among Asians with type 2 diabetes-A prospective cohort study. **2018**, 25, e12453
- 648 Management of glycemic variation in diabetic patients receiving parenteral nutrition by continuous subcutaneous insulin infusion (CSII) therapy. **2018**, 8, 5888 9
- 647 Aspirin and metformin exhibit antitumor activity in murine breast cancer. **2018**, 39, 1414-1422 9
- 646 Difference of seasonal variation between glycated albumin and glycated haemoglobin. **2018**, 55, 583-587 6
- 645 Metformin in the first trimester and risks for specific birth defects in the National Birth Defects Prevention Study. **2018**, 110, 579-586 6
- 644 14-3-3zeta is involved in the anticancer effect of metformin in colorectal carcinoma. **2018**, 39, 493-502 2
- 643 The effects of Internet-based exercise compared with supervised group exercise in people with type 2 diabetes: a randomized controlled study. **2018**, 32, 799-810 7
- 642 Management of Pancreatic Diabetes Secondary to Chronic Pancreatitis. **2018**, 495-502 1
- 641 Metformin-induced anticancer activities: recent insights. **2018**, 399, 321-335 38
- 640 Effect of green tea extract on bone mass and body composition in individuals with diabetes. **2018**, 40, 589-594 16
- 639 The Risk of TB in Patients With Type 2 Diabetes Initiating Metformin vs Sulfonyleurea Treatment. **2018**, 153, 1347-1357 31
- 638 Effect of photodynamic therapy as an adjuvant to non-surgical periodontal therapy: Periodontal and metabolic evaluation in patients with type 2 diabetes mellitus. **2018**, 22, 245-250 9
- 637 Normogluce miantes orales y riesgo cardiovascular. **2018**, 25, 333-339
- 636 Research Questions in Data Science. **2018**, 3-14

635	Changing Patients' Treatment Preferences and Values with a Decision Aid for Type 2 Diabetes Mellitus: Results from the Treatment Arm of a Randomized Controlled Trial. 2018 , 9, 803-814		3
634	The Postprandial-to-Fasting Serum C-Peptide Ratio is a Predictor of Response to Basal Insulin-Supported Oral Antidiabetic Drug(s) Therapy: A Retrospective Analysis. 2018 , 9, 963-971		
633	Basal Insulin Intensification in Patients with Type 2 Diabetes: A Review. 2018 , 9, 877-890		27
632	Tranilast directly targets NLRP3 to treat inflammasome-driven diseases. 2018 , 10,		181
631	Asymptotic Tracking and Robustness of MAS Transitions Under a New Communication Topology. 2018 , 15, 16-32		6
630	Assessment of factors determining an HbA1c concentration $\leq 5\%$ in patients with type 1 diabetes. 2018 , 10, 140-147		1
629	Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 113-120	6.7	32
628	Insights into optimal basal insulin titration in type 2 diabetes: Results of a quantitative survey. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 301-308	6.7	45
627	Diabetes and Cancers. 2018 , 113-126		1
626	Antidiabetic effect of <i>Achillea millefolium</i> through multitarget interactions: α -glucosidases inhibition, insulin sensitization and insulin secretagogue activities. 2018 , 212, 1-7		34
625	Peroxisome proliferator-activated receptor γ (PPAR γ): A master gatekeeper in CNS injury and repair. 2018 , 163-164, 27-58		99
624	Proximal Neuropathy and Associated Skeletal Muscle Changes Resembling Denervation Atrophy in Hindlimbs of Chronic Hypoglycaemic Rats. 2018 , 122, 165-175		0
623	Efficacy and safety of switching from basal insulin to once-daily insulin degludec/insulin aspart in Japanese patients with inadequately controlled type 2 diabetes: A 4-week, randomized, open-label, treat-to-target study. 2017 , 9, 567		3
622	Pharmacotherapy of type 2 diabetes: An update. 2018 , 78, 13-42		103
621	Insulin selectively reduces mitochondrial uncoupling in brown adipose tissue in mice. 2018 , 475, 561-569		18
620	Xenopus-derived glucagon-like peptide-1 and polyethylene-glycosylated glucagon-like peptide-1 receptor agonists: long-acting hypoglycaemic and insulinotropic activities with potential therapeutic utilities. 2018 , 175, 544-557		17
619	Comparison between sodium-glucose cotransporter 2 inhibitors and pioglitazone as additions to insulin therapy in type 2 diabetes patients: A systematic review with an indirect comparison meta-analysis. 2018 , 9, 882-892		5
618	Dapagliflozin as add-on therapy in Asian patients with type 2 diabetes inadequately controlled on insulin with or without oral antihyperglycemic drugs: A randomized controlled trial. 2018 , 10, 589-599		29

617	Prospective Postmarketing Surveillance of Acute Myocardial Infarction in New Users of Saxagliptin: A Population-Based Study. <i>Diabetes Care</i> , 2018 , 41, 39-48	14.6	19
616	Analysis of new therapeutic strategies for diabetes mellitus based on traditional Chinese medicine 经方公式. 2018 , 5, 361-369		1
615	Effect of plasma membrane monoamine transporter genetic variants on pharmacokinetics of metformin in humans. 2018 , 26, 79-85		7
614	EFFECT OF SITAGLIPTIN ON GLYCEMIC CONTROL AND BEYOND - IN PATIENTS WITH TYPE 2 DIABETES MELLITUS. 2018 , 11, 316		
613	Evaluating the impact of type 2 diabetes mellitus on CYP450 metabolic activities: protocol for a case-control pharmacokinetic study. 2018 , 8, e020922		6
612	The protective effect of neonatal oral administration of oleanolic acid against the subsequent development of fructose-induced metabolic dysfunction in male and female rats. 2018 , 15, 82		6
611	Choosing the Best Oral Diabetic Agents in T2 Diabetes Mellitus-Physicians Challenge. 2018 , 09,		1
610	Toxicological and Biochemical Analyses of an Autopsy Case Involving Oral Overdose of Multiple Antidiabetic and Antihypertensive Drugs. 2018 , 2018, 5864658		3
609	Correlation Between Life Style and Dyslipidemia with Impaired Fasting Blood Sugar in State Junior High School and State Senior High School Having Central Obesity. 2018 ,		
608	Issues in Defining the Burden of Prediabetes Globally. 2018 , 18, 105		6
607	Investigating the Reliability of HbA1c Monitoring for Blood Glucose Control During Late Pregnancy in Patients with Gestational Diabetes Mellitus (GDM) with and without β -Thalassemia Minor. 2018 , 9, 2305-2313		5
606	Rationale and development of a randomized pragmatic trial to improve diabetes outcomes in patient-centered medical homes serving rural patients. 2018 , 73, 152-157		2
605	Comparison of the Effect of Glycemic Control in Type 2 Diabetes Outpatients Treated With Premixed and Basal Insulin Monotherapy in China. 2018 , 9, 639		5
604	Incidence of microvascular complications of type 2 diabetes: A 12 year longitudinal study from Karachi-Pakistan. 2018 , 34, 1058-1063		11
603	Glycaemic control for people with type 2 diabetes in Saudi Arabia - an urgent need for a review of management plan. 2018 , 18, 62		21
602	Anthropometric cutoffs and associations with visceral adiposity and metabolic biomarkers after spinal cord injury. 2018 , 13, e0203049		17
601	Exercise and Diabetes Mellitus. 2018 ,		
600	Decreased incidence of diabetes in patients with gout using benzbromarone. 2018 , 57, 1574-1582		10

599	Multinational Consensus: Insulin Initiation with Insulin Degludec/Aspart (IDegAsp). 2018 , 35, 928-936			5
598	Pharmacogenetics of Antidiabetic Drugs. 2018 , 83, 361-389			9
597	Effects of green tea extract on oxidative stress and renal function in diabetic individuals: A randomized, double-blinded, controlled trial. 2018 , 46, 195-201			8
596	Switching From Pre-mixed Insulin to Regimens with Insulin Glargine in Type 2 Diabetes: A Prospective, Observational Study of Data From Adriatic Countries. 2018 , 9, 1657-1668			3
595	Effect of Modifiable Risk Factors on the Incidence and Progression of Diabetic Retinopathy. 2018 , 41-51			
594	Empagliflozin compared with glimepiride in metformin-treated patients with type 2 diabetes: 208-week data from a masked randomized controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2768-2777	6.7		24
593	Comparative Effectiveness of Adaptive Treatment Strategies. 2018 , 253-276			
592	Metformin is associated with a lower risk of active tuberculosis in patients with type 2 diabetes. 2018 , 23, 1063-1073			22
591	Phenformin alone or combined with gefitinib inhibits bladder cancer via AMPK and EGFR pathways. 2018 , 38, 50			14
590	Computational and Pharmacological Evaluation of Ferrocene-Based Acyl Ureas and Homoleptic Cadmium Carboxylate Derivatives for Anti-diabetic Potential. <i>Frontiers in Pharmacology</i> , 2017 , 8, 1001	5.6		8
589	Genotypic and Phenotypic Factors Influencing Drug Response in Mexican Patients With Type 2 Diabetes Mellitus. <i>Frontiers in Pharmacology</i> , 2018 , 9, 320	5.6		12
588	Diabetes Secondary to Pancreatic Diseases. 2018 , 1-17			
587	Hypoglycemia. 2018 , 1-38			
586	GOAL study: clinical and non-clinical predictive factors for achieving glycemic control in people with type 2 diabetes in real clinical practice. <i>BMJ Open Diabetes Research and Care</i> , 2018 , 6, e000519	4.5		17
585	, an Inhibitor of Gluconeogenesis, Responds to Glucose Stimulation and Downregulates Hsp60 among Other Proteins in HepG2 Liver Cell Lines. 2018 , 23,			1
584	Effect of Monacolin K and COQ10 supplementation in hypertensive and hypercholesterolemic subjects with metabolic syndrome. 2018 , 105, 992-996			15
583	Individualised treatment targets in patients with type-2 diabetes and hypertension. 2018 , 17, 18			13
582	PEGylated prodrugs of antidiabetic peptides amylin and GLP-1. 2018 , 292, 58-66			6

581	Regional variations in definitions and rates of hypoglycaemia: findings from the global HAT observational study of 27 585 people with Type 1 and insulin-treated Type 2 diabetes mellitus. 2018 , 35, 1232	6
580	Potential application of testosterone replacement therapy as treatment for obesity and type 2 diabetes in men. 2018 , 138, 161-166	20
579	Differences in All-Cause Health Care Utilization and Costs in a Type 2 Diabetes Mellitus Population with and Without a History of Cardiovascular Disease. 2018 , 24, 280-290	15
578	The safety and efficacy of once-weekly glucagon-like peptide-1 receptor agonist semaglutide in patients with type 2 diabetes mellitus: a systemic review and meta-analysis. 2018 , 62, 535-545	9
577	Understanding the Twisted Structure of Amyloid Fibrils via Molecular Simulations. 2018 , 122, 11302-11310	4
576	Risk Factors of Hypoglycemia in Patients with Type 2 Diabetes Mellitus: A Study Based on Continuous Glucose Monitoring. 2018 , 20, 603-612	17
575	Transcriptome Analyses Reveal Adult Metabolic Syndrome With Intrauterine Growth Restriction in Pig Models. 2018 , 9, 291	10
574	Magnitude of glycemic control and its associated factors among patients with type 2 diabetes at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia. 2018 , 13, e0193442	29
573	Effect of Telephone-Delivered Interventions on Glycemic Control in Type 2 Diabetes Treated with Glargine Insulin. 2019 , 25, 471-476	3
572	Effects of endurance training on hippocampus DJ-1, cannabinoid receptor type 2 and blood glucose concentration in diabetic rats. 2019 , 10, 43-50	0
571	Protein hydrolysates and ultrafiltered 2019 , 99, 587-595	13
570	Post-authorisation Safety Study of Pioglitazone Use and Safety Endpoints of Interest in Denmark After Direct Healthcare Professional Communication. 2019 , 6, 133-140	0
569	The longitudinal effect of subclinical hypothyroidism on urine microalbumin-to-urine creatinine ratio in patients with type 2 diabetes mellitus. 2019 , 19, 84	5
568	The prescription pattern of initial treatment for type 2 diabetes in Beijing from 2011 to 2015. 2019 , 98, e14370	6
567	Frequency of (, and) allelic variants, and their clinical implications, among Mexican patients with diabetes mellitus type 2 undergoing treatment with glibenclamide and metformin. 2019 , 10, 283-295	2
566	Factors associated with clinical inertia in type 2 diabetes mellitus patients treated with metformin monotherapy. 2019 , 35, 2063-2070	3
565	Prevalence of postprandial hyperglycaemia in basal insulin-treated patients with type 2 diabetes mellitus with controlled fasting glycaemia and elevated glycosylated haemoglobin. 2019 , 11, 59	1
564	Baseline Characteristics of Randomized Participants in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). <i>Diabetes Care</i> , 2019 , 42, 2098-2107	14.6 15

563	The Status of Metabolic Control in Patients With Type 2 Diabetes Attending Dasman Diabetes Institute, Kuwait. 2019 , 10, 412	6
562	Diabetes and Cancer. 2019 , 919-937	
561	A Pilot Study towards the Impact of Type 2 Diabetes on the Expression and Activities of Drug Metabolizing Enzymes and Transporters in Human Duodenum. 2019 , 20,	6
560	Research on logistics supply chain of iron and steel enterprises based on block chain technology. 2019 , 101, 635-645	39
559	The effect of apple vinegar consumption on glycemic indices, blood pressure, oxidative stress, and homocysteine in patients with type 2 diabetes and dyslipidemia: A randomized controlled clinical trial. 2019 , 33, 132-138	12
558	Co-expression network analysis revealing the key lncRNAs in diabetic foot ulcers. 2019 , 15, 1123-1132	6
557	Trends in antidiabetic medical treatment from 2005 to 2014 in Taiwan. 2019 , 118 Suppl 2, S74-S82	4
556	Leucine-rich β -glycoprotein predicts proliferative diabetic retinopathy in type 2 diabetes. 2019 , 33, 651-656	8
555	Consideraciones acerca del reporte y la evaluación del fallo terapéutico en farmacovigilancia. 2019 , 67, 287-292	0
554	Assessment of serum vitamin B12 levels and chronic haemato-toxicologic adverse profile induced by metformin pharmacotherapy among type 2 diabetic patients: A prospective analytical study. 2019 , 3, 239784731987436	
553	Prevalence of Hypoglycemia Among Patients With Type 2 Diabetes Mellitus in a Rural Health Center in South India. 2019 , 10, 2150132719880638	7
552	Is the use of metformin in patients undergoing dialysis hazardous for life? A systematic review of the safety of metformin in patients undergoing dialysis. 2019 , 85, 2772-2783	5
551	Clinical associations of an updated medication effect score for measuring diabetes treatment intensity. 2021 , 17, 451-462	4
550	Use of glucose-lowering drugs in Hungary between 2008 and 2017: the increasing use of novel glucose-lowering drug groups. 2019 , 36, 1612-1620	1
549	Comparison of the efficacy and safety of once-daily insulin degludec/insulin aspart (IDegAsp) and long-acting second-generation basal insulin (insulin degludec and insulin glargine 300 units/mL) in insulin-naïve Japanese adults with type 2 diabetes: a pilot, randomized, controlled study. 2019 , 66, 745-752	4
548	Determinants of hypertension among diabetic patients in Public Hospitals of the Central Zone, Tigray, Ethiopia 2018: unmatched case-control study. 2019 , 33, 100	4
547	Antidiabetic medication use in patients with type 2 diabetes and chronic kidney disease. 2019 , 33, 107423	0
546	The Role of Pharmacogenomics in Diabetes. 2019 , 247-269	

545	Enhanced Anti-diabetic Effect of Berberine Combined With Timosaponin B2 in Goto-Kakizaki Rats, Associated With Increased Variety and Exposure of Effective Substances Through Intestinal Absorption. <i>Frontiers in Pharmacology</i> , 2019 , 10, 19	5.6	7
544	Efficacy of Real-Time Continuous Glucose Monitoring to Improve Effects of a Prescriptive Lifestyle Intervention in Type 2 Diabetes: A Pilot Study. 2019 , 10, 509-522		15
543	Lipid profile in type 2 diabetic patients with new dapagliflozin treatment; actual clinical experience data of six months retrospective lipid profile from single center. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2019 , 13, 1031-1034	8.9	13
542	Lilly Insulin Glargine Versus Lantus in Type 2 Diabetes Mellitus Patients: India and East Asia Subpopulation Analyses of the ELEMENT 5 Study. 2019 , 39, 745-756		1
541	Diabetic Gastroparesis. 2019 , 40, 1318-1352		52
540	Trends in global prescribing of antidiabetic medicines in primary care: A systematic review of literature between 2000-2018. <i>Primary Care Diabetes</i> , 2019 , 13, 409-421	2.4	8
539	Prevalence of vitamin B deficiency among metformin-treated type 2 diabetic patients in a tertiary institution, South-South Nigeria. 2019 , 7, 2050312119853433		7
538	Post-marketing Study of Linagliptin: A Pilot Study. <i>Frontiers in Pharmacology</i> , 2019 , 10, 576	5.6	1
537	Effects of metformin on the heart with ischaemia-reperfusion injury: Evidence of its benefits from in vitro, in vivo and clinical reports. 2019 , 858, 172489		15
536	Controversies for Glucose Control Targets in Type 2 Diabetes: Exposing the Common Ground. <i>Diabetes Care</i> , 2019 , 42, 1615-1623	14.6	5
535	A pre-specified statistical analysis plan for the VERIFY study: Vildagliptin efficacy in combination with metformin for early treatment of T2DM. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 2240-2247	6.7	7
534	THE CYTOTOXICITY, GENOTOXICITY AND OXIDATIVE DAMAGE POTENTIAL OF THE ORAL DIPEPTIDYL PEPTIDASE-4 INHIBITOR, LINAGLIPTIN, ON CULTURED HUMAN MONONUCLEAR BLOOD CELLS. 2019 , -5, 9-15		2
533	Serum amino acid profiles and risk of type 2 diabetes among Japanese adults in the Hitachi Health Study. 2019 , 9, 7010		31
532	Type 2 Diabetes Mellitus and Preoperative HbA1c Level Have no Consequence on Outcomes after Laparoscopic Sleeve Gastrectomy-a Cohort Study. 2019 , 29, 2957-2962		5
531	Maltase Decorated by Chiral Carbon Dots with Inhibited Enzyme Activity for Glucose Level Control. 2019 , 15, e1901512		27
530	The determinants of anti-diabetic medication adherence based on the experiences of patients with type 2 diabetes. 2019 , 77, 21		10
529	Glucagon-Like Peptide-1 Receptor Agonists and Strategies To Improve Their Efficiency. 2019 , 16, 2278-2295		27
528	HPLC-QTOF-MS/MS profiling, antioxidant, and α -glucosidase inhibitory activities of <i>Pyracantha fortuneana</i> fruit extracts. 2019 , 43, e12821		8

527	Randomized Trial of a Positive Psychology Intervention for Adolescents With Type 1 Diabetes. 2019 , 44, 620-629		6
526	Peptides from chicken processing by-product inhibit DPP-IV and promote cellular glucose uptake: potential ingredients for T2D management. 2019 , 10, 1619-1628		7
525	Targeting AMPK signaling pathway by natural products for treatment of diabetes mellitus and its complications. 2019 , 234, 17212-17231		59
524	Implications of Removing Rosiglitazone's Black Box Warning and Restricted Access Program on the Uptake of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors Among Patients with Type 2 Diabetes. 2019 , 25, 72-79		8
523	Comparative Effectiveness and Maintenance of Diabetes Self-Management Education Interventions for Marshallese Patients With Type 2 Diabetes: A Randomized Controlled Trial. <i>Diabetes Care</i> , 2019 , 42, 849-858	14.6	24
522	Diabetes management and treatment approaches outside of North America and West Europe in 2006 and 2015. 2019 , 56, 889-897		4
521	Repurposed Biguanide Drugs in Glioblastoma Exert Antiproliferative Effects via the Inhibition of Intracellular Chloride Channel 1 Activity. 2019 , 9, 135		14
520	Public knowledge, attitudes and practices toward diabetes mellitus: A cross-sectional study from Jordan. 2019 , 14, e0214479		24
519	Molecular Mechanism of Metformin Associated Lactic Acidosis (MALA)- an In Silico Exploration. 2019 , 16, 199-209		1
518	Does the use of incretin-based medications increase the risk of cancer in patients with type-2 diabetes mellitus?. 2019 , 28, 489-499		6
517	Addition of Basal Insulin to Oral Antidiabetic Agents in Patients with Inadequately Controlled Type 2 Diabetes Leads to Improved HbA1c Levels: Metabolic Control, Frequency of Hypoglycemia, and Insulin Titration Analysis as Results of a Prospective Observational Study (BALI Study). 2019 , 10, 663-672		4
516	Antihyperglycaemic and tissue-repair effects of extract in streptozotocin-induced diabetic mice. 2019 , 14, 149-155		1
515	Changes in Screening Practices for Prediabetes and Diabetes Since the Recommendation for Hemoglobin A Testing. <i>Diabetes Care</i> , 2019 , 42, 576-584	14.6	13
514	Weight loss in patients with type 2 diabetes receiving once-weekly dulaglutide plus insulin lispro or insulin glargine plus insulin lispro: A post-hoc analysis of the AWARD-4 study across baseline body mass index subgroups. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 1340-1348	6.7	6
513	Phenolic profiles, antihyperglycemic, antihyperlipidemic, and antioxidant properties of pomegranate (<i>Punica granatum</i>) peel extract. 2019 , 43, e12803		38
512	Progression of glucose-lowering diabetes therapy in TECOS. 2019 , 2, e00053		6
511	WITHDRAWN: Association of Type 2 Diabetes Mellitus with the Histopathological Features of Early-Stage Breast Cancer Patients: A Retrospective Cross-Sectional Study in Chinese Women. 2019 , ,		
510	The Standard of Care in Type 2 Diabetes: Re-evaluating the Treatment Paradigm. 2019 , 10, 1-13		12


509	Challenges of Diabetes Care in Older People With Type 2 Diabetes and the Role of Basal Insulin. 2019 , 37, 357-367		1
508	Validity and reliability of anti-diabetic medication adherence scale among patients with diabetes in Baghdad, Iraq: a pilot study. <i>BMJ Open Diabetes Research and Care</i> , 2019 , 7, e000658	4.5	6
507	Metformin Modulates the Mechanisms of Ageing. 2019 ,		
506	In vitro biological evaluation of anti-diabetic activity of organic-inorganic hybrid gold nanoparticles. 2019 , 13, 226-229		5
505	Exploring Pancreatic Metabolism and Malignancy. 2019 ,		1
504	Potentially inappropriate medication in older participants of the Berlin Aging Study II (BASE-II) - Sex differences and associations with morbidity and medication use. 2019 , 14, e0226511		13
503	Duration of type 2 diabetes and remission rates after bariatric surgery in Sweden 2007-2015: A registry-based cohort study. 2019 , 16, e1002985		39
502	Age and glycemic control among adults with type 2 diabetes in the United States: An assessment from the National Health and Nutrition Examination Survey (NHANES) 2013-2014. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2019 , 13, 3069-3073	8.9	4
501	Nanoparticle Delivery Systems in the Treatment of Diabetes Complications. 2019 , 24,		60
500	Challenges And Factors Associated With Poor Glycemic Control Among Type 2 Diabetes Mellitus Patients At Nekemte Referral Hospital, Western Ethiopia. 2019 , 12, 963-974		18
499	Which is better, high-dose metformin monotherapy or low-dose metformin/linagliptin combination therapy, in improving glycemic variability in type 2 diabetes patients with insufficient glycemic control despite low-dose metformin monotherapy? A randomized, cross-over, continuous glucose monitoring-based pilot study. 2019 , 10, 714-722		8
498	Anthropometric outcomes in type 2 diabetic patients with new dapagliflozin treatment; actual clinical experience data of six months retrospective glycemic control from single center. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2019 , 13, 284-288	8.9	1
497	Phytotherapeutic efficacy of the medicinal plant L. 2019 , 26, 985-988		9
496	Bi-directional drug-microbiome interactions of anti-diabetics. 2019 , 39, 591-602		40
495	Role of Metformin in the Treatment of Patients with Thyroid Nodules and Insulin Resistance: A Systematic Review and Meta-Analysis. 2019 , 29, 359-367		17
494	Comparison of a twice daily injection of insulin aspart 50 with insulin aspart 30 in patients with poorly controlled type 2 diabetes. 2019 , 35, 1091-1096		1
493	Metformin; an old antidiabetic drug with new potentials in bone disorders. 2019 , 109, 1593-1601		47
492	Effect of family-oriented diabetes programs on glycemic control: A meta-analysis. 2019 , 36, 387-394		3

491	Multivalent activation of GLP-1 and sulfonylurea receptors modulates β -cell second-messenger signaling and insulin secretion. 2019 , 316, C48-C56		4
490	Evaluation and Perioperative Management of the Diabetic Patient. 2019 , 36, 83-102		2
489	Therapeutic medications against diabetes: What we have and what we expect. 2019 , 139, 3-15		25
488	Nicosamide piperazine prevents high-fat diet-induced obesity and diabetic symptoms in mice. 2019 , 24, 91-96		8
487	Probabilistic sensitivity analysis on Markov models with uncertain transition probabilities: an application in evaluating treatment decisions for type 2 diabetes. 2019 , 22, 34-52		5
486	Increased mortality risk in diabetic patients discharged from hospital with insulin therapy after an acute myocardial infarction: Data from the FAST-MI 2005 registry. 2019 , 8, 218-230		9
485	Adjustment for time-dependent unmeasured confounders in marginal structural Cox models using validation sample data. 2019 , 28, 357-371		4
484	Biomarkers of cardiometabolic health are associated with body composition characteristics but not physical activity in persons with spinal cord injury. 2019 , 42, 328-337		15
483	The effectiveness of patient activation intervention on type 2 diabetes mellitus glycemic control and self-management behaviors: A systematic review of RCTs. <i>Primary Care Diabetes</i> , 2020 , 14, 12-20	2.4	31
482	Antidiabetic Drug Metformin Ameliorates Depressive-Like Behavior in Mice with Chronic Restraint Stress via Activation of AMP-Activated Protein Kinase. 2020 , 11, 31-43		14
481	Screening of traditional Lebanese medicinal plants as antioxidants and inhibitors of key enzymes linked to type 2 diabetes. 2020 , 154, 656-662		9
480	Pharmacokinetics and pharmacodynamics of ronglitflozin, a novel selective inhibitor of sodium-glucose co-transporter-2, in people with type 2 diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 191-202	6.7	3
479	For colorectal cancer patients with type II diabetes, could metformin improve the survival rate? A meta-analysis. 2020 , 44, 73-81		11
478	Plant-Derived Bioactive Peptides: A Treatment to Cure Diabetes. 2020 , 26, 955-968		36
477	A population-based analysis of antidiabetic medications in four Canadian provinces: Secular trends and prescribing patterns. 2020 , 29 Suppl 1, 86-92		3
476	Combination of Oligofructose and Metformin Alters the Gut Microbiota and Improves Metabolic Profiles, Contributing to the Potentiated Therapeutic Effects on Diet-Induced Obese Animals. 2019 , 10, 939		7
475	A Safety Comparison of Metformin vs Sulfonylurea Initiation in Patients With Type 2 Diabetes and Chronic Kidney Disease: A Retrospective Cohort Study. 2020 , 95, 90-100		15
474	Evaluation of endocrine complications in beta-thalassemia intermedia (β TI): a cross-sectional multicenter study. 2020 , 69, 220-227		3

473	Combining In Vitro Data and Physiologically Based Kinetic Modeling Facilitates Reverse Dosimetry to Define In Vivo Dose-Response Curves for Bixin- and Crocetin-Induced Activation of PPAR α in Humans. 2020 , 64, e1900880			4
472	Insulin Resistance in Type 1 Diabetes Mellitus and Its Association with Patient's Micro- and Macrovascular Complications, Sex Hormones, and Other Clinical Data. 2020 , 11, 161-174			13
471	Disturbances in Energy Supply. 2020 , 101-134			
470	Time to Treatment Intensification in Newly Treated Adult Type 2 Diabetes Patients: Comparison of Canada and the United States. 2020 , 44, 312-316			1
469	Effect of a 90 g/day low-carbohydrate diet on glycaemic control, small, dense low-density lipoprotein and carotid intima-media thickness in type 2 diabetic patients: An 18-month randomised controlled trial. 2020 , 15, e0240158			10
468	Diabetic neuropathy is associated with increased pain perception, low serum beta-endorphin and increase insulin resistance among Nigerian cohorts in Ekiti State. 2020 , 6, e04377			1
467	The FDA Metformin Label Change and Racial and Sex Disparities in Metformin Prescription among Patients with CKD. 2020 , 31, 1847-1858			16
466	Cytogenetic effects of antidiabetic drug metformin. 2020 , 1-8			1
465	Spray-Drying Microencapsulation of High Concentration of Bioactive Compounds Fragments from L. Extract and Their Effect on Diabetes Mellitus. <i>Foods</i> , 2020 , 9,	4.9		8
464	Computational and Pharmacological Evaluation of Carveol for Antidiabetic Potential. <i>Frontiers in Pharmacology</i> , 2020 , 11, 919	5.6		10
463	The factors associated with insulin nonpersistence in persons with type 2 diabetes. 2020 , 167, 108356			0
462	Metabolic Alterations Predispose to Seizure Development in High-Fat Diet-Treated Mice: the Role of Metformin. 2020 , 57, 4778-4789			4
461	Intensive Care Unit-Acquired Weakness: Not just Another Muscle Atrophying Condition. 2020 , 21,			19
460	A practical approach to the clinical challenges in initiation of basal insulin therapy in people with type 2 diabetes. 2021 , 37, e3418			5
459	Lanostane Triterpenoids with PTP1B Inhibitory and Glucose-Uptake Stimulatory Activities from Mushroom Collected in North America. 2020 , 68, 10036-10049			3
458	The Effects of Metformin on the Gut Microbiota of Patients with Type 2 Diabetes: A Two-Center, Quasi-Experimental Study. 2020 , 10,			9
457	Bioactive Phytochemicals Isolated from Enhances Glucose-Stimulated Insulin Secretion by Inducing PDX-1. 2020 , 9,			2
456	Real World Use of Antidiabetic Drugs in the Years 2011-2017: A Population-Based Study from Southern Italy. 2020 , 17,			2

455	The Importance of Second-Generation Antipsychotic-Related Weight Gain and Adherence Barriers in Youth with Bipolar Disorders: Patient, Parent, and Provider Perspectives. 2020 , 30, 376-380	7
454	Glycemic Index (GI) or Glycemic Load (GL) and Dietary Interventions for Optimizing Postprandial Hyperglycemia in Patients with T2 Diabetes: A Review. 2020 , 12,	12
453	Impact of high-intensity interval training and sprint interval training on peripheral markers of glycemic control in metabolic syndrome and type 2 diabetes. 2020 , 1866, 165820	3
452	Pilot Implementation of Adapted-Family Diabetes Self-Management Education Into a Clinical Setting. 2020 , 11, 2150132720931289	1
451	Pharmacogenetics of hypoglycemia associated with sulfonylurea therapy in usual clinical care. 2020 , 20, 831-839	3
450	Prevalence and incidence of type 1 diabetes in Ireland: a retrospective cross-sectional study using a national pharmacy claims data from 2016. 2020 , 10, e032916	3
449	Type 2 diabetes mellitus management in patients with chronic kidney disease: an update. 2020 , 19, 467-476	3
448	Metformin use reduced the overall risk of cancer in diabetic patients: A study based on the Korean NHIS-HEALS cohort. 2020 , 30, 1714-1722	8
447	Predicting 5- and 10-Year Mortality Risk in Older Adults With Diabetes. <i>Diabetes Care</i> , 2020 , 43, 1724-1731	11.6
446	A computer aided diagnostic method for the evaluation of type II diabetes mellitus in facial thermograms. 2020 , 43, 871-888	6
445	An emerging new concept for the management of type 2 diabetes with a paradigm shift from the glucose-centric to beta cell-centric concept of diabetes - an Asian perspective. 2020 , 21, 1565-1578	7
444	Physicians' choices in the first- and second-line management of type 2 diabetes in the Kingdom of Saudi Arabia. 2020 , 28, 329-337	4
443	Pharmacological interventions part IV: Metabolic modifiers. 2020 , 361-416	
442	Glucosidase inhibitory and nitric oxide production inhibitory activities of alkaloids isolated from a twig extract of <i>Polyalthia cinnamomea</i> . 2020 , 28, 115462	8
441	Characterizing the Retinal Phenotype in the High-Fat Diet and Western Diet Mouse Models of Prediabetes. 2020 , 9,	19
440	Efficacy and Safety of Basal Insulin-Based Treatment Versus Twice-Daily Premixed Insulin After Short-Term Intensive Insulin Therapy in Patients with Type 2 Diabetes Mellitus in China: Study Protocol for a Randomized Controlled Trial (BEYOND V). 2020 , 37, 1675-1687	0
439	Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body Weight. <i>Diabetes Care</i> , 2020 , 43, 940-947	14.6 6
438	Cost-effectiveness of empagliflozin compared with liraglutide based on cardiovascular outcome trials in Type II diabetes. 2020 , 9, 781-794	6

437	Functional loss of pancreatic islets in type 2 diabetes: How can we halt it?. 2020 , 110, 154304		14
436	Synergistic effect of metformin and EGFR-TKI in the treatment of non-small cell lung cancer.. 2020 , 9, 372-381		1
435	Effect of metformin on the mortality of colorectal cancer patients with T2DM: meta-analysis of sex differences. 2020 , 35, 827-835		4
434	Impact of Simultaneous Versus Sequential Initiation of Basal Insulin and Glucagon-like Peptide-1 Receptor Agonists on HbA1c in Type 2 Diabetes: A Retrospective Observational Study. 2020 , 11, 995-1005		7
433	Glucose-sensitive materials for delivery of antidiabetic drugs. 2020 , 203-228		0
432	Effect of dipeptidyl peptidase-4 inhibitors on cisplatin-induced acute nephrotoxicity in cancer patients with diabetes mellitus: A retrospective study. 2020 , 15, e0229377		3
431	Higher versus standard starting dose of insulin glargine 100 U/mL in overweight or obese Chinese patients with type 2 diabetes: Results of a multicentre, open-label, randomized controlled trial (BEYOND VII). <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 838-846	6.7	3
430	A Phase I Study on the Pharmacokinetics and Pharmacodynamics of DJT1116PG, a Novel Selective Inhibitor of Sodium-glucose Cotransporter Type 2, in Healthy Individuals at Steady State. 2020 , 42, 892-905.e3		
429	Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists: JACC Focus Seminar. 2020 , 75, 1956-1974		21
428	Association Between Preoperative Metformin Exposure and Postoperative Outcomes in Adults With Type 2 Diabetes. 2020 , 155, e200416		24
427	Delay in ATP-dependent calcium inflow may affect insulin secretion from pancreatic beta-cell. 2020 , 84, 202-221		0
426	Prevalence and correlation of glycemic control achievement in patients with type 2 diabetes in Iraq: A retrospective analysis of a tertiary care database over a 9-year period. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020 , 14, 265-272	8.9	8
425	The Clinical Role of Insulin Degludec/Insulin Aspart in Type 2 Diabetes: An Empirical Perspective from Experience in Australia. 2020 , 9,		0
424	Synthesis and evaluation of novel peptidomimetics bearing -aminobenzoic acid moiety as potential antidiabetic agents. 2020 , 12, 991-1013		0
423	Anti-hyperglycemic activity of myricetin, through inhibition of DPP-4 and enhanced GLP-1 levels, is attenuated by co-ingestion with lectin-rich protein. 2020 , 15, e0231543		10
422	Impact of metformin on survival outcome of esophageal squamous cell carcinomas patients undergoing surgical resection: a multicenter retrospective study. 2020 , 12, 830-838		2
421	Novel glucose lowering agents are associated with a lower risk of cardiovascular and adverse events in type 2 diabetes: A population based analysis. 2020 , 310, 147-154		3
420	Couple-based collaborative management model of type 2 diabetes mellitus for community-dwelling older adults in China: protocol for a hybrid type 1 randomized controlled trial. 2020 , 20, 123		1

419	The medications and health care utilization of patients newly diagnosed with type 2 diabetes mellitus: A nationwide population-based cohort study. 2021 , 120, 130-136		0
418	Metformin and risk of cancer among patients with type 2 diabetes mellitus: A systematic review and meta-analysis. <i>Primary Care Diabetes</i> , 2021 , 15, 52-58	2.4	10
417	Accelerated diabetic wound healing by topical application of combination oral antidiabetic agents-loaded nanofibrous scaffolds: An in vitro and in vivo evaluation study. 2021 , 119, 111586		23
416	The suggested chemopreventive association of metformin with prostate cancer in diabetic patients. 2021 , 39, 191.e17-191.e24		
415	The role of polysaccharides from natural resources to design oral insulin micro- and nanoparticles intended for the treatment of Diabetes mellitus: A review. 2021 , 256, 117504		9
414	Risk of Skin Cancer Associated with Metformin Use: A Meta-Analysis of Randomized Controlled Trials and Observational Studies. 2021 , 14, 77-84		2
413	Effect of the dipeptidyl peptidase-4 inhibitor linagliptin on atherosclerotic lesions in Watanabe heritable hyperlipidemic rabbits: iMap-IVUS and pathological analysis. 2021 , 36, 127-135		
412	Recurrent Self-evolving TakagiâBugeñoâRan Fuzzy Neural Network (RST-FNN) Based Type-2 Diabetic Modeling. 2021 , 125-136		
411	Cardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: a Meta-Analysis. 2021 , 10, 210-222		1
410	Automated Diagnosis of Diabetes Mellitus Based on Machine Learning. 2021 , 37-56		
409	Diabetes Mellitus and Renal Function: Current Medical Research and Opinion. 2021 , 17, e011121190176		0
408	 2021 , 86, 214-227		
407	Efficacy of telemedicine on glycaemic control in patients with type 2 diabetes: A meta-analysis. 2021 , 12, 170-197		11
406	Diabetes and atrial fibrillation in hospitalized patients in the United States. 2021 , 44, 340-348		2
405	A Focused Review of the Metabolic Side-Effects of Clozapine. 2021 , 12, 609240		10
404	Hepatoprotective Effects of Polydatin-Loaded Chitosan Nanoparticles in Diabetic Rats: Modulation of Glucose Metabolism, Oxidative Stress, and Inflammation Biomarkers. 2021 , 86, 179-189		2
403	Cardiovascular and renal risk reduction in type 2 diabetes---which choice?. 2021 , 99, 322-323		
402	Use of Insulin Degludec/Insulin Aspart in the Management of Diabetes Mellitus: Expert Panel Recommendations on Appropriate Practice Patterns. 2021 , 12, 616514		1

401	The Effect of Bariatric Surgery versus Intensive Medical Care on Prevention of Microalbuminuria in Patients with Type 2 Diabetes: 3 Year Experience of a Prospective Study. 2020 , 9, 202-207	0
400	Role of UPP pathway in amelioration of diabetes-associated complications. 2021 , 28, 19601-19614	5
399	2021 ,	0
398	Knowledge, attitude, and practice towards diabetes mellitus among outpatient diabetic elderly persons: a descriptive study. 1	
397	Evaluation of the Effectiveness of Post-Stroke Metformin Treatment Using Permanent Middle Cerebral Artery Occlusion in Rats. 2021 , 14,	6
396	Metformin prevents stroke damage in non-diabetic female mice with chronic kidney disease. 2021 , 11, 7464	5
395	Safety and pharmacokinetic interaction between fotaliptin, a dipeptidyl peptidase-4 inhibitor, and metformin in healthy subjects. 2021 , 17, 725-731	
394	Metformin Modifies the Gut Microbiota of Mice Infected with. 2021 , 14,	2
393	Polyphenol-rich extract and fractions of Terminalia phaeocarpa Eichler possess hypoglycemic effect, reduce the release of cytokines, and inhibit lipase, glucosidase, and amilase enzymes. 2021 , 271, 113847	4
392	Chronic Inflammatory Status Observed in Patients with Type 2 Diabetes Induces Modulation of Cytochrome P450 Expression and Activity. 2021 , 22,	11
391	Effect of a Smartphone App on Weight Change and Metabolic Outcomes in Asian Adults With Type 2 Diabetes: A Randomized Clinical Trial. 2021 , 4, e2112417	3
390	Meta-Assessment of Metformin Absorption and Disposition Pharmacokinetics in Nine Species. 2021 , 14,	2
389	Comparison between different types of exercise training in patients with type 2 diabetes mellitus: A systematic review and network metanalysis of randomized controlled trials. 2021 , 31, 1985-1992	3
388	Efficacy of a Combination of Metformin and Vildagliptin in Comparison to Metformin Alone in Type 2 Diabetes Mellitus: A Multicentre, Retrospective, Real-World Evidence Study. 2021 , 14, 2925-2933	2
387	Preoperative Management of Endocrine, Hormonal, and Urologic Medications: Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement. 2021 , 96, 1655-1669	3
386	Repurposing metformin to treat age-related neurodegenerative disorders and ischemic stroke. 2021 , 274, 119343	12
385	Long-acting insulin in a public health system: analysis of compliance with clinical protocol in public pharmacies. 2021 , 26, 2301-2310	
384	Role of Insulin in Health and Disease: An Update. 2021 , 22,	7

- 383 STAT1 potentiates oxidative stress revealing a targetable vulnerability that increases phenformin efficacy in breast cancer. **2021**, 12, 3299 5
- 382 Supramolecular architecture in sulfonylurea, sulfonyldiurea and sulfonyltriurea drugs: Synthesis, X-ray structure and Hirshfeld surface analysis. **2021**, 1233, 130158
- 381 Poor Glycemic Control and Its Contributing Factors Among Type 2 Diabetes Patients at Adama Hospital Medical College in East Ethiopia. **2021**, 14, 3273-3280 4
- 380 First-in-Human, Double-Blind, Randomized, Placebo-Controlled Trial of TQ-F3083, a New Dipeptidyl Peptidase-4 Inhibitor, in Healthy Chinese Adults. *Frontiers in Pharmacology*, **2021**, 12, 689523 5.6 0
- 379 The prognostic outcome of 'type 2 diabetes mellitus and breast cancer' association pivots on hypoxia-hyperglycemia axis. **2021**, 21, 351 0
- 378 Water-Soluble Gold(III)-Metformin Complex Alters Mitochondrial Bioenergetics in Breast Cancer Cells. **2021**, 16, 3222-3230 4
- 377 A spotlight on underlying the mechanism of AMPK in diabetes complications. **2021**, 70, 939-957 1
- 376 Potassium bromate-induced nephrotoxicity and potential curative role of metformin loaded on gold nanoparticles. **2021**, 104, 368504211033703
- 375 Multicomponent Crystal of Metformin and Barbitol: Design, Crystal Structure Analysis and Characterization. **2021**, 26, 0
- 374 Relation of cardiac function to insulin resistance as evaluated by hyperinsulinemic-euglycemic clamp analysis in individuals with type 2 diabetes. **2021**, 0
- 373 Comparison between the Effect of Laparoscopic Sleeve Gastrectomy and Laparoscopic Mini-gastric Bypass on Type 2 Diabetes Mellitus in Obese Patients: A Prospective Study. **2021**, 14, 131-135
- 372 Variations in Serum Vitamin B12 Levels among Metformin Receiving and Non-Receiving Type 2 Diabetes Mellitus Patients - A Case Control Study in a Tertiary Care Hospital in Puducherry. **2021**, 8, 2835-2841
- 371 Potential Therapeutic Applications of Synthetic Conotoxin s-cal14.2b, Derived from , for Treating Type 2 Diabetes. **2021**, 9, 2
- 370 Clinical Outcomes and Oral Health-Related Quality of Life after Periodontal Treatment with Community Health Worker Strategy in Patients with Type 2 Diabetes: A Randomized Controlled Study. **2021**, 18, 0
- 369 Pharmaceutical Drugs and Natural Therapeutic Products for the Treatment of Type 2 Diabetes Mellitus. **2021**, 14, 20
- 368 study of the drug-drug interaction potential of cetagliptin and clinical study of pharmacokinetic interaction of cetagliptin and metformin in healthy volunteers. **2021**, 51, 1122-1131 2
- 367 Improvement of glycemic control in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. **2021**, 31, 2539-2546 4
- 366 Optimization of bilayer tablet manufacturing process for fixed dose combination of sustained release high-dose drug and immediate release low-dose drug based on quality by design (QbD). *International Journal of Pharmaceutics*, **2021**, 605, 120838 6.5 3

365	Antihyperglycemic Algorithms for Type 2 Diabetes: Focus on Nonglycemic Outcomes. 2021 , 34, 248-256		
364	Multifactorial Basis and Therapeutic Strategies in Metabolism-Related Diseases. 2021 , 13,		5
363	A valid self-help tool to measure the role of spousal support in the care of persons with diabetes mellitus. 1		
362	Role of Gliclazide in safely navigating type 2 diabetes mellitus patients towards euglycemia: Expert opinion from India. 2021 , 4, 100102		
361	Efficacy and Safety of Metformin Use in Rheumatoid Arthritis: A Randomized Controlled Study. <i>Frontiers in Pharmacology</i> , 2021 , 12, 726490	5.6	2
360	Structural Perspectives and Advancement of SGLT2 Inhibitors for the Treatment of Type 2 Diabetes. 2021 ,		
359	Sesquiterpenes and polyphenols with glucose-uptake stimulatory and antioxidant activities from the medicinal mushroom <i>Sanghuangporus sanghuang</i> . 2021 , 19, 693-699		1
358	Biological activity of 23 β -trihydroxyolean-12-ene on glucose homeostasis. 2021 , 907, 174250		
357	Making sense of diabetes medication decisions: a mixed methods cluster randomized trial using a conversation aid intervention. 2021 , 1		1
356	Sequential Multiple Assignment Randomized Trial (SMART) to identify optimal sequences of telemedicine interventions for improving initiation of insulin therapy: A simulation study. 2021 , 21, 200		3
355	Association between FGF19, FGF21 and lipocalin-2, and diabetes progression in PCOS. 2021 , 10, 1243-1252		1
354	Effectiveness of a smoking cessation algorithm integrated into HIV primary care: Study protocol for a randomized controlled trial. 2021 , 110, 106551		0
353	Current Status of Diabetes in Palestine: Epidemiology, Management, and Healthcare System. 2021 , 1053-1081		
352	Effects of metformin on the prevention of bisphosphonate-related osteonecrosis of the jaw-like lesions in rats. 2021 , 65, 219-224		6
351	Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes. 2021 , 14, 107-116		1
350	Hypoglycaemia in Type 2 Diabetes and in Elderly People. 230-262		2
349	Management and treatment of diabetes mellitus. 2012 , 771, 356-80		16
348	Weight reduction in diabetes. 2012 , 771, 438-58		6

347	Sixty Years of Drug Discovery for Type 2 Diabetes: Where Are We Now?. 2020 , 2076, 1-30	5
346	Common Clinical Conditions in Long-Term Care. 2011 , 75-121	1
345	Diabetes Secondary to Pancreatic Diseases. 2020 , 523-539	1
344	GLP-1 agonists and dipeptidyl-peptidase IV inhibitors. 2011 , 53-74	26
343	Diabetes Mellitus. 2014 , 163-169	2
342	Hyperglycemia Prediction Using Machine Learning: A Probabilistic Approach. 2019 , 304-312	3
341	Management of Insulin Through Co-Solute Engineering: A Therapeutic Approach. 2020 , 283-315	1
340	Effects of Nutritional Supplements on Human Health. 2019 , 105-140	2
339	Type 2 Diabetes Mellitus. 2011 , 1371-1435	18
338	D'sordres glychmiques. 2010 , 51-76	1
337	SGLT inhibitors as antidiabetic agents: a comprehensive review.. 2020 , 10, 1733-1756	9
336	AMPK is associated with the beneficial effects of antidiabetic agents on cardiovascular diseases. 2019 , 39,	30
335	Epigenetic modification and therapeutic targets of diabetes mellitus. 2020 , 40,	13
334	Improvement in the Quality of HbA1c Determination by Using Commutable Specimens With IFCC-Assigned Values. 2017 , 48, 148-153	1
333	The Glitazars Paradox: Cardiotoxicity of the Metabolically Beneficial Dual PPAR α and PPAR γ Activation. 2020 , 76, 514-526	4
332	Recent diabetes issues affecting the primary care clinician. 2011 , 104, 456-61	2
331	A novel approach to optimise glycaemic control in insulin users. 2015 , 2015,	3
330	Redesigning ambulatory care management for uncontrolled type 2 diabetes: a prospective cohort study of the impact of a Boot Camp model on outcomes. <i>BMJ Open Diabetes Research and Care</i> , 2019 , 7, e000731	4.5 6

329	mTORC1 inhibitors rapamycin and metformin affect cardiovascular markers differentially in ZDF rats. 2017 , 95, 281-287	5
328	An energetic tale of AMPK-independent effects of metformin. 2010 , 120, 2267-70	114
327	Bayesian Adaptive Designs. 2017 , 177-196	3
326	Inhaled Insulin: More Compelling than Ever. 2016 , 23-30	1
325	Personalized glucose forecasting for type 2 diabetes using data assimilation. 2017 , 13, e1005232	47
324	Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. 2012 , 7, e33411	401
323	Effects of metformin on CD133+ colorectal cancer cells in diabetic patients. 2013 , 8, e81264	54
322	Potential therapeutic competition in community-living older adults in the U.S.: use of medications that may adversely affect a coexisting condition. 2014 , 9, e89447	55
321	Hepatic FoxO1 acetylation is involved in oleanolic acid-induced memory of glycemic control: novel findings from Study 2. 2014 , 9, e107231	13
320	Medium Renewal Blocks Anti-Proliferative Effects of Metformin in Cultured MDA-MB-231 Breast Cancer Cells. 2016 , 11, e0154747	11
319	Cost-Effectiveness of Saxagliptin versus Acarbose as Second-Line Therapy in Type 2 Diabetes in China. 2016 , 11, e0167190	6
318	Algorithms of Specialized Medical Care for Diabetes Mellitus Patients. 2011 , 14, 2-72	19
317	Standards of specialized diabetes care. Edited by Dedov II, Shestakova MV (6th edition). 2013 , 16, 1-120	28
316	Insulin degludec is a new ultra-long-acting insulin analogue. 2014 , 17, 91-104	3
315	Risk factors and management of pasireotide-associated hyperglycemia in acromegaly. 2020 , 9, 1178-1190	9
314	Clinical Outcomes in Patients with Diabetes Mellitus Using a Medically Supervised Commercial Weight Reduction Program Compared to Standard Care in an Endocrine Specialty Clinic. 2016 , 3, 1-6	1
313	[Proposal for the modification of metformin use in patients with chronic kidney disease]. 2012 , 153, 1527-35	1
312	Unsatisfactory glycemic control in type 2 Diabetes mellitus patients: predictive factors and negative clinical outcomes with the use of antidiabetic drugs. 2016 , 52, 801-812	1

311	Optimal therapy of type 2 diabetes: a controversial challenge. 2014 , 6, 187-206	32
310	Metformin impairs Rho GTPase signaling to induce apoptosis in neuroblastoma cells and inhibits growth of tumors in the xenograft mouse model of neuroblastoma. 2014 , 5, 11709-22	28
309	Incretin therapy--present and future. 2011 , 8, 307-22	21
308	The role of incretin therapy at different stages of diabetes. 2011 , 8, 323-38	20
307	Obesity, Diabetes and Cancer: A Mechanistic Perspective. 2015 , 2015,	3
306	Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus. 2010 , 3, 49-53	1
305	Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies. 2010 , 3, 227-42	8
304	Repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update. 2010 , 3, 145-54	3
303	Impact of obesity and type 2 diabetes on health-related quality of life in the general population in England. 2009 , 2, 179-84	14
302	PTP1b Inhibition, A Promising Approach for the Treatment of Diabetes Type II. 2019 , 19, 246-263	24
301	Docking Assisted Prediction and Biological Evaluation of Sideritis L. Components with PTP1b Inhibitory Action and Probable Anti-Diabetic Properties. 2019 , 19, 383-392	3
300	Type-3c Diabetes Mellitus, Diabetes of Exocrine Pancreas - An Update. 2019 , 15, 382-394	17
299	Real-World Clinical Effectiveness and Tolerability of Hydroxychloroquine 400 Mg in Uncontrolled Type 2 Diabetes Subjects who are not Willing to Initiate Insulin Therapy (HYQ-Real-World Study). 2019 , 15, 510-519	16
298	Change in Glycemic Control With Use of a Digital Therapeutic in Adults With Type 2 Diabetes: Cohort Study. 2018 , 3, e4	26
297	InsuOnline, an Electronic Game for Medical Education on Insulin Therapy: A Randomized Controlled Trial With Primary Care Physicians. 2017 , 19, e72	23
296	Synergism effects of pioglitazone and extract in streptozotocin-induced nephropathy via attenuation of oxidative stress. 2017 , 20, 497-502	8
295	Metabolomics and Cell Therapy in Diabetes Mellitus. 2019 , 8, 41-48	4
294	The Effect of the Chronic Administration of DPP4-Inhibitors on Systemic Oxidative Stress in Rats with Diabetes Type 2. 2019 , 20, 199-206	1

293	Renal Function in Type 2 Diabetes Following Gastric Bypass. 2016 , 113, 827-833		13
292	Insulin vs GLP-1 analogues in poorly controlled Type 2 diabetic subjects on oral therapy: a meta-analysis. <i>Journal of Endocrinological Investigation</i> , 2013 , 36, 168-73	5.2	6
291	Antidiabetic and Hypolipidemic Potential of 3, 4-dihydroisoquinolin-2(1H)- Sulfonamide in Alloxan Induced Diabetic Rats. 2015 , 11, 226-235		5
290	Structural Characterization and Anti-Diabetic Activity of Polysaccharides from Agaricus bisporus Mushroom. 2018 , 12, 14-20		1
289	Pharmacological management of type 2 diabetes in newly diagnosed older adults. 2009 , 35, 16-21		2
288	Introducing insulin into diabetes management: transition strategies for older adults. 2011 , 37, 10-5		5
287	Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea. 2019 , 43, 432-446		2
286	Switching to Once-Daily Insulin Degludec/Insulin Aspart from Basal Insulin Improves Postprandial Glycemia in Patients with Type 2 Diabetes Mellitus: Randomized Controlled Trial. 2020 , 44, 532-541		3
285	Knowledge and practices related to diabetes mellitus among adults with diabetes in the Mopani District, Limpopo Province, South Africa. 2016 , 75,		1
284	Utilization study of antidiabetic agents in a teaching hospital of Sikkim and adherence to current standard treatment guidelines. 2016 , 8, 223-8		10
283	Inhaled insulin: A "puff" than a "shot" before meals. 2015 , 6, 126-9		4
282	Association of Comorbid and Metabolic Factors with Optimal Control of Type 2 Diabetes Mellitus. 2016 , 8, 31-9		7
281	Efficacy and safety of biphasic insulin aspart and biphasic insulin lispro mix in patients with type 2 diabetes: A review of the literature. 2016 , 20, 288-99		3
280	Liraglutide: A review of its therapeutic use as a once daily GLP-1 analog for the management of type 2 diabetes mellitus. 2011 , 15, 9-17		19
279	Management of hyperglycemia in geriatric patients with diabetes mellitus: South Asian consensus guidelines. 2011 , 15, 75-90		19
278	Pleiotropic effects of incretins. 2012 , 16 Suppl 1, S47-56		24
277	Metformin-associated Encephalopathy in Hemodialysis. 2019 , 29, 194-196		3
276	Vitamin B12 deficiency and the knowledge and practice of physicians regarding screening for vitamin B12 deficiency among type 2 diabetic patients on metformin in selected hospitals in Riyadh, Saudi Arabia. 2019 , 8, 2306-2311		3

275	Diabetes in the Elderly: Exercising Your Clinical Skills. 2010 , 25, 1-37	1
274	Mild renal impairment and the efficacy and safety of liraglutide. 2011 , 17, 345-55	31
273	Body Mass Index and Breast Cancer Risk: A Retrospective Multi-Institutional Analysis in Saudi Arabia. 2013 , 02, 7-10	4
272	A New and Enantioselective Chromatographic Method for Linagliptin on Amylose Coated Chiral Stationary Phase. 2016 , 07, 556-567	5
271	A Retrospective Observational Analysis of Clinical Outcomes before and after the Publication of the AACE/ACE Guidelines. 2014 , 05, 717-723	1
270	The effect of weight loss on fasting blood sugars and hemoglobin A1c in overweight and obese diabetics and non-diabetics. 2012 , 02, 126-130	7
269	Metformin Intoxication: A Case of a Combination of Severe Hypoglycaemia and Severe Lactic Acidosis (LA). 2015 , 05, 111-114	2
268	Metformin: A possible drug for treatment of endometrial cancer. 2012 , 02, 1-6	8
267	Glycemic and cardiovascular parameters improved in type 2 diabetes with the high nutrient density (HND) diet. 2012 , 02, 364-371	10
266	Are proton pump inhibitors a new antidiabetic drug? A cross sectional study. 2011 , 2, 217-20	24
265	Starting glargine in insulin-naïve type 2 diabetic patients based on body mass index is safe. 2014 , 5, 69-75	2
264	HLA alleles may serve as a tool to discriminate atypical type 2 diabetic patients. 2014 , 5, 711-6	2
263	Importance of telemedicine in diabetes care: Relationships between family physicians and ophthalmologists. 2015 , 6, 1005-8	12
262	Association of mutation and atypical diabetes in a Uruguayan population. 2018 , 9, 157-164	6
261	Metformin associated lactic acidosis in Auckland City Hospital 2005 to 2009. 2016 , 5, 367-71	10
260	Resveratrol-Dependent Down-regulation of Receptor for Advanced Glycation End-products and Oxidative Stress in Kidney of Rats With Diabetes. 2015 , 13, e23542	48
259	Pharmacokinetics of Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, and Glimepiride Following Co-administration in Healthy Volunteers: A Randomised, Open-label, Crossover Study. 2012 , 1, 14	11
258	Use of oral antidiabetic drugs (metformin and pioglitazone) in diabetic patients with breast cancer: how does it effect serum Hif-1 alpha and 8Ohdg levels?. 2012 , 13, 5143-8	21

- 257 Evaluation of Effects of Metformin in Primary Ovarian Cancer Cells. **2015**, 16, 6973-9 17
- 256 Glucose, Blood Pressure, and Lipid Control in Korean Adults with Diagnosed Diabetes. **2012**, 24, 406-416 14
- 255 Antipsychotic olanzapine-induced misfolding of proinsulin in the endoplasmic reticulum accounts for atypical development of diabetes. **2020**, 9, 6
- 254 Two Cases of Successful Type 2 Diabetes Control with Lifestyle Modification in Children and Adolescents. **2017**, 26, 71-75 4
- 253 Metformin Use and Metformin-associated Lactic Acidosis in Intensive Care Unit Patients with Diabetes. **2019**, 11, e4739 6
- 252 Time-restricted feeding improves blood glucose and insulin sensitivity in overweight patients with type 2 diabetes: a randomised controlled trial. **2021**, 18, 88 3
- 251 Setting analytical performance specifications using HbA1c as a model measurand. **2021**, 523, 407-414 3
- 250 Outpatient cardiovascular diseases and diabetes medicines dispensing in the population with government health insurance in Syria between 2018 and 2019: a retrospective analysis. **2021**, 21, 1088
- 249 Vildagliptin. **2008**, 30,
- 248 Issledovanie effekta i deystviya liraglutida pri sakharnom diabete (LEADTM) Expert Rev. Endocrinol. Metab. 4(2), 119-129 (2009). **2009**, 12, 11-20 1
- 247 THE ROLE OF ACARBOSE IN THE TREATMENT AND PREVENTION OF DIABETES MELLITUS TYPE 2: NEW OPPORTUNITIES IN CARDIOVASCULAR RISK DECREASE. **2009**, 15, 640-647
- 246 Considering insulin for type-2 diabetes. **2009**, 2009,
- 245 Fiches cliniques. **2010**, 397-404
- 244 Determining the Factors that Influence the Insulin Requirements in Type 2 Diabetic Patients. **2010**, 25, 110 2
- 243 Management of Type 2 Diabetes Mellitus. **2010**, 897-915
- 242 A Study for the Factors Influencing Insulin Requirements in Type 2 Diabetic Patients. **2010**, 25, 101
- 241 Thérapeutique des d'sordres glychniques. **2010**, 119-174
- 240 How to use Type 2 Diabetes Treatments in Clinical Practice: Combination Therapies. 494-513

239 Insulin Use. **2011**, 123-151

238 Clinical utility of fixed combinations of sitagliptin-metformin in treatment of type 2 diabetes. **2010**, 3, 363-72

2

237 The importance of combined glycemic control in patients with type 2 diabetes mellitus. **2010**, 56, 43-51

2

236 Medical Management of Kidney Transplant Recipients. **2011**, 311-332

235 Cost-Effectiveness of Glycemic Control. **2011**, 391-402

234 Cardiovascular implications of modern algorithm of hypoglycemic therapy: ?Florentine hypothesis?. **2010**, 13, 30-37

233 Diabetes Mellitus. **2011**, 731-755

232 Outpatient Anesthesia. **2011**, 588-616

231 Metformin and Lactic Acidosis. **2011**, 685-693

230 Diabetes and Cardiovascular Disease. **2011**, 345-370

229 Type 2 Diabetes: Pharmacological Treatment of Hyperglycaemia. 102-138

228 High Blood Pressure: The Silent Killer. **2011**, 33-48

1

227 Incorporating new therapy into established clinical practice guidelines. **2011**, 104, 383-4

226 How can we avoid the danger of hypoglycemia, one of the most serious complications of therapy of type 2 diabetes mellitus? The role of DPP-4 inhibitors. **2011**, 57, 48-52

225 Effect of Ipragliflozin (ASP1941), a Novel Selective Sodium-Dependent Glucose Co-Transporter 2 Inhibitor, on Urinary Glucose Excretion in Healthy Subjects. **2011**, 1

224 Focus on Incretin-Based Therapies for Patients with Type 2 Diabetes and Cardiovascular Disease. **2011**, 17, 13-19

1

223 Focus on Incretin-Based Therapies for Elderly Patients with Type 2 Diabetes. **2011**, 17, 20-26

222 Risk Factor Management of Atherosclerotic Peripheral Vascular Disease. **2012**, 175-192

- 221 [Incretin-based therapy for treating patients with type 2 diabetes]. **2011**, 152, 1931-40 1
- 220 The Effectiveness of Diamel in the Treatment of Type 2 Diabetic Patients Receiving Insulin Therapy: A Randomized, Controlled Clinical Trial. **2012**, 02, 117-124
- 219 How should we treat glucose intolerance as a risk factor for pancreatic cancer?. **2012**, 27, 139-144
- 218 Children's Health. **2012**, 1045-1099
- 217 Management Strategies for Diabetes. **2012**, 19-33
- 216 Metabolic Disorders. **2012**, 727-766
- 215 Modern approaches to the treatment of type 2 diabetes mellitus and its complications. **2012**, 58, 61-64
- 214 The clinical application of glibenclamide: the problem of safety and efficacy. **2012**, 58, 65-69
- 213 The importance and advantages of the timely prescription of insulin to the patients with type 2 diabetes mellitus. **2012**, 58, 56-60
- 212 [Intensive insulin therapy in type 2 diabetes mellitus]. **2012**, 153, 1487-93
- 211 New prospects in the treatment of diabetes mellitus. **2012**, 15, 109-114 3
- 210 The Efficacy and Safety of Saxagliptin in Haemodialysis Patients. **2013**, 03, 83-88
- 209 Effectiveness of therapy with basal insulin analogs to improve glycemic control in type 2 diabetes mellitus patients poorly controlled with oral antidiabetic drugs in combination or not with NPH insulin. **2013**, 2, 20
- 208 Efficacy and safety of alogliptin in type 2 diabetic patients undergoing hemodialysis. **2013**, 46, 633-640
- 207 PANCREATIC AND EXTRA-PANCREATIC EFFECTS OF INCRETINS AND PERSPECTIVES FOR STUDYING ENTEROINSULIN HORMONAL SYSTEM DURING GESTATIONAL DISORDER OF CARBOHYDRATE METABOLISM. **2013**, 12, 132-147 0
- 206 The new therapeutic modalities for the treatment of type 2 diabetes mellitus: insulin detemir added to liraglutide. **2013**, 59, 50-55 1
- 205 Oral Therapies for Type 2 Diabetes. **2014**, 375-384
- 204 Weight Gain on Glucose-Lowering Agents. **2014**, 263-277

- 203 Glucose-lowering therapies in patients with diabetes mellitus and chronic kidney disease. **2013**, 16, 97-102 3
- 202 Vascular Complications of Diabetes Mellitus. **2014**, 1-65
- 201 Efficacy and Safety of Patient-Led Dosage Adjustments of Insulin Glargine: A Preliminary Report of Basal-Supported Oral Therapy for Japanese Type 2 Diabetes Patients. **2014**, 04, 77-84
- 200 Ma-Pi 2 macrobiotic diet intervention during 21 days in adults with type 2 diabetes mellitus, Ghana 2011. **2014**, 2, 3
- 199 Unique glycemic and cardio-renal protective effects of metformin therapy among type-2 diabetic patients: a lesson from a five-year cross-sectional observational study of 1590 patients. 1, 0
- 198 Metabolic Syndrome. **2014**, 69-114
- 197 Introduction: Type-2 Diabetes. **2015**, 343-345
- 196 Metformin and Cancer Treatment. **2015**, 6, 316-317
- 195 Transition to Insulin in Patients with Type-2 Diabetes. **2015**, 359-368
- 194 Pharmacoepidemiological and pharmaco-economic analyses of the utilization of hypoglycaemic drugs in patients with type 2 diabetes mellitus in Moscow. **2015**, 18, 32-46 4
- 193 B'ô che v' thu nghiem In vitro liposome metformin. **2016**, 43, 19
- 192 Background and Objectives. **2016**, 5-28
- 191 Examining Failure in a Dynamic Decision Environment: Strategies for Treating Patients with a Chronic Disease. **2016**, 103-124
- 190 Introduction. **2016**, 1-9
- 189 Insulin Initiation in Type 2 Diabetes âWhy, When and How?. **2016**, 23, 87-94
- 188 Treatment of Type 2 Diabetes with Ayurveda: A Case Report. **2016**, 7, 239-242
- 187 LOW RISK OF CARDIOVASCULAR DISEASES WITH METFORMIN COMPARED WITH OTHER ANTI-DIABETIC DRUGS IN PATIENTS WITH TYPE 2 DIABETES. **2016**, 3, 3202-3205
- 186 Sodium-glucose Cotransporter-2 Inhibitors: Moving Beyond the Glycemic Treatment Goal. **2017**, 21, 909-918

185 Antidiabetic Medicinal Plants. **2017**, 147-174

184 Late Metabolic Complications After Pancreatectomy. **2017**, 357-364

183 Newer Long-Acting Basal Insulin Preparations. **2017**, 23, 13-17

182 Antioxidant and Antidiabetic Activity of Aqueous Ethanolic Extract of Momordica charantia L. (Cucurbitaceae var. Gutti) Fruit in Streptozotocin (STZ) Induced Diabetes Rats. **2017**, 12, 59-70

181 Prevalence and Pattern of Dyslipidemia among Type 2 Diabetes Mellitus Patients in a Tertiary Center Hospital of Nepal. **2017**, 4,

180 Telemedicine is Cost Effective Compared with Standard Care in Type 2 Diabetes Mellitus - A Randomized Trial with an Economic Analysis in an Outpatient Clinic. **2017**, In Press,

179 COMPARATIVE STUDY OF METFORMIN AND VILDAGLIPTIN FOR MANAGEMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS. **2017**, 6, 5372-5375

178 Change in Glycemic Control With Use of a Digital Therapeutic in Adults With Type 2 Diabetes: Cohort Study (Preprint).

177 Hypoglycemia. **2018**, 617-654

1

176 Data-Adaptive Estimation in Cluster Randomized Trials. **2018**, 195-215

175 Traitement du diabète sucré. **2018**, 333-359.e1

174 Diabetes Secondary to Pancreatic Diseases. **2018**, 523-539

173 Fall 8: Therapie â25 Jahre, ?, DM Typ 1. **2018**, 29-31

172 Building a Caring-Based Hyperglycemic Crisis Prevention Model for Patients With Diabetes Mellitus, Thailand. **2018**, 22, 4-13

171 Cardiovascular death risk reduction in type 2 diabetes patients with confirmed cardiovascular diseases. **2018**, 58-64

1

170 Comparison of Exercise Intensity of Strengthening Exercise Program for Stroke Patients with Type II Diabetes Mellitus. **2018**, 13, 105-112

2

169 Dapagliflozin Kullanan Diyabetik Hastalarda Serum Elektrolit Değerlerinin 6 Aylık Değerlerini Gösteren Tek Merkez Gerçek Klinik Deneyim Verileri.

168 Current Status of Diabetes in Palestine: Epidemiology, Management, and Healthcare System. **2019**, 1-29

167 Fiches cliniques. **2019**, 541-557

166 Hypoglycemia. **2019**, 1-38

165 Current Status of Diabetes in Palestine: Epidemiology, Management, and Healthcare System. **2019**, 1-29

0

164 Clinical Practice Guidelines, Evidence-Based Medicine, and Diabetes. **2019**, 333-355

163 Diabetes Secondary to Pancreatic Diseases. **2019**, 1-17

162 Thérapeutique des d'sordres glychiques. **2019**, 141-252

161 Insulin Resistance Is a Common Core Tethered to Diabetes and Pancreatic Cancer Risk. **2019**, 197-213

160 A Prospective, Randomized, Open Label, Single-Centre Study for Assessment of Safety and Effectiveness of Recombinant Human Insulin 30/70 + Insulin Glulisine compared to Recombinant Human Insulin NPH + Regular in the Management of Type 2 Diabetes Mellitus Patients in the Philippines.. **2019**, 3, 260-269

159 Sitagliptin monoterapisi ile kombinasyon tedavilerinin karlılıklarını

158 Metformin poisoning treated with high dose insulin dextrose therapy: a case series. **2019**, 26, 72-78

1

157 The joint effect of hydro-alcoholic extract of nettle root and metformin on ovarian tissue of diabetic model of Wistar rat. **2019**, 6, 131-139

0

156 Diabetes as a Systemic Factor for Peri-implantitis. **2020**, 59-67

155 Classification of Prediabetes and Healthy Subjects in Plantar Infrared Thermal Imaging Using Various Machine Learning Algorithms. **2020**, 85-96

1

154 Optimizing the Interaction of Exercise Volume and Metformin to Induce a Clinically Significant Reduction in Metabolic Syndrome Severity: A Randomised Trial. **2020**, 17,

1

153 Metformin Ameliorates Oxidative Stress Induced by Diabetes Mellitus and Hepatocellular Carcinoma in Rats. **2020**, 9, 115-128

6

152 The art and science of drug titration. **2020**, 11, 2042098620958910

1

151 Factors that affect the Glycemic Control Achieved by Switching to Insulin Degludec/ Aspart in Insulin-Treated Patients with Type 1 and Type 2 Diabetes in a Real-World Setting: a Non-interventional, Retrospective Cohort Study. **2020**, 16, 443-448

0

150 Hypoglycemia. **2020**, 615-652

149	Analysis of drug prescription appropriateness according to the STOPP/START criteria of the elderly patients with type 2 diabetes mellitus in the endocrinology department of a multi-speciality hospital. 2020 , 47-56	1
148	Effects of Metformin on the Survival Rate of CMF (Cyclophosphamide, Methotrexate and 5-fluorouracil)-treated Rats. 2020 , 16, 201-204	2
147	Prevalence and spectrum of diabetic peripheral neuropathy and its correlation with insulin resistance - An experience from eastern India.	
146	Influence of gender on the distribution of type 2 diabetic complications at the obafemi awolowo teaching hospital, Ile-Ife, Nigeria. 2020 , 20, 294-307	1
145	Impact of diabetes on the increased risk of hepatic cancer: An updated review of biological aspects. 2021 , 100025	0
144	Change in Glycemic Control With Use of a Digital Therapeutic in Adults With Type 2 Diabetes: Cohort Study.	
143	Insulin pump therapy and continuous glucose monitoring in adults with type 2 diabetes: where are we now?. 2020 , 1, 314-330	1
142	Management of Diabetes Mellitus in Acute and Chronic Cardiorenal Syndromes. 2021 , 295-313	
141	Taking the stress out of insulin initiation in type 2 diabetes mellitus. 2009 , 55, 608-11	1
140	A dipeptidyl peptidase-4 inhibitor for adults with type 2 diabetes. 2010 , 35, 2-4	
139	Dipeptidyl Peptidase-4 (DPP-4) Inhibitors In the Management of Diabetes. 2010 , 35, 509-13	32
138	Liraglutide (victoza): the first once-daily incretin mimetic injection for type-2 diabetes. 2010 , 35, 498-529	15
137	Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes. 2010 , 3, 215-26	5
136	Management of obesity, insulin resistance and type 2 diabetes in children: consensus and controversy. 2009 , 2, 185-202	2
135	Impact of rosiglitazone meta-analysis on use of glucose-lowering medications. 2010 , 4, e50-9	4
134	Cellular and molecular effects of thiazolidinediones on bone cells: a review. 2011 , 2, 240-6	5
133	Cross-sectional pilot study about the health status of diabetic patients in city of Misurata, Libya. 2012 , 12, 81-6	6
132	Changes in bone biological markers after treatment of Iranian diabetic patients with pioglitazone: No relation to polymorphism of PPAR- γ (Pro12Ala). 2013 , 18, 366-7	

131	The effects of green tea consumption on metabolic and anthropometric indices in patients with Type 2 diabetes. 2013 , 18, 1080-6	22
130	Patient tolerance and acceptance of colesevelam hydrochloride: focus on type-2 diabetes mellitus. 2015 , 40, 62-7	4
129	Statins and Finasteride Use Differentially Modify the Impact of Metformin on Prostate Cancer Incidence in Men with Type 2 Diabetes. 2014 , 1,	5
128	Genetic variants of OCT1 influence glycemic response to metformin in Han Chinese patients with type-2 diabetes mellitus in Shanghai. 2015 , 8, 9533-42	15
127	Assessing the efficacy and safety of combined DPP-4 inhibitor and insulin treatment in patients with type 2 diabetes: a meta-analysis. 2015 , 8, 14141-50	15
126	The role of noggin in regulation of high glucose-induced apoptosis and insulin secretion in INS-1 rat beta cells. 2015 , 18, 1137-42	1
125	Efficacy of oral versus insulin therapy for newly diagnosed diabetes in low-income settings. 2017 , 1, 17-22	1
124	Metformin reduces radiation-induced cardiac toxicity risk in patients having breast cancer. 2019 , 9, 1017-1026	9
123	Efficacy and Safety of Dulaglutide Compared to Liraglutide: A Systematic Review and Meta-analysis in Patients with Type 2 Diabetes Mellitus. 2019 , 18, 2180-2190	
122	Estimation of YKL-40 Levels in Serum and Gingival Crevicular Fluid in Chronic Periodontitis and Type 2 Diabetes Patients among South Indian Population: A Clinical Study. 2019 , 10, 304-310	1
121	Mechanisms of metformin inhibiting cancer invasion and migration. 2020 , 12, 4885-4901	13
120	The clinical application of metformin in children and adolescents: A short update. 2020 , 91, e2020086	1
119	Turkish Gastroenterology Association, Pancreas Study Group, Chronic Pancreatitis Committee Consensus Report. 2020 , 31, S1-S41	
118	The Reciprocal Relationship between LDL Metabolism and Type 2 Diabetes Mellitus.. 2021 , 11,	2
117	State of Evidence on Oral Health Problems in Diabetic Patients: A Critical Review of the Literature. 2021 , 10,	0
116	MLR-1023 Treatment in Mice and Humans Induces a Thermogenic Program, and Menthol Potentiates the Effect. 2021 , 14,	0
115	bile Health Bometrics to Enhance Exercise and Physical Actiity dherence in yp 2 Diabetes (MOTIVATE-T2D): protocol for a feasibility randomised controlled trial. 2021 , 11, e052563	
114	Antidiabetic Effects of the Senolytic Agent Dasatinib. 2021 , 96, 3021-3029	1

- 113 Turkish Gastroenterology Association, Pancreas Study Group, Chronic Pancreatitis Committee Consensus Report. **2020**, 31, 1-41 o
- 112 Correction to: "Cardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: A Meta-Analysis".. **2022**, 11, 89-101
- 111 hIAPP-Amyloid-Core Derived d-Peptide Prevents hIAPP Aggregation and Destabilizes Its Protofibrils.. **2022**, 1
- 110 Multinational Observational Study to Understand Insulin Treatment Intensification: Japanese Subgroup Analysis of the MOSAIC Study.. **2022**, 13, 265
- 109 Effects of alcoholic extract of Terminalia Chebula dried fruit on blood biochemical profile in diabetic rats. 1
- 108 Metformin Induced Cognitive Impairment and Neuroinflammation in CMF-Treated Rats. **2022**, 18, 228-235
- 107 Evaluating the Incidence and Risk Factors Associated With Mild and Severe Hypoglycemia in Insulin-Treated Type 2 Diabetes.. **2022**, 30, 9-17 o
- 106 Italian guidelines for the treatment of type 2 diabetes.. **2022**, o
- 105 [Effect of trimetazidine on cardiac function and exercise tolerance in hypertension patients with diabetic]. **2019**, 48, 282-288
- 104 Oral Therapies for Type 2 Diabetes. **2022**, 325-334
- 103 Metformin and Breast Cancer: Where Are We Now?. **2022**, 23, 4
- 102 Genome-wide CRISPR screen identifies synthetic lethality between DOCK1 inhibition and metformin in liver cancer.. **2022**, 1 o
- 101 Effects of Metformin as Add-On Therapy against Glioblastoma: An Old Medicine for Novel Oncology Therapeutics.. **2022**, 14, o
- 100 Italian guidelines for the treatment of type 2 diabetes.. **2022**, 59, 579 o
- 99 Effect of Metformin as an add-on therapy on neuregulin-4 levels and vascular-related complications in adolescents with type 1 diabetes: A randomized controlled trial.. **2022**, 109857 o
- 98 Effects of high- and moderate-intensity resistance training sessions on glycemia of insulin-treated and non-insulin-treated type 2 diabetes mellitus individuals. 1
- 97 variant rs163184 is a potential biomarker of glycemic response to exenatide.. **2022**, o
- 96 Self-care practice and glycemic Control among type 2 diabetes patients on follow up in a developing country: a prospective observational study. 1

- 95 Programming of cardio metabolic health: the role of maternal and fetal hyperinsulinaemia.. **2022**, 1
- 94 5,6-dehydrokawain improves glycaemic control by modulating AMPK target genes in *Drosophila* with a high-sucrose diet-induced hyperglycaemia. **2022**, 2, 100261
- 93 Safety of add-on sulfonylurea therapy in patients with type 2 diabetes using metformin: a population-based real-world study.. *BMJ Open Diabetes Research and Care*, **2021**, 9, 4-5 2
- 92 Frontiers in Anti-Cancer Drug Discovery: Challenges and Perspectives of Metformin as Anti-Angiogenic Add-On Therapy in Glioblastoma.. **2021**, 14, 2
- 91 Screening of *Manilkara zapota* (L) P. Royen stem bark ethanolic extract for in vitro α -glucosidase inhibition, preliminary antidiabetic effects, and improvement of diabetes and its complications in alloxan-induced diabetes in Wistar rats. **2022**, 46, 0
- 90 Evaluation of antidiabetic, antioxidant and antilipidemic potential of natural dietary product prepared from *Cyphostemma digitatum* in ratsâmodel of diabetes. **2022**, 11, 197-203
- 89 Glycaemic Control of Asian Patients with Type-2 Diabetes Mellitus On Tiered Up-Titration of Metformin Monotherapy: A One-Year Real-World Retrospective Longitudinal Study in Primary Care.. **2022**, 109874
- 88 Developing a novel exenatide-based incretin mimic (B-Ex): Expression, purification and structural-functional characterization.. **2022**, 130150
- 87 Data_Sheet_1.DOCX. **2018**,
- 86 Data_Sheet_2.xlsx. **2018**,
- 85 Image_1.tif. **2020**,
- 84 Image_10.tif. **2020**,
- 83 Image_2.tif. **2020**,
- 82 Image_3.tif. **2020**,
- 81 Image_4.tif. **2020**,
- 80 Image_6.tif. **2020**,
- 79 Image_7.tif. **2020**,
- 78 Image_8.tif. **2020**,

77 Image_9.tif. **2020**,

76 Table_1.xlsx. **2020**,

75 DataSheet1.DOCX. **2018**,

74 Image1.TIF. **2018**,

73 Image10.TIF. **2018**,

72 Image11.TIF. **2018**,

71 Image12.TIF. **2018**,

70 Image13.TIF. **2018**,

69 Image14.TIF. **2018**,

68 Image15.TIF. **2018**,

67 Image2.TIF. **2018**,

66 Image3.TIF. **2018**,

65 Image4.TIF. **2018**,

64 Image5.TIF. **2018**,

63 Image6.TIF. **2018**,

62 Image7.TIF. **2018**,

61 Image8.TIF. **2018**,

60 Image9.TIF. **2018**,

59	For what reasons should metformin be used in the management of polycystic ovary syndrome?. <i>Journal of Endocrinological Investigation</i> , 2012 , 35, 87-9	5.2	1
58	Estimation of YKL-40 levels in serum and gingival crevicular fluid in chronic periodontitis and type 2 diabetes patients among South Indian population: A clinical study. 2019 , 10, 304		1
57	Unhealthy Dieting During the COVID-19 Pandemic: An Opinion Regarding the Harmful Effects on Brain Health.. <i>Frontiers in Nutrition</i> , 2022 , 9, 876112	6.2	0
56	Beneficial Effects of the Ketogenic Diet in Metabolic Syndrome: A Systematic Review. <i>International Journal of Diabetology</i> , 2022 , 3, 292-309	1	2
55	Real-world outcomes of addition of insulin glargine 300 U/mL (Gla-300) to GLP-1 RA therapy in people with type 2 diabetes: The DELIVER-G study.. <i>Diabetes, Obesity and Metabolism</i> , 2022 ,	6.7	
54	Effect of Airborne Low Intensity Multi Frequency ultrasound (ALIMFUS) on glycemic control, lipid profile and markers of inflammation in patients with uncontrolled type 2 diabetes: A multicentre proof of concept, randomized double blind Placebo controlled study.. <i>Diabetes and Metabolic</i>	8.9	
53	Phytochemical Analysis, α -Glucosidase and α -Amylase Inhibitory Activities and Acute Toxicity Studies of Extracts from Pomegranate Bark, a Valuable Agro-Industrial By-Product.. <i>Foods</i> , 2022 , 11,	4.9	1
52	Supercomplex supercomplexes: Raison d'être and functional significance of supramolecular organization in oxidative phosphorylation. <i>Biomolecular Concepts</i> , 2022 , 13, 272-288	3.7	1
51	Thrice daily consumption of a novel, premeal shot containing a low dose of whey protein increases time in euglycemia during 7 days of free-living in individuals with type 2 diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2022 , 10, e002820	4.5	1
50	Syntheses, in vitro, and in silico studies of rhodanine-based schiff bases as potential α -Amylase inhibitors and radicals (DPPH and ABTS) scavengers. <i>Molecular Diversity</i> ,	3.1	
49	Targeted treatment for type 2 diabetes mellitus and sleep disorders from a clinical and neuroimaging perspective. <i>Intelligent Medicine</i> , 2022 ,		
48	Vitamin B12 Deficiency and Clinical Neuropathy with Metformin Use in Type 2 Diabetes. <i>Journal of Xenobiotics</i> , 2022 , 12, 122-130	1	1
47	Comparison of Five Expressions of Handgrip Strength for Predicting Cardiovascular Disease Risk Factors in Chinese Middle-Aged Community Residents. <i>Frontiers in Public Health</i> , 10,	6	
46	Active coating of immediate-release evogliptin tartrate to prepare fixed dose combination tablet with sustained-release metformin HCl. <i>International Journal of Pharmaceutics</i> , 2022 , 623, 121927	6.5	0
45	Vicious cycle between severity of childhood obesity and pandemic: Potential impact of metformin. <i>Obesity Medicine</i> , 2022 , 33, 100433	2.6	0
44	Effects of H1-Antihistamines on Hepatocellular Carcinoma Risk in Patients with Type 2 Diabetes Mellitus. <i>SSRN Electronic Journal</i> ,	1	
43	Variational autoencoders learn transferrable representations of metabolomics data. <i>Communications Biology</i> , 2022 , 5,	6.7	0
42	Part Three: A Brief Primer of Non-Insulin Treatments for Type 2 Diabetes Mellitus in Older People. 2022 , 37, 251-259		1

41	Insulin resistance in children. <i>Current Opinion in Pediatrics</i> , 2022 , 34, 400-406	3.2	
40	Type 2 diabetics followed up by family physicians: Treatment sequences and changes over time in weight and glycated hemoglobin. <i>Primary Care Diabetes</i> , 2022 ,	2.4	
39	Impact of talk test based aerobic exercise on glycaemic control and anthropometric measures among patients with type 2 diabetes mellitus. <i>Comparative Exercise Physiology</i> , 1-8	0.7	
38	Metformin's effects on varicocele, erectile dysfunction, infertility and prostate-related diseases: A retrospective cohort study. <i>Frontiers in Pharmacology</i> , 13,	5.6	0
37	Malnutrition in elderly patients with type 2 diabetes mellitus in a Nigerian tertiary hospital: A cross-sectional study. 2022 , 1, 100030		1
36	Factores asociados a la insatisfacción con el tratamiento farmacológico en pacientes con diabetes mellitus tipo 2: estudio transversal. 2022 ,		
35	CCNE1 is a potential target of Metformin for tumor suppression of ovarian high-grade serous carcinoma. 1-15		0
34	Long-term Remission of Type 2 Diabetes and Patient Survival After Biliopancreatic Diversion with Duodenal Switch.		0
33	Agonistas del receptor de GLP-1 en el manejo del paciente con diabetes mellitus tipo 2. Una aproximación para el nefrólogo. 2022 ,		
32	Onion and garlic polysaccharides: A review on extraction, characterization, bioactivity, and modifications. 2022 , 219, 1047-1061		3
31	Cost-Effectiveness of Dulaglutide Versus Liraglutide for Management of Type 2 Diabetes Mellitus in Iran. 2022 , 32, 54-61		0
30	The Effect of Nutrition Education Using MyPlate on Lipid Profiles, Glycemic Indices, and Inflammatory Markers in Diabetic Patients. 2022 , 11, 171		0
29	Comparing time to intensification between insulin degludec/insulin aspart and insulin glargine: A single-center experience from India. 2022 , 13, 171		0
28	Rate of glycaemic control and associated factors in patients with type 2 diabetes mellitus treated with insulin-based therapy at selected hospitals in Northwest Ethiopia: a multicentre cross-sectional study. 2022 , 12, e065250		1
27	Effects of H1-Antihistamines on Hepatocellular Carcinoma Risk in Patients With Type 2 Diabetes Mellitus. 2022 , 101393		1
26	Presence and development of diabetic retinopathy in 153 238 patients with type 2 diabetes in the Danish Registry of Diabetic Retinopathy.		0
25	Development of composite carbon quantum dots-insulin formulation for oral administration. 2022 , 76, 103833		0
24	An Overview of Herbal-Based Antidiabetic Drug Delivery Systems: Focus on Lipid- and Inorganic-Based Nanoformulations. 2022 , 14, 2135		0

- 23 Metformin-induced AMPK activation promotes cisplatin resistance through PINK1/Parkin dependent mitophagy in gastric cancer. 12, ○
- 22 Comparison of two titration programs for adding insulin detemir to oral antidiabetic drugs in patients with poorly controlled type 2 diabetes mellitus. ○
- 21 Hypoglycemia prevention practice and associated factors among diabetes mellitus patients in Ethiopia: Systematic review and meta-analysis. **2022**, 17, e0275786 ○
- 20 Longitudinal assessment of the quality of life and patterns of antidiabetic medication use in patients with type 2 diabetes, Saudi Arabia perspective, DISCOVER study. 1-22 ○
- 19 Causal deep learning reveals the comparative effectiveness of antihyperglycemic treatments in poorly controlled diabetes. **2022**, 13, ○
- 18 Type 2 diabetes mellitus and cognitive function: understanding the connections. Publish Ahead of Print, 1
- 17 Self-care practice and its predictors among adult diabetic patients on follow-up at public health care diabetic referral clinics, Debre Markos, Ethiopia. **2022**, 30, 102041 ○
- 16 Evaluation for the Relationship Between Normal Serum Level of Thyroid Hormones and Left Ventricular Systolic and Diastolic Dysfunction. **2022**, 13, ○
- 15 Prognostic Relevance of Type 2 Diabetes and Metformin Treatment in Head and Neck Melanoma: Results from a Population-Based Cohort Study. **2022**, 29, 9660-9670 ○
- 14 Management of type 2 diabetes with a treat-to-benefit approach improved long-term cardiovascular outcomes under routine care. **2022**, 21, ○
- 13 Weight-centric treatment of type 2 diabetes mellitus. **2022**, 4, 100045 ○
- 12 The Synergistic Action of Metformin and Glycyrrhiza uralensis Fischer Extract Alleviates Metabolic Disorders in Mice with Diet-Induced Obesity. **2023**, 24, 936 ○
- 11 Understanding the relationship between sleep and quality of life in type 2 diabetes: A systematic review of the literature. 135910532211408 ○
- 10 Synthesis and characterization of conducting polymer/alginate composite hydrogels: Effect of conducting polymer loading on the release behaviour of metformin drug. **2023**, 372, 121193 ○
- 9 In Vitro Evaluation of Antidiabetic Potential of Cleistocalyx nervosum var. paniala Fruit Extract. **2023**, 12, 112 ○
- 8 Pathophysiology, Diagnostic Criteria, and Approaches to Type 2 Diabetes Remission. **2023**, ○
- 7 Safety of metformin continuation in diabetic patients undergoing invasive coronary angiography: the NO-STOP single arm trial. **2023**, 22, ○
- 6 Evaluation of drug utilisation pattern and cost associated with diabetes mellitusType 2 management in Saudi Arabia. 58, ○

- 5 Providing Diabetes Education through Phone Calls Assisted in the Better Control of Hyperglycemia and Improved the Knowledge of Patients on Diabetes Management. **2023**, 11, 528 ○
- 4 Secondary Metabolite Profiling, Antioxidant, Antidiabetic and Neuroprotective Activity of *Cestrum nocturnum* (Night Scented-Jasmine): Use of In Vitro and In Silico Approach in Determining the Potential Bioactive Compound. **2023**, 12, 1206 ○
- 3 Metformin, a biological and synthetic overview. **2023**, 86, 129241 ○
- 2 Metformin promotes bacterial surface aggregation by inhibiting the swimming motility of flagellated *Escherichia coli*. ○
- 1 Role of obesity related inflammation in pathogenesis of peripheral artery disease in patients of type 2 diabetes mellitus. ○